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Mycophenolate Mofetil (MMF) is an immunosuppressive pro-drug of mycophenolic acid (MPA), first 
approved by the US Food and Drug Administration (FDA) in 1995 for the prevention of rejection post 
solid organ transplantation (SOT). A narrow therapeutic index, poor predictability of exposure from 
trough drug level monitoring, large inter transplant as well as inter and intra subject variability and lack 
of guidelines for optimal dosing are the primary reasons that make it very crucial to apply 
pharmacokinetic (PK) and pharmacodynamic (PD) concepts to individualize the dosing of MPA in 
transplant sub-populations. A target range of the active form, MPA measured by the area under the 
concentration time curve (AUC) in renal transplant recipients of 30-60 mg*h/L has been shown to be 
associated with better graft and overall survival.  This work attempts at optimizing dosing of MMF in 
pediatric HSCT recipients and in adult lung transplant recipients by using different dosing regimens, 
therapeutic drug monitoring and modeling approaches. We evaluated the safety and feasibility of a 
personalized pharmacokinetics-based dosing approach in pediatric HSCT patients using a novel 
continuous infusion (CI) method of administration of MMF to improve MPA exposure.  
We further evaluated the feasibility of a PK and PD focused dosing of MMF in adult lung transplant 
(LT) recipients. Total plasma concentrations of MPA measured by a UPLC-MS assay were inversely 
related to the inosine-5′-monophosphate dehydrogenase (IMPDH) activity, with the lowest activity 
being seen at the maximum MPA concentration. In a pilot study conducted in LT recipients, although 
statistically not significant, the pre-dose IMPDH activity at the bronchoscopy visit tended to be higher in 
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patients who rejected compared to those who did not have any rejection episodes. Finally, a robust 
physiologically based pharmacokinetic (PBPK) model of MPA was built and validated in healthy 
Caucasian and Chinese volunteers, pediatric patients, kidney transplant recipients and patients with 
varying degree of renal impairment with an intent to apply this in clinical practice to lung and pediatric 
HSCT patients. The promising results from this work can serve as the foundation for future studies 
optimizing the use of MPA in transplant patients. 
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1.0  INTRODUCTION 
2 
 
1.1 IMMUNOSUPPRESSIVE DRUGS AFTER SOLID ORGAN 
TRANSPLANTATION 
Organ transplantation is the treatment of choice for end-stage organ disease, autoimmune and 
several genetic disorders. Treatment outcomes in particular acute rejection and infection rates 
and graft survival of solid organ and stem cell transplantation have dramatically changed over 
the past decade, primarily due to improvements in immunosuppression and to better medical care 
post-transplantation. Immunosuppressive drugs form an integral part of the pharmacotherapy. 
Over the years, the use of induction and maintenance therapy has evolved [1].  
  Table 1 presents an overview of the currently used immunosuppressive drugs in 
transplantation[2].  These drugs act on different targets in the immune system and primarily 
classified as induction therapy and maintenance therapy agents. 
1.1.1 Induction regimen 
Induction therapy as the name suggests incudes agents used early in transplantation 
typically intraoperatively or immediately post-transplantation. The goal of induction therapy is to 
prevent acute rejection by providing a high degree of immunosuppression in the early post 
transplantation period.  
Biological agents are the most normally used for induction therapy. Antithymocyte 
globulin is the most frequently used induction agent post kidney transplantation. Other induction 
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therapy agents include basiliximab, daclizumab and alemtuzumab. Induction therapy, by 
providing a high degree of immunosuppression and thereby delaying the use of calcineurin 
inhibitors plays an important role in the prevention of CNI-induced nephro-toxicity after 
transplantation[3] . No standard induction immunosuppressive regimen exists for patients 
undergoing renal transplantation and the choice of regimen often depends on the preferences of 
the center and the clinicians. 
1.1.2 Maintenance regimen 
This is typically initiated post-transplant and often consists of a combination of 2-3 
immunosuppressive agents. Calcineurin inhibitors like tacrolimus or cyclosporine form an 
integral part of maintenance immunosuppression. Tacrolimus and mycophenolate derivatives 
have largely replaced the use of cyclosporine and azathioprine (AZA), respectively, and are the 
preferred CNI and antimetabolite agent for maintenance therapy in solid organ and stem cell 
transplantation. Mycophenolic acid derivatives- the pro-drug mycophenolate mofetil (MMF) and 
the delayed release enteric coated mycophenolic acid in combination with a CNI have 
demonstrated lesser risk of early and late allograft rejection, better toxicity profiles and have also 
prolonged graft survival and hence have become the standard of care in most transplant centers.   
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Table 1. Overview of immunosuppressive drugs currently used in solid organ transplantation 
Brand Name Drug Regimen Comments 
Deltasone Prednisone Induction/Maintenance Associated with severe side effects 
Imuran Azathioprine Maintenance one-year graft survival of around 70%, higher toxicity 
Cellcept/Myfortic Mycophenolic acid Maintenance Similar efficacy as azathioprine, better toxicity profile 
Neoral Cyclosporine Maintenance Form backbone of maintenance immunosuppressive regimen 
Tacrolimus has a lower risk of acute rejection and allograft loss 
than cyclosporine 
Prograf/ Advagraf Tacrolimus Maintenance 
Certican Sirolimus Maintenance Place in maintenance immunosuppression still under investigation; 
often used to limit CNI nephrotoxicity Rapamune Everolimus Maintenance 
 ATG Induction Oldest available drug for induction therapy 
Mab Campath Alemtuzumab Induction Similar to ATG while less toxic 
Simulect Basiliximab Induction Less effective and less toxic than ATG 
Nulojix Belatacept Maintenance Promising new agent under investigation 
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1.2 MYCOPHENOLATE MOFETIL AND ITS USE IN SOLID ORGAN AND STEM 
CELL TRANSPLANT PATIENTS 
Immunosuppressive agents play a critical role in prevention of graft rejection post solid organ as 
well as GVHD in stem cell transplantation. Calcineurin inhibitors like cyclosporine (CsA) and 
tacrolimus (TAC) have formed the backbone of a typical immunosuppressive regimen. MMF an 
anti-proliferative agent was approved by the FDA in 1995 for prophylaxis of organ rejection 
(accessed from: https://www.gene.com/download/pdf/cellcept_prescribing.pdf). Its approval was 
based on data from three clinical trials conducted in de-novo kidney transplant recipients at a 
fixed dose of 1000 mg or 1500 mg administered twice daily for prevention of acute rejection in 
adult renal transplant recipients.  [4-6] It has gained widespread acceptance in all solid organ 
transplants because of a better toxicity profile and better overall outcomes as compared to 
azathioprine. [7] The primary mode of action of MPA, the active component of MMF is by 
inhibition of  cell cycle in the S phase by competitive and reversible inhibition of the enzyme 
IMPDH, which is involved in the conversion of inosine monophosphate (IMP) to xanthosine 
monophosphate (XMP). Unlike other cell types, T and B Lymphocytes are primarily dependent 
on this pathway and cannot use the alternative salvage pathway for purine synthesis and 
proliferation. 
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1.3  FORMULATIONS OF MYCOPHENOLIC ACID 
MMF is a prodrug of the active form MPA and was primarily designed to improve the oral 
bioavailability of MPA. The morpholinoethyl ester derivative of MPA showed improved 
solubility at gastric pH < 5 indicating rapid in-vivo dissolution in the upper gastrointestinal (GI) 
tract. [8] Mycophenolate mofetil doses can be converted to equivalent MPA content by 
multiplying by a factor of 0.739. It is available for oral administration as capsules (250mg), 
tablets (500mg) and as a powder for suspension (200 mg/mL when constituted). MMF is also 
available in the intravenous form for patients who are unable to swallow the oral dose, especially 
during the immediate post-transplant period. It is marketed by Genentech, a member of Roche 
group.   
MPA is also available as a delayed release enteric coated tablet marketed as Myfortic by 
Novartis Pharmaceuticals. It is available at 180 mg and 360 mg doses. A 720-mg dose of 
Myfortic (2 x 360 mg) closely approximates the MPA exposure from 1000 mg MMF. [9] 
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1.4 CLINICAL PHARMACOKINETICS OF MYCOPHENOLIC ACID  
Pharmacokinetics of mycophenolic acid has been studied in solid organ transplant patients 
especially in kidney and liver transplant recipients. Limited data is available on the 
pharmacokinetics of this drug in other SOT patients and HSCT patients.  The pharmacokinetics 
of this drug shows high inter as well as intra-patient variability. Although several studies report 
differences in the pharmacokinetics across different transplant patients, MMF is given at a fixed 
flat dose and is not routinely therapeutically monitored. Different physiological changes 
occurring as a result of transplantation could alter the exposure of the drug and thereby 
contribute to the observed variability in MPA pharmacokinetics in these patient populations.  
1.4.1 Absorption 
Mycophenolic acid is a highly lipophilic drug. Based on biopharmaceutical classification system 
(BCS) it is a class II drug with high permeability, but low solubility. MMF is rapidly hydrolyzed 
following oral administration to MPA, reaching undetectable concentrations in plasma within 30 
minutes.[10-12] The maximum plasma concentration of MPA is attained within 2 hours after 
oral dosing. The oral dosage form has a high bioavailability (~96%) leading to a 1:1 dose 
conversion when switching a patient from an intravenous to oral dosing. Enteric coated 
mycophenolate sodium (EC-MPS), the delayed release formulation of MPA, attains peak 
concentrations much later, around ~4 hours. [13] In-vitro dissolution studies of EC-MPS show 
high solubility at neutral pH as observed in intestine but with limited solubility in the gastric pH. 
The manufacturer reported bioavailability of EC-MPS to be 72%.  Poor post-operative 
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absorption as seen in certain solid organ transplant recipients can lead to reduced bioavailability 
of MPA. Any change in the activity or expression of the esterases that are responsible for 
hydrolysis of MMF can also potentially lead to incomplete absorption of MPA after oral 
administration of MMF. 
1.4.2 Protein Binding and Distribution 
Mycophenolic acid has a blood to plasma ratio of 0.59, indicating that it is distributed primarily 
in the plasma and partitions to a lesser extent in the cell fractions of blood, and supports the 
rationale of measuring mycophenolic acid levels in plasma. [14, 15] It is more than 95% bound 
to the plasma protein, albumin. Only the free, unbound form is available for anti-proliferative 
activity. An in-vitro study has shown that an increase in serum albumin from 2 to 4 g/dl serum 
can decrease the free fraction from approximately 3 to 1.5%[15]. The volume of distribution of 
MPA at steady state is not significantly different between the intravenous (3.6 L/kg) and oral 
administration (4L/kg), suggesting that the oral bioavailability of mycophenolic acid is close to 
100%.  The binding of MPA to albumin depends on the availability of albumin and the 
competition of MPA with the glucuronide metabolite MPAG, (which is also highly protein 
bound) for the binding site in albumin.  Disease state can have a significant impact on the protein 
binding and distribution of MPA. Albumin concentrations are low in patients with renal and liver 
impairment and in the early post-transplant period. 
Mycophenolic acid is an intermediate clearance drug with an extraction ratio ranging from 0.3-
0.7[16, 17]. For an intermediate clearance drug, factors that may influence its clearance include 
protein binding, intrinsic enzymatic activity of the liver, and the blood flow to the liver. 
9 
 
Renal impairment seen post-transplant can lead to increase in MPAG levels due to 
accumulation of MPAG which then leads to displacement of MPA from the binding sites on 
albumin leading to an increase in the free fraction of MPA and corresponding increase in MPA 
distribution and clearance. Hepatic impairment can lead to decreased serum albumin 
concentration and thereby increase the free fraction of MPA resulting in increased clearance. In 
liver transplant recipients, the concentration of albumin increases with time post transplantation.  
Pisupati et al. have shown that plasma protein binding of MPA is increased as the concentration 
of albumin is increased and as the concentration of bilirubin decreased with time post-
transplantation[18].  The concentration of MPAG is about 20-100-fold higher than MPA. De 
Winter et al. conducted a study to evaluate the effect of protein binding on the pharmacokinetics 
of mycophenolic acid in renal transplant recipients. The results of this study showed that a 
decrease in plasma albumin concentrations from 0.6 to 0.4 mmol/L, resulted in a decrease in total 
MPA concentrations, with a negligible effect on free MPA, total MPAG and free MPAG 
concentrations. The free fraction of both, MPA and MPAG are inversely related to the albumin 
concentration and were seen to double when albumin concentrations decreased from 0.6 to 0.4 
mmol/L. The effect was magnified in patients who were on cyclosporine (MPA: 2.4–5.3%, 
MPAG: 13.7–26.1%) based immunosuppression therapy as compared to those on tacrolimus 
(MPA: 2.7–4.1%, MPAG: 14.9–21.3%). The study also showed a decrease in MPA exposure as 
calculated by the AUC based on total MPA in patients with low albumin concentrations. [19] 
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1.4.3 Metabolism and Elimination 
Mycophenolic acid is primarily metabolized by phase II pathway involving uridine diphosphate 
glucuronosyltransferases (UGTs) enzymes to MPAG and acyl glucuronide metabolites MPAG 
and Ac-MPAG metabolites (Figure 1). The plasma concentration of MPAG is about 20-100-fold 
higher than MPA. MPAG has no activity against IMPDH, but Ac-MPAG has been shown to 
have some activity against IMPDH, in-vitro.[20, 21] Glucuronidation  of MPA primarily occurs 
in the  liver and to certain extent in the kidney and GI tract.[22] UGT1A8 and UGT1A9 and to a 
minimal extent UGT1A1, 1A7 and 1A10 are involved in the formation of the major metabolite, 
MPAG. UGT1A8 and 1A10 are primarily responsible for the metabolism of MPA in the GI tract, 
while UGT1A9 is primarily responsible for hepatic metabolism. Ac-MPAG, the secondary 
metabolite of MPA is generated by UGT2B7.  Due to their high hepatic and renal expression 
UGT1A9 and UGT2B7 are considered the major isoforms of involved in the metabolism of 
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MPA[23].
 
Figure 1. Schematic representation of fate of MMF in human body 
 
 
 
 
Clinical studies conducted with radiolabeled mycophenolate mofetil indicate that 87% of 
the dose of MPA is excreted in the form MPAG in urine and 6% in faeces as MPA. Excretion of 
MPAG and Ac-MPAG in the urine is impacted by tubular reabsorption. [10] MPA and Ac-
MPAG are detected in small proportion in the urine. The elimination half-life of mycophenolic 
acid is 16-18 hours in healthy volunteers, and ranges between 8-16 hours in solid organ 
transplant patients.  
EHC: enterohepatic circulation; GI: gastrointestinal; MMF: mycophenolate mofetil; MPA: 
mycophenolic acid; MPAG:mycophenolic acid glucuronide; Ac-MPAG: Acyl mycophenolic 
acid glucuronide 
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The hepatic clearance can be explained by the following equation: 
Hepatic Clearance: Clh = Q [(fu x Clint)/(Q+ fu x Clint)] 
 
Where, 
Clh = Hepatic clearance 
 
Q = hepatic blood flow 
 
fu = fraction of free drug (not bound) and  
 
Clint = intrinsic capacity of the hepatocytes to metabolize a drug. 
 
For intermediate clearance drugs clearance is determined by the fraction unbound and the 
intrinsic clearance. Changes in fraction unbound can lead to changes in the total concentration of 
MPA but does not affect the unbound MPA concentrations.  
HSCT recipients show a significant difference in pharmacokinetics of MPA compared to 
SOT patients. The elimination half-life of MPA is reported as 2-3 hours in adult as well as in 
pediatric stem cell transplant recipients. Winter et al studied the differences in the clearance of 
mycophenolic acid across SOT, HSCT patients and patients with autoimmune disease. [24] The 
MPA clearance was much higher in HSCT patients (45.6 L/h) as compared to other SOT 
recipients (30.2 L/h) and patients with autoimmune disease (10.7 L/h).  
1.4.4 Enterohepatic recycling 
Multiple peak phenomenon is seen in the concentration time profiles of several compounds. As 
discussed in a detailed review by Davies et al[25], this can occur as a consequence of several 
factors. In case of mycophenolic acid, the secondary peaks occur between 6-8 hours post oral 
dose. MPA is converted to MPAG in the liver which is secreted into the bile via multi-drug 
resistance protein (MRP-2) transporter. The MPAG in the gut is then converted to MPA by the 
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gut bacteria and the reabsorption of MPA results in the secondary peak. The percent contribution 
of enterohepatic recycling towards the overall MPA exposure is very variable and can range 
between 10-60% [26-28].  
Transplant recipients who are on concomitant cyclosporine dosing have decreased MPA 
exposure. This occurs as a result of cyclosporine mediated inhibition of biliary secretion of 
MPAG mediated by MRP2. [29, 30] External factors including but not limited to the type of food 
taken and the time of food intake can also influence MPA enterohepatic circulation (EHC), 
further complicating the prediction of MPA pharmacokinetics. Modeling approaches for 
describing the EHC of MPA have evolved over time. [27, 31-33] Typical empiric compartment 
models, either one or two compartment models with first order absorption have been used to 
describe the EHC of MPA. More complex absorption model with inclusion of lag time have been 
used to describe the EHC. Such models are believed to account for the gall bladder emptying. 
[34] Other models like the Erlang and transit absorption models are used to describe skewed or 
delayed absorption profiles. Erlang model successfully elucidates the changes associated with 
MPA disposition and physiological aspects associated with it. This model includes MPA and its 
glucuronide metabolite MPAG, and adequately reflects the complex enterohepatic circulation of 
MPA. [35-37] 
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1.5 VARIABILITY IN PHARMACOKINETICS OF MYCOPHENOLIC ACID IN 
TRANSPLANT PATIENTS 
Regardless of the dosage form or the type of patient population, large inter- and intra-individual 
variability in the plasma concentration of mycophenolic acid and its metabolite plasma has been 
documented in the literature. Several factors have been demonstrated to be significantly 
associated with the variability in the pharmacokinetics of mycophenolic acid. Physiological 
factors like albumin concentration, renal and hepatic function as also age, enzyme ontogeny and 
other factors including drug- drug interactions, contribute to changes in the MPA exposure and 
clearance. [38] This extreme variability in the exposure calls for routine monitoring of MPA 
exposure and dose adjustments should be made accordingly to achieve optimal clinical 
outcomes. Unfortunately, currently there is no personalized dosing approach that is routinely 
used for MPA in transplant patients.  
1.5.1 Age 
Clearance of MPA is more rapid in children under the age of 12 years, and therefore higher doses 
based on body weight basis are required to achieve similar mycophenolic acid exposure 
compared to that in adults. Population pharmacokinetic studies conducted in pediatric solid 
organ as well as stem cell transplant have shown age of the patients to have a significant effect 
on the clearance of MPA.[39, 40]  
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1.5.2 Liver dysfunction 
MPA is primarily metabolized in liver by phase II enzymes. Hepatic impairment is known to 
alter the pharmacokinetics of MPA. Parker et al.[41]  have shown that in patients with hepatic 
impairment, the serum albumin level is decreased leading to an increase in the unbound or free 
fraction of MPA, and thereby increasing MPA clearance. In another study conducted in renal 
transplant patients, mild hepatic impairment seen in the immediate post-transplant phase, 
resulted in a significantly decreased exposure of total MPA as measured by the area under the 
concentration time curve (34.3 ± 22.3 mg*h/L vs. 50.2 ± 27.4mg*h/L, p = 0.01 [mean ± SD]) 
and by trough concentration (1.43 ± 1.07mg/L vs. 2.35 ± 1.62 mg/L, p = 0.03).[42] 
 
1.5.3 Renal dysfunction 
Delayed graft function is seen especially in patients receiving cadaveric kidney 
transplantation.[43-45] A study conducted by Johnson et al in healthy volunteers with varying 
degree of renal impairment indicated that MPA clearance is unaffected by renal function after a 
single oral dose of MMF.[46]  Most studies conducted in kidney transplant patients however 
have shown a  decrease in MPA exposure in patients with impaired renal function in the 
immediate post-transplantation period. Changes in pharmacokinetics of MPA post kidney 
transplantation are primarily time dependent. In studies that have reported a decrease in MPA 
exposure have proposed that excessive accumulation of MPAG, due to impaired graft function is 
the reason for decreased MPA exposure. The excess MPAG displaces the albumin bound MPA, 
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making more MPA available for metabolism by the phase II enzymes. The improvement in renal 
function in the first months after kidney transplantation and the subsequent increase in the 
albumin concentration contribute to the progressive increase in MPA dose–corrected exposure 
seen in the early phase post kidney transplantation. The slow rise in the serum albumin levels 
after transplantation, leads to reduced free MPA fraction and decreased MPA clearance. 
Contrasting results were observed in another study in renal transplant recipients with a stable 
graft function. An inverse relationship was observed between MPA exposure and renal function. 
The study suggested two plausible but unproven mechanisms via which this increase in exposure 
is mediated. Firstly, the increased MPAG concentrations in patients because of the impaired 
renal function can increase MPAG excretion into the bile, leading to increased enterohepatic 
recycling of MPA and subsequently increased MPA exposure. The other possible reason could 
be decreased metabolism of MPA by inhibition of UGT probably due to uremic toxins, which 
can reduce the hepatic clearance of MPA.[47] 
1.5.4 Effect of Food and Gastric Emptying 
In a study conducted by Bullingham et al in patients with rheumatoid arthritis, food was shown 
to decrease the maximum concentration (Cmax) and increase the time required to attain the Cmax 
but did not significantly alter the overall exposure of MPA. The time for the occurrence of 
secondary peak occurring due to enterohepatic recycling was also delayed by 2 hours, suggesting 
slowed gastric emptying.[48]  A clinical trial conducted in kidney transplant patients to study the 
effect of gastric emptying on the pharmacokinetics of MPA showed similar results.[49] 
Pharmacokinetic analysis of MPA was performed with simultaneous measurement of gastric 
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emptying by breath tests using 14C-octanoate/13C-glycine. Delayed gastric emptying was 
associated with a slower rate of absorption of MPA. The study cautions researchers to account 
for this effect when developing and validating limited sampling strategies for monitoring MPA 
exposure in patients with gastric disorders. 
1.5.5 Drug-drug interactions 
Drug interactions with MPA could result from UGT induction or inhibition or induction or 
inhibition of MRP2, a transporter involved in the enterohepatic recycling of MPA.Rifampin 
mediated UGT enzymes induction in the kidney, liver and intestine was first reported in a case 
study as a possible reason for the decreased MPA exposure when given to patients on MMF [50]. 
Another study conducted in 8 kidney transplant recipients showed that the MPA 12 hours 
exposure decreased significantly after rifampin co-administration (17.5% decrease [95% CI, 
5.18%-29.9%]; P=.0234). This was primarily mediated by induction of MPA glucuronidation 
capacity and increased formation clearance of MPA leading to increased exposure to the 
glucuronide metabolites MPAG and Ac-MPAG [51]. 
The findings of a retrospective study conducted by Alvarez et al suggested that patients 
with elevated sirolimus concentrations are at a higher risk for MMF toxicity, while those with 
lower sirolimus exposure are at a higher risk for [52] rejection suggested a potential DDI 
between sirolimus and MPA; however the mechanism is still unclear. 
 Cyclosporine is known to inhibit the EHC of MPAG in the gut leading to decreased 
MPAG conversion to MPA and thereby decreasing MPA exposure. A 33% increase in clearance 
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was observed in stem cell transplant patients receiving cyclosporine as compared to those 
receiving tacrolimus [53].  
A study conducted in rheumatoid arthritis patients suggested drug-drug interaction 
between antacids and MPA; chelation and reduced absorption  was suggested as a possible 
mechanism for the reduced exposure (Cmax and AUC) of MPA and MPAG due to reduced 
absorption [48].  
Studies conducted with antibacterial agents such as norfloxacin, metronidazole in healthy 
volunteers suggested a decrease in MPA exposure of 10%, 19% respectively and a 33% 
reduction for the combination of norfloxacin and metronidazole [54]. 
The only known report of an increase in MPA exposure is seen in a patient when MMF was given with 
valproic acid, with inhibition of UGT2B7 as the potential cause of this interaction [55].  
 
 
 
 
 
 
 
 
Table 2(adapted from Jaklic et al.) [56] summarizes the potential drug-drug-interaction 
(DDI) affecting MPA pharmacokinetics. 
19 
 
 
 
 
 
 
 
 
 
 
Table 2. Potential DDI affecting MPA pharmacokinetics. 
DDI: drug-drug-interaction; MPA: Mycophenolic Acid; AUC: Area under concentration-time curve 
 
Category Drug Effect on MPA 
Pharmacokinetics 
Reference 
Immunosuppresant Cyclosporine Increase in MPA 
clearance by 33% 
Li et al[53] 
Proton Pump 
Inhibitor 
Pantoprazole Decrease in MPA 
AUC by 37% 
Kofler et al[57] 
Omeprazole Decrease in MPA 
AUC by 23% 
Kees et al[58] 
Lansoprazole Decrease in MPA 
AUC by 25% 
Miura et al[59] 
Antibiotics Ciprofloxacin Decrease in MPA 
trough concentration 
by 46% 
Goutelle et al[60] 
Amoxicilin/Clavulanic 
acid 
Decrease in MPA 
trough concentration 
by 46% 
Ratna et al[61] 
Anti-epileptic Valproic acid Increase in AUC Annapandian et al[55] 
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1.5.6 Chronopharmacokinetics 
There are two publications discussing the chronopharmacokinetics of MPA. A study conducted 
by Tedesco- Silva H Jr [62] suggested circadian variation in PK as seen by a marked  decrease in 
MPA exposure (Cmax and AUC) and increase in oral clearance during nighttime as compared to 
daytime. The effect was greater when MPA was administered as EC-MPS in combination with 
cyclosporine as compared with everolimus (32% versus 17%). Another study conducted by 
Satoh et al. [63] reported a significantly higher MPA AUC during the daytime as compared to 
nighttime (P=0.049). Although chronopharmacologic changes may be clinically less relevant for 
drugs having a wider therapeutic index, it may be more important for drugs having a narrow 
therapeutic index.  
1.5.7 Genetic Polymorphism 
1.5.7.1 UGT polymorphism 
Glucuronidation is an essential pathway for metabolism of various endogenous compounds and 
xenobiotics. The 3 UGT sub families, namely 1A1, 2A and 2B encode for a total of 16 enzymes. 
6 of these (UGT 1A1, 1A6, 1A7, 2B4, 2B7 and 2B15) have been characterized for genetic 
polymorphism.[64] Genetic polymorphisms of UGT enzymes are of toxicological, 
pharmacological and physiological significance. It is the primary pathway of MPA metabolism.  
UGTs 1A9, 1A8 and 2B7 are involved in MPA metabolism and this occurs in the liver and to a 
smaller extent in kidney and intestine [65]. Hepatic UGT1A9 is responsible for >50% of MPA 
21 
 
metabolism to MPAG [22, 66]. UGT1A8 and UGT1A10 are predominantly located in the 
gastrointestinal tract and have a relatively smaller contribution to disposition of MPA in humans.  
The first study exploring the impact of genetic polymorphism  of UGTs on MPA exposure was 
reported  in 95 Caucasian kidney transplant recipients, who were on tacrolimus and steroid 
therapy [64]. The study showed a 50% reduction in the average 12-hour exposure in patients who 
were either carriers of UGT1A9 – 275T>A or – 2152C>T or both, compared to the non-carriers 
of this polymorphism. These single nucleotide polymorphisms (SNPs) were associated with a 
15-43% reduction in exposure in a long term study spanning over 5 years [67] and in another 
study a 26% reduction in exposure was observed. [68].  
Other UGT1A9 SNPs that are studied include −98T>C (UGT1A9*3), −440C>T and 
−331T>C. The SNP UGT1A9*3 was associated with higher MPA exposure (AUC or trough 
concentrations) in patients treated with MMF. The study reported 49% and 54% higher MPA 
AUC in patients on tacrolimus and cyclosporine, respectively compared to the corresponding 
non-carriers [69]. Other studies have also reported similar observations [64, 70, 71].   
Clinical outcomes like acute rejection were often examined as a secondary outcome in 
most studies. The authors who studied UGT1A9 – 275T>A or – 2152C>T SNPs also studied 
UGT2B7 SNPs [64], −125C and −138A, and found that SNPs of 1A9 and 2B7 were significantly 
associated with development of acute rejection in patients treated with cyclosporine.  
1.5.7.2 MRP2 polymorphism 
MPA gets converted in the liver to MPAG and undergoes MRP-2 mediated biliary secretion. A 
study conducted in pediatric kidney transplant recipients showed that patients having MRP2-
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24T>C who also had UGT1A9-440C>T or UGT2B7-900A>G showed a 2.2 higher dose-
dependent and BSA-normalized MPA-AUC compared with carriers of no or only 1 UGT-SNP. 
[72] Another study [73] showed that patients with the C24T variant allele in MRP2 who were on 
MMF and concomitant macrolide treatment showed a significantly reduced exposure as 
measured by AUC as compared to those who were not on macrolide treatment. However, these 
studies are confounded by concomitant medication and/or effect of UGT polymorphism. There is 
no substantial evidence of MRP-2 polymorphism mediated impact on  MPA PK.  
1.5.7.3 IMPDH polymorphism 
MPA acts by inhibiting enzymes IMPDH I and II. MPA PK and PD have shown approximately 
10-fold variability among transplant patients. Recently published studies in transplant recipients 
have hypothesized that inter-individual variability in IMPDH activity may be attributed to SNPs 
in genes coding for IMPDH I and II. 
Reports evaluating the relationship of IMPDH genotype to pharmacokinetic and clinical 
outcomes are contradictory. A study evaluating 8 SNPs of IMPDH in de novo kidney transplant 
patients identified the SNP, 3757T>C for IMPDH II with a variant allele (C) to be associated 
with increased IMPDH activity (p=0.04) in de-novo kidney transplant recipients. [74] 
For IMPDH I, 2 SNPs, rs2278293 and rs2278294, are significantly associated the 
incidence of biopsy-proven acute rejection (BPAR) within a year after kidney transplantation 
[75, 76].In a larger study [77], rs2278294 SNP was significantly associated with lower risk of 
rejection and a higher risk of leucopenia during the first year post-transplantation. 
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1.6 APPROACHES FOR OPTIMIZING MMF DOSING IN TRANSPLANTATION 
1.6.1 Fixed dose administration 
MMF is often administered at a fixed dose. However, there have been several studies that have 
explored concentration controlled (CC) MMF dosing based on a target MPA exposure. An 
extensive study conducted by Wang et al [78] included data from 4 randomized controlled trials 
that included 1755 kidney transplant patients. The results of this study established no significant 
differences between concentration controlled and fixed-dose MMF for treatment failure 
(P=0.52), serum creatinine clearance (weighted mean difference, 2.46; 95% CI, -1.15 to 6.07; 
P=0.18), total gastrointestinal adverse events (P=0.53), diarrhea (P=0.35), anemia (P=0.12), 
leukopenia (P=0.25), thrombocytopenia (P=0.41), and malignancy (P=0.23).  
A similar study was conducted in 901 kidney transplant recipients where patients were 
randomized to a concentration-controlled group with a target exposure over a dosing interval as 
measured by AUC 45µg*hr/ml (n=452) or a fixed-flat dose (n=449) of MMF regimen [79]. The 
number of patients attaining the target MPA 12-hour AUC values of 30 to 60 mg hr/L was 
comparable between the two groups. The primary endpoint was treatment failure as measured by 
a BPAR, graft loss, death within first 12 months post-transplantation. This study did not show a 
significant difference in the incidence of treatment failure or BPAR (P>0.05) between the 
concentration-controlled and the fixed-dose groups primarily due to non-adherence to dose 
adjustments required in the immediate post-transplant phase. This study however did show that 
there is a significant relationship between immediate post-transplant MPA exposure and BPAR 
, highlighting the importance of attaining target concentrations early on in these patients. 
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Another study has explored a weight based dosing of MMF in 53 Asian kidney transplant 
recipients [80]. This study showed that steady state 12-hr AUC is significantly associated with 
TBW-adjusted MMF dose.  An AUC0-12 of 45 µg*hr/ml at steady state could be attained with an 
MMF dose of 12 mg/kg BID dosing.  
The OPTICEPT trial [81] compared clinical outcomes of patients who were either on 
fixed dose MMF-standard dose calcineurin inhibitor (CNI) (A), concentration controlled MMF- 
standard dose CNI (B) or concentration controlled MMF- low dose CNI (C). Doses were titrated 
to maintain MPA concentrations greater than 1.3 µg/ml for cyclosporine treated and 1.9 µg/ml 
for tacrolimus treated patients. Patients in group C had lower rate of treatment failure. Also, 
patients that had a higher MPA exposure had significantly less rejection. It can be inferred that 
concentration controlled MMF can be potentially used in CNI sparing immunosuppressive 
regimen. 
Another trial, CLEAR[82] explored intensified dosing (1.5 g twice daily on days 1 to 5, 
then 1.0 g twice daily) or standard dosing (1.0 g twice daily) of MMF in combination with 
tacrolimus and prednisone. Although there were no significant differences in clinical outcomes 
between the two groups when comparing the overall exposure, AUCs were significantly higher 
in the 1.5 g twice daily (BID) arm on days 3 and 5, which consequently resulted in a trend for 
fewer treated acute rejections at 6 months. 
Conclusively, these large multi-center clinical trials showed that intensified MMF dosing 
was well tolerated and resulted in an overall increase in the MPA exposure and reduced acute 
rejection. The OPTICEPT trial primarily established the non-inferiority of concentration-
controlled dosing as compared to fixed dosing of MMF. It also highlighted previously 
established fact that higher MPA exposure is associated with better clinical outcomes in terms of 
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acute rejection and overall survival. These studies also emphasized the importance of monitoring 
AUC rather than trough concentrations owing to the poor correlation between trough 
concentration and AUC.  
1.6.2 Therapeutic drug monitoring 
Therapeutic drug monitoring (TDM) refers to the measurement of drug concentration in body 
fluids at designated intervals to maintain a concentration of a drug in a therapeutic range to 
optimize drug dosing based on individual exposure [83]. TDM is a common practice for drugs 
like voriconazole [84], posaconazole, [85] and cyclosporine [86, 87] and tacrolimus [88] which 
form the backbone of drug treatment in transplantation. TDM is important when there is a 
correlation between the drug concentration and clinical effect, for drugs having a narrow 
therapeutic index, for drug showing large inter and inter-patient variability, when there are no 
good clinical markers of efficacy. For mycophenolate mofetil, trough concentration is a poor 
representation of overall exposure and is also poorly correlated to the clinical outcomes [89, 90]. 
Shaw et al [91] evaluated the relationship between MPA PK and clinical outcomes from 11 
prospective studies conducted in solid organ transplant recipients. Of these, 8 studies were 
performed in kidney transplant recipients, and three in heart transplant patients. All these studies 
have used cyclosporine or tacrolimus as the primary immunosuppressive drug. Overall the 
following conclusions can be drawn: (i) MPA exposure as measured by the AUC is a good 
predictor of acute rejection and also some hematologic toxicity; (ii) Targeting a 12 hour AUC of 
30-60 µg*hr/ml is associated with better clinical outcomes in terms of graft survival in SOT 
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recipients, (iii) trough values of MPA is a marginal predictor of rejection events but are highly  
variable and poorly correlate with MPA AUC. 
1.6.3 Pharmacokinetic profiling 
Clinical pharmacokinetic profiling refers to quantitation of the rate and extent to which a drug is 
absorbed distributed and eliminated from patients. Determination of AUC0-12 is considered to be 
the best measure of MPA exposure.  This is generally carried out over a dosing interval and is 
typically less time consuming and relatively easier to perform as compared to pharmacodynamic 
monitoring. However, such studies are often limited by the volume of sample that can be drawn 
(especially in special populations like pediatric subjects) and clinical feasibility. Strategies for 
ideal monitoring of MPA exposure have been largely debated. In a consensus report published 
by Kuypers et al[92] different characteristics of pharmacokinetic monitoring strategies and the 
advantages and disadvantages were discussed. The review summarized that single time point 
measurements although clinically feasible can only be used in the same population that was used 
to develop the regression equation. It is also limited by inaccuracy of the timing of measurement 
and may not always have a strong association with the AUC. On the other hand, multiple time 
point, and Bayesian estimation approaches are better associated with AUC but are more time 
consuming and require complex mathematical modeling.  
Several studies conducted in solid organ and stem cell transplant patients have underlined the 
importance of AUC monitoring. The target MPA AUC0-12 ranges used in these studies have been 
derived from several studies to be in the range of 30 and 60 µg*hr/ml.  The upper limit was 
determined based on no additional efficacy of higher target AUC. The recommended target MPA 
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trough concentration of 1.3 µg/ml and 1.9 µg/ml when given with CsA and tacrolimus 
respectively were derived from the corresponding AUC values, assuming that 80% of patients 
treated will attain the lower limit of the target AUC exposure.   
 Two big trials, APOMYGRE and Fixed dose concentration-controlled trials showed the 
importance of monitoring of MPA AUC. Patients in the APOMYGRE trial achieving a target 12-
hour AUC of 40 µg*hr/ml had a significantly lower incidence of biopsy-proven acute rejection 
(BPAR; 7.7 versus 24.6%; P>0.01). Another study conducted by Kuypers et al [67] in de-novo 
kidney transplant recipients established similar AUC range. This target level was useful for 
subjects who had MMF related leukopenia or anemia, however, this AUC had no clinical utility 
in guiding MMF dosing in patients with gastrointestinal or infectious adverse events. These 
studies did hint at future strategies for better TDM. It was established through these studies that a 
Bayesian estimation based on 3 time point within the first 3 hours of MMF dosing can be 
potentially used to predict the overall exposure. Dosage adjustments helped enable the clinicians 
to achieve target MPA AUC in 91% by day 14 as compared to 56% in the fixed dosing group.   
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Table 3 Summary of Limited sampling strategies in transplant patients 
Sampling time 
(hours) 
Correlation Equation used  Method used Conclusion Reference 
1,3,9 0.82 17.28 + 0.89C1h + 
1.76C3h + 6.09C9h 
Stepwise multiple 
regression analysis 
71% of estimated AUCs comprised 
within 85%–115% of actual full AUC 
Pawinski et al[93] 
1,2,3 and 6 0.89 8.53 + 1.09C1h + 
1.07C2h + 1.65C3h + 
3.59C6h 
83% of estimated AUCs comprised 
within 85%–115% of actual full AUC 
0,1,3,6 0.84 9.02 + 3.77C0 + 
1.33C1 + 1.68C3 + 
2.96C6 
Previously reported LSS 
strategies 
Superior in predicting AUC0–12 in 
cyclosporine co-treated cohort  
Barraclough et 
al[94] 
0,1,2, 4 0.76 6.02 + 5.61C0 + 
1.28C1 + 0.9C2 + 
2.54C4 
1,2 and 4 0.84 9.328 + 1.311C1 + 
1.455C2 + 2.901C4 
Multiple regression 
analysis 
Better prediction of MPA AUC in 
steroid free regimen 
Poulin et al[95] 
0,1,3 and 6 0.8 12.3 + 4.7 C0+ 1.2 
C1+ 2.7 C3+ 1.8 C6 
Maximum a posteriori 
Bayesian estimator 
(MAP-BE) 
Good predictive performance and offers 
flexibility with respect to 
sample times 
Winter et al[96] 
0,2 and 4 0.7  0.26C0 + 2.06C2 + 
3.82C4 + 20.38 
3 samples at C0, Multiple 
regression 
Recommended for MPA when restricted 
to samples collected up to 4 hours 
Miura et al [97] 
0, 0.5, 2   7.75 + 6.49C0 + 
0.76C 0.5h + 2.43C2 
Linear regression (82%) estimated AUC values were 
within 15% of the value of AUC0-12  
Pawinski et al 
[98] 
0,1,2 and 6 0.84 7.99+1.40C2+2.47C4 
+9.54C6 
Stepwise linear regression 
analysis 
83% of IV and 70% of PO AUC0-12 
predictions fell within ±20% 
Ng et al[99] 
1,2,3 and 4 0.81 - Multiple stepwise linear 
regression analysis 
Appropriate estimation of LSS for MPA 
in renal transplants treated with EC-
MPS  
Sommerer et al 
[100] 
AUC: area under concentration-time curve; MPA: mycophenolic acid; IV: intravenous; LSS: limited sampling strategy; EC-MPS: enteric coated mycophenolate sodium.
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1.6.4 Limited sampling strategy (LSS) 
The main limitation of using AUC based approach is the practical difficulty in having the patient 
stay in the clinic for over 10 hours. Although the recommended target AUC0-12hours for MPA is 
between 30 and 60 µg*hr/ml, most transplant centers find it difficult to implement a 12-hour 
MPA monitoring primarily due to the technical difficulties and lack of clinical feasibility to 
conduct multiple repeated sampling.  
 Prediction of the disposition of a drug from limited blood sampling schedule (often with 3 or 
fewer concentrations) was proposed as a possible approach by Moore et al [101].  Different 
single time point, or abbreviated sampling techniques are used for monitoring of MPA exposure 
in transplant and other patient populations. A summary of the results from major studies is 
presented in Table 3. Bayesian estimation approaches have also been used to design and validate 
a limited sampling strategy. TDM of MPA that is based on LSSs is preferred in SOT patients 
compared with drug dosing that is based on single MPA (trough) concentrations. LSSs provide a 
good estimation of the AUC within a dosing interval, which is associated with early 
postoperative efficacy (avoidance of acute rejection) and can thereby improve early graft 
outcome in terms of acute rejection.  
The major advantage of these strategies is the reduced cost; labor and inconvenience on the 
investigators’ end and a shorter hospital stay on the patients’ end and faster turnaround time of 
the results.  LSSs are increasingly being used in other clinical setting like bioequivalence studies 
and PK-PD analysis. 
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1.6.5 Pharmacodynamic monitoring 
Hale et al [102] conducted the first pharmacokinetic-pharmacodynamic (PK-PD) study in 
transplant recipients. They described a sigmoidal relationship between the MPA exposure and 
likelihood of rejection and is illustrated in Figure 2. Langman et al [103] reported that the 
maximum inhibition of IMPDH activity occurred at peak concentrations of MPA and observed a 
consequent increase in IMPDH activity as the drug was eliminated from the body with very little 
or no inhibition at 24 hours post-dose. Over the last decade, measurement of IMPDH activity is 
increasingly being used in an attempt to evaluate the efficacy of MMF directly. IMPDH is an 
enzyme that is involved in the de-novo synthesis of guanosine nucleotides. It catalyzes the 
conversion of IMP to XMP in presence of the oxidized form of the coenzyme Nicotinamide 
adenine dinucleotide (NAD+).  Initially radiometric assays were developed for measurement of 
IMPDH activity. However, these assays were not consistent, and it was difficult to obtain 
reproducible results using these methods. Several high-performance liquid chromatography 
(HPLC) method has been reported for measurement of IMPDH activity. IMPDH activity is 
indirectly determined by measuring XMP ex-vivo by incubating peripheral blood mononuclear 
cell (PBMC) lysates with IMP and NAD+ [104-107]. Studies conducted in renal transplant 
patients have shown an inverse correlation between MPA concentration and IMPDH activity. In 
most studies, the maximum inhibition of IMPDH was achieved 1 to 2 hours after dosing. In a 
number of studies, large inter-patient variability was observed in IMPDH activity, with a relative 
small intra-patient variability in respectively healthy persons, patients on dialysis and kidney 
transplant recipients.  
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Figure 2. Exposure (AUC)-Response (rejection) relationship of MPA in renal transplant recipients 
 
A study reported by Thi et al. [108] correlated the total MPA and intracellular PBMC MPA 
concentrations to IMPDH activity. Inhibition of IMPDH activity at 1.5 hours correlated better 
with total MPA exposure (p = 0.027) measured as plasma AUC than with AUC in PBMC 
(p = 0.323) calculated after 3.5 hours. This study suggested that measurement of MPA 
concentrations in PBMCs does not provide any better correlation with the IMPDH activity than 
plasma MPA concentrations. There is an inverse relationship between total MPA exposure in 
plasma and IMPDH activity as shown in Figure 3 [109]. Several other studies have established 
an integrated population PK-PD model describing an inhibitory Emax model in adult and pediatric 
solid organ  transplant recipients [35, 110-112] Budde et al. [112] compared the 
pharmacokinetics and pharmacodynamics of 2 formulation of MPA: MMF and the extended 
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release EC-MPS in kidney transplant recipients. They observed a similar degree of inhibition of 
IMPDH between the 2 formulations. As suggested by Budde et al [109] additional analysis of 
IMPDH activity can facilitate in better interpretation of the pharmacokinetic data. The estimated 
half maximal inhibitory concentration (IC50) of 0.97 µg/ml was lower than the observed MPA 
plasma concentration of 1-5 µg/ml.  The integrated PK-PD model in pediatrics estimated an IC50 
of 1.7 µg/ml [35]. 
A  PK-PD study [113] comparing intensified  regimen (days 0 through 14: 2880 mg/day; 
days 15 through 42: 2160 mg/day; followed by 1440 mg/day) versus standard dosing (1440 
mg/day) of EC-MPS suggested that intensified regimen resulted in significantly higher MPA 
exposure and also lower IMPDH activity on day 3 after transplantation (P<0.05). Also, BPAR 
was lower (2.6%) in the intense regimen group as compared to standard dosing regimen (13.5%).  
However, the overall safety was comparable between the 2 groups.  
MMF dose reductions are known to be associated with inferior graft outcomes. Few 
studies have investigated the association between transplant naïve IMPDH activity, MMF dose, 
reduction in dose and the outcomes in transplant recipients. Glander et al. [114] from their study 
concluded that 62.5% of patients on standard MMF dose (1 g BID.) requiring dose reductions 
within 3 years post-transplant had significantly lower IMPDH activity. Another trial [115] in 
renal transplant recipients showed  an increasing trend  in the baseline IMPDH activity in 
rejecting as compared to the non-rejecting subjects (p=0.019). The study concluded that 
quantitation of the recipient's pre-transplant IMPDH activity in PBMC lysate could provide a 
useful tool for evaluating a recipient's sensitivity to MMF. Monitoring of pre-transplant activity 
in stem cell transplant recipients revealed contrasting results. A higher IMPDH activity was 
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associated with a lower rate of grades 2–4 acute and grades 3–4 acute GHVD (P=0.03) and lower 
day +28 T-cell donor chimerism ≥95. This could be explained by a previous study that showed 
that higher T cell chimerism was associated with higher probability of acute GVHD.  [116] 
These studies hint at the potential use of the pre-transplant and continuous IMPDH monitoring in 
the initial phase post- transplant as criteria to define rejection and infection phenotypes in 
transplantation.  
 
Figure 3 Relationship between total MPA concentration and ex-vivo IMPDH activity as fitted using an Emax 
model (r
2
=0.68) in 18 stable kidney transplant recipients. 
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1.6.6 Modeling based MMF optimization 
Novel pharmacometric approaches are being used to optimize dosing of drug with narrow 
therapeutic index. It encompasses the application of mathematical and statistical approaches to 
characterize the pharmacokinetic and dynamics of the drug. It plays an important role in early 
stage leading into phase I trials to drug approval and labeling decisions.  There has been an 
increase in the use of modeling and simulation in new drug applications filings submitted to the 
regulatory agency. Pediatric pharmacometric reviews increased by 5 times from 2000 to 2008. 
Modeling and simulation will play a significant role in pediatric drug applications with the use 
rising to a 100% by 2020. [117] 
MPA is not just characterized by its narrow therapeutic index, but also has a large inter 
and intra-patient variability leading to poor dose-exposure response. Most modeling approaches 
for describing MPA pharmacokinetics have used non-linear mixed effects modeling by 
describing pharmacokinetic parameters as fixed effects associated with inter and intra individual 
variability. NONMEM allows use of sparse data across studies conducted with small sample 
size. Most of population analyses of total and unbound MPA were conducted in adult and 
pediatric solid organ transplant patients. In most studies a 2- compartment model with and 
without lag time was used as the structural model. A few advanced mechanistic models have 
been described to incorporate enterohepatic recycling and exposure associated with it in the 
model in patients with childhood-onset systemic lupus erythematosus [36], and renal transplant 
recipients [118].  
There were significant differences in pharmacokinetics of MPA across transplant 
population and across adults and pediatric subjects. For example, clearance was seen to be higher 
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in adult and pediatric stem cell transplant recipients (24.2L/h -36.9L/h) [53, 119] as compared to 
solid organ transplant recipients (12.9L/h to 17 L/h). [37, 120]. Table 4 summarizes the median 
(range) pharmacokinetics of MPA for same dose in adult and pediatric solid organ and HSCT 
patients. Effect of different covariates like concomitant tacrolimus or cyclosporine 
administration, MMF dose, albumin concentration, creatinine clearance, age, weight, time pot-
transplant, genotype on bioavailability, clearance and volume of distribution were also evaluated. 
 
Table 4. Comparison of Pharmacokinetic parameters of MPA after 1mg BID dose of MMF in adult 
and pediatric solid organ and HSCT patients. 
Pharmacokinetic 
Parameters 
  
Adult Kidney 
transplant 
Pediatric Kidney 
transplant 
Adult HSCT Pediatric HSCT 
Clearance (L/h) 
(mean) 
32[121] - 45[24] 42[12] 
AUC
0-12
 (µg*hr/mL) 28 (14.4-
58.8)[40] 
33.5 (13.9-58.4) 
[40] 
19 (8.7-35.2) 
[122] 
12.5 (4.5-49.2) 
[123] 
Cmax (µg/mL) 8.9 (2.5-
24.7)[40]  
18.8 (5.3-45.7) 
[40] 
4.8 (2-11.4) 
[122] 
5 (1.8-18) [123] 
 
 
Bayesian modeling enables estimation of AUC using sparse sampling and D-optimally 
sampled dataset. By using Bayesian algorithms, flexible and clinically feasible sampling 
windows can be designed.  Bayesian estimation of individual AUC was done based on three 
blood sample measurements and covariates. The predictive performances of the Bayesian 
procedure were evaluated in an independent group of patients. Samples drawn at 20 minutes, 1 
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and 3 hours post dose gave the best estimation of individual AUC with acceptable accuracy (bias 
7.7%) and precision (RMSE 12.4%) [124]and in another study with a bias (% RMSE) of -5.7% 
(20.5%), -8.2% (14.4%), and +0.4% (12.0%) on D7, D30 and more than 3 months post-
transplant [125]. Another study has reported sampling times of pre-dose (0 hr), 1 and 4 hours 
post-dose for estimation of overall AUC [126]. Other studies have used more sampling points for 
up to 6 [127] and 12 hours [128] for estimation of AUC.  
A more clinically practical tool in the form of a web-based Bayesian estimator was 
developed by researchers in France. The tool individualized MMF dose and estimated 
pharmacokinetic parameters based on demographic data, co-medication and MPA concentrations 
sampled at 20min, 1 hour and 3 hours post-dose. A retrospective study evaluating the impact of 
this tool showed that 72-80% of the AUCs estimated with this tool were within the target 12-
hour AUC 0f 30-60µg/mL [129]. Although these methods are accurate (bias <10%), they have 
inconsistent precision with %RMSE ranging from 4-34% [130]. Nevertheless, these observations 
do provide substantial evidence that Bayesian dosage prediction can be used clinically for 
achieving target MPA AUC. 
In the past decade, physiologically based pharmacokinetic modeling is increasingly used 
in the industry for prediction exposure of new drug. It is also used for better understanding the 
physiological factors that may affect the drug exposure and consequently the drug response. It is 
a ‘bottom up’ approach as it accounts for a drug’s physico-chemical properties like logP, 
molecular weight permeability and the pathophysiological factors and trial design into the built 
model and gives a better control on determining the factors that could affect a drug’s exposure. 
The classical ‘top down’ approach (Figure 4) is generally based on the observed PK, data, 
empirical compartmental kinetic data and population PK-PD data. The top down approach is 
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limited in its capacity to capture the changes in PK due to absorption, EHC and DDIs. Although 
this approach has been extensively used for describing PK of immunosuppressive drugs like 
tacrolimus and sirolimus, there is no data on MPA. Recently, Stemkens et al [131], described a 
PBPK model of MPA using Gastroplus®, a commercially available software. However, this 
model was not well validated.  
 
 
Figure 4 Schematic representation of typical PBPK modeling strategy 
  
38 
 
1.7 PATIENT POPULATION IN THE CURRENT STUDY 
Since its approval for prophylaxis of organ rejection, MMF pharmacokinetics has been 
extensively studied in kidney and liver transplant recipients.  Different techniques to optimize 
MMF dosing have been studied.  The successful prophylactic use of MMF for acute rejection in 
solid organ transplantation has triggered increasing application of MMF in the prophylaxis and 
treatment of acute and chronic GVHD in HSCT and in other solid organ settings like lung and 
heart transplant recipients. Over the last decade MMF has been extensively used off label in 
HSCT and LT recipients but is not well studied in these populations. MPA monitoring and 
IMPDH activity measurements have been reported to be beneficial in kidney transplant 
recipients but it did not increase overall outcomes. This is primarily due to already high graft and 
patient survival in kidney transplant recipients. However, graft and patient survival is much 
lower in HSCT and LT recipients. While TAC and CsA monitoring optimizes their overall 
survival rate, there is scope to improve graft survival with MPA monitoring in lung transplant 
patients. Through this work we had a unique opportunity to characterize and suggest approaches 
for optimizing the use of MMF in the less studied HSCT and LT recipients.  
1.7.1 Stem cell transplant recipients 
Important aspects of the pharmacokinetics of MPA in HSCT patients include lower exposure 
than other populations with substantial intra and inter-individual variability.  Various factors that 
are unique to stem cell transplantation can lead to differences in pharmacokinetics of MPA in 
these patients. These patients often suffer from mucosal injury in the GI tract caused by 
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chemotherapy and/or radiation therapy, presence of GVHD and graft-versus-tumor (GVT) effect 
and concomitant use of other medications. Also unlike SOT, the immunosuppression is tapered 
off and eventually discontinued making it very crucial to monitor MPA disposition in the early 
phase post-transplant when there is a higher likelihood of development of GVHD [132]. 
The glucuronide metabolite MPAG undergoes enterohepatic recycling and is converted 
back to MPA by gut bacteria which contributes to 40% of MPA AUC [10].  Enterohepatic 
recycling is however not observed in stem cell transplant recipients [133, 134]. This may be 
explained by the mucosal damage associated with chemotherapy and loss of gut bacteria due to 
the use of antibacterial agents. Another important factor is the relatively lower and highly 
variable bioavailability seen in HSCT patients reported in a few studies.[135-137]  
Third major reason could be the increased MPA clearance. Based on a population 
pharmacokinetic analysis study in HSCT patients, weight normalized MPA clearance was higher 
in smaller children and showed a downward trend with increasing body weight [138]. The 
mechanisms underlying these age-dependent differences are unclear but are probably related to 
developmental changes in all components of drug disposition. 
The relationship between MMF exposures and its efficacy is still unclear, and optimal 
targets have yet to be defined in HSCT patients, especially in pediatric patients. Current MMF 
dosing strategies warrant careful evaluation to ensure optimal plasma concentrations, dosing 
regimens, duration of therapy and upper limit of toxicity for individuals. To elucidate the 
advantage of MMF use in the HSCT population, multi-center sufficiently powered 
pharmacokinetic and pharmacodynamics studies focused on personalized dosing are needed to 
improve clinical outcomes in HSCT patients. 
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1.7.2 Pediatric patients 
 MMF had been used off-label in pediatric kidney transplantation before 2001.  A study [139] 
conducted in 1998 showed that MMF in combination with CsA and steroids was well tolerated in 
children between 4 and12 years for the treatment of acute rejection in kidney transplantation. 
The US license specifies a much younger age limit of 3 months on the label. In the UK, it is only 
licensed for kidney transplantation in combination with corticosteroids and cyclosporine in 
pediatric patients for age 2 years and over. 
Many of the studies that reported   PK data in children were conducted as a part of adult 
trials and included only a small number of children. There is a scarcity of exclusive randomized 
clinical trials in children. The manufacturer recommended pediatric dose is 600 mg/m2. PK 
profiles of MPA when dosed as 600 mg/m2 twice daily in combination with CsA are comparable 
with those in adults on 1 g daily dosing [140]. 
There are no regulatory guidelines for MMF dosing in children and it is often 
extrapolated from adult data at an initial dosage of around 40 mg/kg/day [141]. Some studies 
have reported the need for higher doses of up to 50 mg/kg/day [142].  
Jacobson et al have studied MMF PK in pediatric HSCT population. Age related changes 
in clearance and polypharmacy as seen in HSCT patients, and the use of chemotherapy can have 
a substantial effect on pharmacokinetics in pediatric HCT recipients as compared to other SOT 
recipients and adult subjects. Very little information is available on the pharmacology of MPA in 
children following HSCT. In this work, we have characterized the pharmacokinetics of MPA and 
its metabolite and proposed a novel individualized dosing regimen based on PK. 
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Owing to higher clearance of MPA, MMF is dosed more frequently at every 8 hours in 
pediatric patients suggesting a need of a higher and more frequent dosing.  Higher MMF doses as 
used by Jacobson et al.  did not increase risk of infection complications and the risk of infection-
related mortality as compared to the lower dose. This  provides an opportunity to personalize 
novel MMF dosing strategies that provide a continued higher exposure for GVHD prophylaxis in 
pediatric HSCT patients. 
 
1.7.3 Lung transplant recipients 
In kidney and liver transplant one-year survival rate is over 90% and 5-year survival rate is 
nearly 80%. In LT recipients the 5-year survival is as low as 50%. Acute cellular rejection 
(ACR) continues to be a major problem.  This highlights the need of better immunosuppression 
protocols in this patient population. Tacrolimus and cyclosporine are routinely monitored in 
transplant patients. Although approximately 80 percent of lung transplant recipients in the United 
States receive MMF as a core constituent of their maintenance immunosuppression, MPA is not 
routinely monitored. This provides an opportunity for clinical researchers to optimize MMF 
dosing to improve outcomes in lung transplant recipients.   Among the solid organ transplant 
recipients, lung transplant population is the least studied for monitoring MPA pharmacokinetics. 
There is a scarcity of PK studies in lung transplant recipients let alone an individualized MMF 
dosing study based on limited sampling strategy. Also, there have been no reports of IMPDH 
monitoring in lung transplant recipients. Although immunosuppression regimens have 
significantly improved in lung transplant recipients, there is no consensus on the optimal dosing 
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regimen and there are no FDA approved medications to treat rejection making acute and chronic 
transplant rejection the important obstacles to successful lung transplantation [143]. There are 
very few studies conducted exclusively in lung transplant patients without cystic fibrosis.  All 
existing studies in LT recipients show that MPA exposure is low in these patients. There are no 
systematic PK-PD studies conducted to facilitate the understanding of disposition of MPA in this 
population. Clinical studies should be designed to exclusively focus on identification of MMF 
dosing strategies to optimize efficacy and minimize rejection in lung allograft recipients. The 
purpose of a pilot study conducted as a part of this work was to characterize the pharmacokinetic 
profile and evaluate the pharmacodynamics activity of MPA in adult LT recipients.  
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1.8 HYPOTHESIS 
HSCT and LT recipients are characterized by poor post-transplant outcomes due to higher rates 
of infection and rejection. These transplant populations provide researchers an opportunity to 
optimize immunosuppression regimen. The CNI inhibitors, TAC and CsA are monitored 
routinely and doses are titrated to a target exposure. Although MMF is increasingly being used as 
a part of maintenance immunosuppression is not monitored and is instead given as a fixed dose. 
A complete understanding of the pharmacokinetics and pharmacodynamics MMF and its active 
(MPA) and inactive (MPAG) metabolites in transplant patients will help in optimizing MMF 
based immunosuppression in transplant patients, especially in the less studied lung transplant and 
pediatric stem cell transplant recipients. We hypothesize that 
1) Fixed-dose flat dose of MMF will lead to suboptimal exposure and a large inter-
subject variability in the exposure of MPA in HSCT and LT patients. 
2) Pharmacokinetic monitoring and exposure-based individualization in the early 
post-transplant phase will facilitate a better control on patients’ immunosuppression 
regimen and impact long term outcomes.  
3) A PBPK model can form the basis for future modeling-based studies and dosing 
recommendations in transplant patients.  
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4) Pharmacokinetic and pharmacodynamic monitoring of MMF in lung transplant 
recipients could provide a more feasible way to measure mycophenolate activity within 
lung transplant recipients in order to optimize therapy.  
We have evaluated the above hypotheses in pediatric stem cell transplant recipients and 
lung transplant using novel dosing regimen (Chapter 2.0 ), PK-PD (Chapter 3.0  and 4.0 ) and 
modeling (Chapter 5.0 ) approaches. 
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1.9 GAPS IN CURRENT MMF DOSINF AND OPPORTUNITIES FOR 
IMPROVEMENT 
There is extensive data on pharmacokinetics of MPA and MPAG in liver and renal transplant 
patients. MPA exposure is well correlated with clinical outcomes. Moreover, these solid organ 
transplant population has more than 80% graft and overall survival in 5 years. Pharmacokinetics 
of this drug is however not studied extensively in lung and HSCT patients. This provided us a 
unique opportunity to study the PK of MPA in these populations and improve graft survival in 
pediatric HSCT and LT patients by personalizing MMF dosing. 
Limited sampling strategies for monitoring MPA PK together with PD measurement have 
been developed, validated and extensively used in kidney and liver transplant recipients but their 
utility has not yet been established in pediatric HSCT and LT patients owing to low cell count 
and limitations of PD assay. There is an unmet need of establishing highly sensitive ands robust 
assays for quantitation of PK and PD activity with a shorter turnaround time and can be 
potentially used for therapeutic drug PK and PD monitoring of MPA.  
PBPK modeling strategies have been established and successfully used for to explain the 
variability in exposure and bioavailability for other immunosuppressive drugs like 
sirolimus[144] and provided insight into its disposition and factors contributing to between 
subject variability. A PBPK model has not been ever developed and validated in healthy or 
transplant population. This gave us an opportunity to build and validate as PBPK model for MPA 
and extend its use further to individualize dose adjustments. 
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1.10 SCOPE AND SPECIFIC AIMS OF THIS WORK 
Since the introduction of MMF in 1995 for treatment of rejection in transplantation, significant 
clinical research has been done to optimize and individualize MMF therapy in transplant 
patients. All these efforts are targeted to improve graft survival and prevent infection. . In kidney 
transplant recipients, there is an association between the exposure as measured by the AUC and 
the rejection free survival outcomes. Graft and patient survival is more than 90% in kidney 
transplant patients. However, in LT recipients, the national survival rate averages reported in the 
US by UNOS are at a staggering 51 % at 5 years. Higher incidence of infection is also observed 
in LT patients.  Immunosuppressive drugs play a prominent role in the overall outcomes post LT.  
The calcineurin inhibitor like CsA and TAC that form the backbone of immunosuppressive 
therapy are routinely monitored. MMF, which is used in 80% of the transplant centers in the US 
drugs is not monitored in spite of the high inter and intra-patient variability. It is used off label as 
a fixed flat dose in LT patients. Although 12-hour AUC of 30-60 µg*hr/ml has been established 
as a target through various studies in kidney transplant patients, the lack of clinical feasibility of 
such studies urges for LSS as a viable option for PK monitoring.  IMPDH activity, the 
pharmacological target of MPA is related to the MPA exposure and can be used as a surrogate 
marker to quantitate MPA based immunosuppression. However, there are very few prospective 
clinical studies that have explored the PK-PD of MPA in LT recipients. The retrospective study 
in this work was designed to investigate the association between incidence of infection and 
rejection during the first-year post lung transplant with trough IMPDH activity. The prospective 
component of this study was designed as a pilot PK-PD study to characterize the PK of MPA and 
explore its association with PD response as measured by the ex-vivo IMPDH activity.  
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 MPA PK is not well studied in pediatric HSCT patients. There are no guidelines for 
MMF dosing in pediatric HSCT patients. Also, the kinetics of MPA in these patients is 
characterized by a short half-life resulting in sub-therapeutic levels within 4 hours of dosing. As 
HSCT patients are not able to tolerate oral dosing, this necessitates a clinically impractical more 
frequent IV dosing of MMF. The alternative regimen to maintain optimal levels is a novel 24-
hour continuous infusion (CI) of MPA.   This CI based dosing strategy has been used for the CNI 
drugs but has not been tested for MMF. This, to our knowledge is the very first attempt of dosing 
this drug as a CI to improve outcomes.  
The high inter and intra-patient variability in MPA exposure, small therapeutic window and lack 
of correlation between trough levels of MPA and overall exposure necessitates the need for 
better dosing strategies for MMF. Therefore, the overall aim of this dissertation was to explore 
different approaches to individualize the MPA therapy and improve clinical outcomes in MPA 
treated transplant recipients. 
Personalizing drug dosing can be achieved by various approaches. Through this 
dissertation work we attempted to evaluate different PK, PK-PD and modeling strategies to 
optimize dosing of MMF in transplant patients. We expect that the observed findings will make 
for a strong foundation for dosing strategies aiming at individualized MPA therapy in transplant 
recipients. The objectives for individual chapter are as follows: 
1) To evaluate safety and feasibility of AUC-based mycophenolate mofetil targeting 
for GVHD prophylaxis in pediatric patients undergoing hematopoietic stem cell 
transplantation.  To evaluate the utility of a novel CI dosing regimen of MPA in pediatric 
HSCT recipients (Chapter 2.0 ). 
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2) To explore the pharmacokinetics of MPA in adult lung transplant recipients and 
explore the PK-PD relationship between MPA exposure and IMPDH activity. 
(Chapter 3.0 ) 
3) To establish the feasibility of pharmacodynamic monitoring ex-vivo in adult lung 
transplant recipients (Chapter 4.0 ). 
4) To establish and validate a physiologically based pharmacokinetic (PBPK) model 
of MPA in healthy Caucasian and Chinese adult population and to predict the exposure of 
MPA in pediatric population (Chapter 5.0 ). 
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2.0  PHARMACOKINETICS OF INTRAVENOUS, ORAL AND A NOVEL 
CONTINUOUS INFUSION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE 
METABOLITE IN PEDIATRIC STEM CELL TRANSPLANT RECIPIENTS 
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2.1 ABSTRACT 
Mycophenolate mofetil, an ester prodrug of MPA, is used increasingly for GVHD prophylaxis. 
Dose-escalation strategies in pediatric hematopoietic stem cell transplantation recipients have 
failed to achieve target MPA exposure. Here we have described the pharmacokinetics and 
clinical results of a new MMF dosing approach in pediatric HCT recipients undergoing 
myeloablative transplantation. We have evaluated the safety and feasibility of a 
pharmacokinetics-based dosing approach using a novel CI method of administration of MMF in 
pediatric HSCT recipients. All patients received a myeloablative conditioning with cyclosporine 
A and MMF for GVHD prophylaxis. Blood samples were collected from 19 patients over a 
dosing interval. They were initiated on day 0 at a dose of 15 mg/kg every 8 hours. 
Concentrations of MMF, MPA, MPAG in the plasma were measured using HPLC coupled with 
mass spectrometry. Non-compartmental pharmacokinetic analysis was performed using 
WinNonlin. Based on pharmacokinetic data from IV short infusion, MMF was converted to CI to 
target a Css of 1.7-3.3 µg/ml corresponding to a total MPA AUC0-24 of 40 to 80 µg*hour/mL. The 
MMF dose was adjusted to maintain a total MPA steady-state concentration (Css) of 1.7 to 3.3 
µg/mL.  
During the CI schedule, MPA AUC0-24 was maintained at a mean of 40.1 µg*hour/mL 
(range, 20.6 to 63.8), and 17 of 19 patients (89%) achieved MPA Css within target of 1.7 to 
3.3 µg/mL. Ninety five percent of patients (18/19) achieved neutrophil engraftment at a median 
of 13 days (range: 8 to 41) post-transplant and platelet engraftment at 39 days (range: 17 to 298) 
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days post-transplant. Six of 18 assessable patients (33%) developed stages II to IV acute GVHD 
and 2 of 15 (13%) developed chronic GVHD. The MMF dose was reduced in 9 patients due to 
gastrointestinal symptoms (n=6), low blood counts (n=4), and viral infection (n=3). Five patients 
with acute lymphoblastic leukemia relapsed, of whom 4 have died. Fifteen of 19 patients are 
alive with a median follow-up of 2.4 years (range, 0.4 to 4.9), with 3-year event-free and overall 
survival rates of 68% and 79%, respectively. 
In this pilot study, we observed no toxic deaths, excellent engraftment, and low rates of 
grades III to IV acute and chronic GVHD. We observed significantly shorter half-life and higher 
drug clearance in pediatric HCT recipients compared with stable pediatric renal transplant 
patients or adult transplant patients. CI regimen deserves further validation in a larger cohort of 
pediatric patients undergoing myeloablative transplantation. 
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2.2 INTRODUCTION 
Graft-versus-host disease is the major cause of morbidity and mortality after allogeneic HSCT 
second only to the primary disease that may lead to death in these patients [145]. Different 
centers implement various GVHD prophylaxis protocols, but they all include administration of a 
calcineurin inhibitor, either cyclosporine A or tacrolimus, and a second agent, such as 
methotrexate. The rate of grades II-IV acute GVHD (aGVHD) is high despite the use of 
methotrexate along with calcineurin inhibitors. Studies have shown that methotrexate post-
transplant is often associated with an increase in risk of mucositis, delay in time to myeloid 
engraftment, and potential pulmonary toxicity [146]. Over recent years, mycophenolate mofetil 
has increasingly been used off-label in adults and pediatric stem cell transplant patients. 
Replacement of methotrexate with MMF has been associated with a faster engraftment time and 
reduced risk of mucositis [147]. Although the incidence of grades II to IV aGVHD appears to be 
similar, recent data, including a meta-analysis that compared MMF with 
methotrexate/calcineurin inhibitor, suggested a higher incidence of grades III to IV aGVHD with 
MMF [148, 149]. 
 Clinical pharmacokinetic studies evaluating the pharmacokinetics of MPA in pediatric 
HSCT patients [123, 150, 151] are scarce primarily due to concerns over volume of blood that 
can be drawn for pharmacokinetic analysis [152]. The current dosing strategies in pediatric 
HSCT patients are based on body weight or body surface area. However, age-dependent 
pharmacokinetics of MPA has been reported in several studies [39, 40, 123]. The terminal half-
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life in adult and pediatric solid organ transplant patients has been reported to be 8 to 12 hours 
[153]. However, much shorter half-life has been observed in HSCT patients. The observed 
shorter half-life in HCT patients suggests the need for at least a three or four times daily dosing 
regimen of MMF in pediatric patients [154]. There are no guidelines for dosing of MMF in 
pediatric HSCT patients and dosing regimen has primarily been extrapolated from exposure data 
in solid organ transplant recipients. Exposure response relationships for MPA are much better 
defined in adult kidney recipients, in whom the established therapeutic exposure is a total MPA 
AUC0-12 of 30-60 µg*hour/mL or trough concentrations in the range of 1 to 3.5 mg/mL[155]. 
Pharmacokinetics studies suggest lower MPA exposure in HCT recipients, with some studies 
showing exposure as low as 30% to 50%, with standard starting MMF doses that are used in 
kidney transplant recipients. These studies also suggested a higher dose requirement of MMF 
dose. The unbound MPA AUC in the immediate week post-transplant was seen to be 
significantly associated with a greater cumulative incidence of grade II-IV GVHD [122, 156, 
157]. After intravenous or oral administration of MMF to pediatric HCT patients, the plasma 
concentration drops to < 1µg/ml within 4 hours post dose. Low MPA trough levels have been 
associated with higher rates of aGVHD and graft rejection and lower response rates in the 
treatment of aGVHD [151, 154, 158].    
Several dose escalation and frequent dosing strategies have failed to achieve consistent 
MPA exposure, especially in the early post-transplant period after conditioning therapy [136]. 
Haentzschel et al.[159] demonstrated feasibility of MMF dosing to a targeted AUC in adult 
HSCT recipients. However, increasing the dose of MMF has often lead to higher MPA 
concentrations and corresponding increase in toxicity[150]. Increasing the frequency of dosing, 
given the short half-life, is also not very practical. An alternative method to achieve target MPA 
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levels and avoid high drug exposure is to dose MMF as a CI, the way cyclosporine and 
tacrolimus are administered. Here we have described the pharmacokinetics and clinical outcomes 
of this novel MMF dosing approach in pediatric HSCT recipients undergoing myeloablative 
transplantation. 
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2.3 MATERIALS AND METHODS 
2.3.1 Patients 
This study was performed in pediatric patients receiving allogeneic stem cell transplant at the 
Children’s Hospital of Pittsburgh of the University of Pittsburgh Medical Center between 
December 2009 and May 2013. The study was approved by the University of Pittsburgh 
institutional review board (IRB# 09120501) and registered at www.clinicaltrials.gov 
(NCT01487577). Informed consent was obtained from the guardians, and assent or consent from 
patients in accordance with the Declaration of Helsinki. Patients meeting the following inclusion 
criteria were included in the study.  
Inclusion Criteria: 
1) Age 6 months to 21 years 
2) Myeloablative conditioning 
3) HLA-identical sibling donor, HLA-A, -B, -C, and -DRB1 allele-matched unrelated 
volunteer donor, or 4 of 6 HLA-A, -B, and -DRBb1 allele-matched cord blood unit 
4) Cord blood units: minimum pre-freezing nucleated cell dose of 3 107 /kg for malignant 
diseases and 5 107 /kg for nonmalignant diseases.  
Exclusion criteria: 
1) HIV infection or uncontrolled bacterial, viral, fungal, or other infection 
2) Prior HSCT within 12 months 
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3) Organ dysfunction defined as total serum bilirubin > 2.5 mg/dL or liver enzymes 5 times 
the upper limit of normal for age, glomerular filtration rate < 70 mL/min/1.73 m2 , left 
ventricular ejection fraction ≤ 40%, or shortening fraction ≤ 26% and forced expiratory 
volume in 1 second (FEV1), forced vital capacity (FVC), and carbon monoxide diffusing 
capacity (DLCO) ≤ 50% of predicted or if unable to perform pulmonary function tests, 
O2 saturation ≤ 92% of room air\ 
4) Lansky or Karnofsky performance score ≤ 70%.  
2.3.2 Study Design 
2.3.2.1 Conditioning and GVHD Prophylaxis Regimen 
All patients received a myeloablative conditioning regimen consisting cyclophosphamide or 
busulfan and cyclophosphamide. Patients receiving allogeneic bone marrow or umbilical cord 
blood transplants received anti-thymocyte globulin (ATG) at a dose of 30 mg/kg/day for 3 days 
or fludarabine at a dose of 30 mg/m2/day for 5 days. Cyclosporine and MMF were used as 
GVHD prophylaxis agents. Intravenous cyclosporine was started 2 days prior to transplant as a 
continuous infusion at a dose of 5 mg/ kg/day and adjusted to maintain whole blood Css of 160 
to 250 ng/mL. Patients were switched to oral therapy when they tolerated oral intake and 
continued upto 100 days. In the absence of aGVHD, the dose of cyclosporine was tapered by 
approximately 10% per week through day 180.  
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2.3.2.2 MMF Dosing and Pharmacokinetics 
Intravenous MMF was initiated at a dose of 15 mg/kg every 8 hours from day 0 and administered 
as a constant 2-hour infusion. The first MMF pharmacokinetics study was performed after a 
minimum of 5 doses to allow achievement of steady state. Based on the total body clearance 
calculated from the i.v. pharmacokinetics study, MMF was administered as an intravenous 
continuous infusion over 24 hours using a solution of 10 mg/mL MMF in 5% dextrose in water, 
at an infusion rate (infusion rate=Css X total body clearance) to achieve a target total MPA 
AUC0-24 of 40 to 80 µg*hour/mL. Oral dosing of MMF thrice a day was initiated when patients 
were able to tolerate oral medications. MMF was continued until day 42 and, in the absence of 
aGVHD, tapered off over 8 weeks. A flowchart of the study design is represented in Figure 5 . 
 
Figure 5. Study Design of Pharmacokinetic study of MMF in pediatric stem cell transplant 
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2.3.3 Blood Sampling and Assay 
Blood samples (2 mL) were drawn in ethylenediaminetetra acetic acid (EDTA)-containing 
Vacutainer tubes, placed on ice and refrigerated immediately, and centrifuged at 4°C at 3000 rpm 
for 10 minutes using an Eppendorf Centrifuge 5702R (Hauppauge, NY). Samples were 
processed within 30 to 60 minutes of blood draw. The plasma concentrations of MMF, total 
MPA and MPAG were measured using a validated HPLC mass spectrometry method (Waters 
Corporation, Milford, MA). The coefficient of variation of the assay was less than 10% of all 
concentrations tested. Serial blood samples were collected within a dosing interval by taking 
samples just before the dose (0 hour) and at 2, 3, 4, 5, 6, and 8 hours post-dose. While on CI of 
MMF, total MPA levels were measured thrice a week and on an average MMF dose was 
adjusted 3 times for patients in order to maintain a total MPA Css of 1.7 to 3.3 µg/mL. The 
pharmacokinetics study of oral dosing was performed after a minimum of 5 doses thereby 
allowing the drug to reach steady state. Serial blood samples were collected over a single dosing 
interval just before the dose (0 hour) and at 0.5, 1, 2, 3, 6, and 8 hours. While on oral MMF, total 
trough MPA levels were measured 3 times weekly, with dosing adjustments made to maintain a 
total MPA trough concentration (Ctrough) of 1 to 3.5 µg/mL. 
2.3.4 Non-Compartmental Pharmacokinetic Analysis 
Pharmacokinetic analysis for MMF, MPA and MPAG was done by noncompartmental analysis 
using WinNonlin software (version 6; Pharsight Corp, Mountain View, CA). The maximum 
concentration in plasma (Cmax) and the time to Cmax (Tmax) were estimated by visual inspection of 
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the concentration versus time profiles. The terminal elimination rate constant (λz) was estimated 
by linear regression of at least the last 3 data points, and half-life (t1/2) was calculated by dividing 
0.693 by λz. The area under the plasma concentration-time profile from the time of dosing until 
infinity was calculated by the log-linear trapezoidal method in WinNonlin with extrapolation 
beyond the last measured concentration, according to: AUC0- ∞ = AUC0-8 + C8/ λz. AUC0-8 at 
steady state is equivalent to AUC0- ∞ after a single dose. AUC0-24 at steady state was estimated as 
3* AUC0-8 at steady state Total systemic clearance (CL) was estimated using the equation CL = 
Dose / AUC0- ∞ and the volume of distribution at steady state (Vss) was determined from area 
under the moment curve using the following equations: Vss= [(Dose)*(AUMC0- ∞)/ (AUC0- ∞) 
2
]. 
Results are reported as median and range. We also calculated AUC by using samples collected 
upto 4 hours. 
2.3.5 Safety Assessment 
Safety Endpoint and Criteria for MMF Dose Modification Key safety endpoints were day 100 
transplant-related mortality, grades III to IV aGVHD, and neutrophil engraftment. Patients were 
monitored for any grade III or greater adverse events, using Common Terminology Criteria for 
Adverse Events (version 4.0). Study guidelines for MMF dose reduction or discontinuation were 
based on BMT Clinical Trials Network trial 0802 (https://web.emmes.com/study/ 
bmt2/protocol/0802_protocol/0802%20aGVHD_v3.pdf). All patients received antifungal, 
antiviral, and antibacterial prophylaxis in accordance with standard practice at our institution. 
Filgrastim was given to all transplant recipients from the day of transplant and discontinued at 
achievement of myeloid engraftment as per the treating physician.  
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2.3.6 Clinical Endpoints  
Neutrophil engraftment was defined as 3 consecutive days of an absolute neutrophil count > 
0.5  x 10
9
 /L after transplantation. Platelet engraftment was defined as a platelet count of more 
than 20,000/mL without transfusion for up to 7 days leading into it. aGVHD was scored based on 
the modified Keystone criteria and Chronic GVHD diagnosis and grading were based on the 
2005 National Institutes of Health Consensus Conference [160, 161]. The major clinical study 
endpoints were sustained donor engraftment, incidence and severity of GVHD, relapse, and 
overall survival. 
2.3.7 Statistical Analysis 
The primary endpoint of the study was to determine the safety and feasibility of personalized 
AUC-based MMF dosing approach according to the plasma levels. Linear regression was 
performed top determine the correlation between 4 hour AUC to overall exposure.  Secondary 
endpoints were engraftment as measured by platelet and absolute neutrophil count, the incidence 
and severity of aGVHD, and the risk associated with persistence and or recurrence of disease. 
Survival analysis and progression-free survival were estimated from Kaplan-Meier curves using 
censoring at last follow-up or on death. Categorical variables are represented as frequencies and 
percentages while continuous variables are summarized as mean± standard deviation and range 
of values. Owing to the small sample size, nonparametric tests were used, and a multivariate 
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analysis was not performed. Fisher’s exact test was used to compare dichotomous variables, and 
the Wilcoxon rank sum test was used to compare continuous variables. A statistical comparison 
of different parameters was made using a paired, 2-tailed Student t-test. p < 0.05 was considered 
statistically significant. All statistical analysis was performed using SPSS.  
62 
 
2.4 RESULTS 
2.4.1 Patient and Transplant Characteristics  
Patient and transplant characteristics are summarized in Table 5. All assessable patients (N=19) 
have completed MMF therapy and are included in MMF pharmacokinetic and clinical outcomes 
analyses with a median follow-up of 2.4 ±1.5 years (range= 0.4 to 4.9). The mean age at 
transplant was 9.0±6.8 years (range: 0.9 to 21.0). Ten patients were female and 9 were male. 
Seventeen patients were transplanted for hematologic malignancies and 2 patients for 
nonmalignant diseases. Eight of 12 cases with acute lymphoblastic leukemia were in second 
remission, 2 in first remission, 1 in third remission, and 1 primary induction failure; all 3 cases 
with acute myelogenous leukemia were in first remission. Patients were conditioned with 
cyclophosphamide-total body irradiation (n =11) or busulfan-cyclophosphamide (n= 8). In 
addition, of the 12 unrelated donor transplants, 9 patients received equine ATG and 3 received 
fludarabine.
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 Table 5. Summary of Patient and transplant characteristics 
 
Number of patients 19 
 
  
 
Age, y, mean + SD (range) 9.0 + 6.8 (0.9 – 21.0) 
 
  
 
Gender (female / male) 10 / 9 
 
  
 
Race/ethnicity  
 
  
 
Caucasian 15 
 
  
 
Asian Indian 2 
 
  
 
Black / Caucasian 1 
 
  
 
Black 1 
 
  
 
Diagnosis  
 
  
 
ALL 12 
 
  
 
AML / Therapy-related MDS 5 
 
  
 
Congenital erythropoietic porphyria 1 
 
  
 
Severe congenital neutropenia 1 
 
  
 
Stem cell source  
 
  
 
Sibling bone marrow 7 
 
  
 
Unrelated donor bone marrow 6 
 
  
 
Unrelated umbilical cord blood 6 
 
  
 
HLA allele match  
 
  
 
Sibling: HLA Identical 7   
 
  
 
Unrelated donor: A,B,C,DRb1,DQb1 matched 6   
 
  
 
Cord blood: A,B,C,DRb1 matched /mismatched 2 / 4   
 
  
 
Conditioning regimen  
 
  
 
Cy + TBI + Other 11 
 
  
 
Bu + Cy + Other 8 
 
  
 
Nucleated cell dose, median, range  
 
  
 
Bone marrow (n=11), x10E08/kg 2.80 (1.76-6.30)   
 
  
 
Cord blood, post-thaw (n=4), x10E07/kg 7.09 (4.18-13.10)   
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2.4.2 Pharmacokinetics of MMF, MPA and MPAG 
2.4.2.1 Pharmacokinetics of MMF 
It was feasible to prepare MMF solutions to contain adequate MMF for a CI over 24 hours. 
There were no infusion-related incidents in the patients. The first pharmacokinetics study was 
performed on intermittent IV, MMF after 3 to 5 doses. Based on the results of the first IV. 
pharmacokinetics study, MMF was administered as a CI after a median of 6 days (range: 4 to 12) 
after transplant. Patients were switched from CI to oral MMF after a median of 22 days (range: 
7 to 43). The second pharmacokinetics study was performed on conversion to oral dosing after 3 
to 5 doses. Patients were on MMF for a median of 94 days (range: 13 to 154), and the drug was 
weaned off after 47 days (range: 26 to 111).  
MMF was quantifiable during the short infusion phase with the maximum levels seen at 2 
hours at the end of infusion as seen in Figure 6 . After cessation of infusion the concentrations 
rapidly declined with most levels being below the limit of quantification for most patients.  
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Figure 6. Individual MMF concentration time profiles of 19 HSCT patients after a 2-hour short 
infusion of MMF given at a dose of 15mg/kg. 
 
2.4.2.2 Pharmacokinetics of MPA  
Table 6. Pharmacokinetic parameters of MPA post IV short, IV continuous infusion and Oral dosing 
(expressed as median (range)) 
 PK parameters (units) Short Infusion (n = 19) Continuous Infusion (n = 19) Oral (n = 14) 
Half-life (hours) 1.7 (1.2-2.2)   1.4 (1-2.2) 
Volume of distribution 
(L/kg) 
1.6 (1-5.4)   1.3 (.5-4.3) 
Clearance (mL/min/kg) 10.2 (6.8-30.8) 15.1 (7.2-73) 10.9 (4.9-26.6) 
AUC0-24(μg·hour/mL) 46.5 (16.7-65.9) 40.1 (20.6-63.8) 36.1 (11.9-95.9) 
Ctrough (μg/mL) 0.35 (.1-.7) — 0.6 (.15-3.8) 
Cavg (μg/mL) 1.9 (.6-2.7) 1.7 (.9-2.7) 1.5 (.5-4.0) 
Mean Cmax(μg/mL) 5.9 (1.5-9)   5.6 (1.3-12.1) 
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Short infusion:   
There was a considerable inter-patient variation in MPA pharmacokinetics (Figure 7and Table 
6). The median values were Cmax 5.9 µg/mL (range, 1.5 to 9), half-life 1.7 hours (range, 1.2 to 
2.2), and AUC0-24 46.5 µg*hour/mL (range: 16.7 to 65.9). There was a 4-fold inter-patient 
variability in total AUC between patients. The Ctrough MPA plasma concentrations (median: 0.35 
µg/mL; range: 0.1 to 0.7) were poorly correlated with the total AUC0-24 (r
2
 = 0.37), while the 
AUC0-24 correlated well with the 4-hour abbreviated AUC (r
2
 > 0.98) (Figure 8).  
 
Figure 7. Concentration time profiles of MPA in 19 pediatric HSCT patients on IV short infusion of 
MMF dosed at 15mg/kg. 
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Figure 8. Correlation of estimated AUC0-24 (3* AUC0-8) versus AUC0-4 of MPA in 19 pediatric HSCT 
patients on IV short infusion of MMF 
 
 
 
Continuous Infusion:  
On CI administration of MMF, the median pharmacokinetic values were Css 1.7 µg/mL (range: 
0.9 to 2.7), clearance 15.1 mL/min/kg (range: 7.2 to 73), and AUC0-24 40.1 µg*hour/ mL (range: 
20.6 to 63.8). There was a 4-fold variation in the Css and over 6-fold variation in the total body 
clearance of MPA. Regression analysis showed no time-dependent change in total body 
clearance of MPA. With CI administration of MMF, the plasma MPA concentrations were 
achieved within a 1.7- to 3.3-µg/mL target in 17 of 19 patients (89%) (Figure 9and Table 6). The 
steady state clearance of individual patient during the IV continuous dosing is depicted in Figure 
10 and individual clearance showed no time dependent changes as depicted in Figure 11. 
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Figure 9. Steady state concentrations in 19 pediatric HSCT patients on continuous IV infusion of 
MMF 
 
 
 
Figure 10. Steady state clearance of 19 HSCT patients on continuous IV infusion of MMF  
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Figure 11. Weight normalized clearance over time in 19 patients receiving 24-hour continuous dosing 
of MMF 
 
 
 
 
Oral administration:  
There was a considerable inter-patient variation in MPA pharmacokinetics (Figure 12and Table 
6). The median values were Cmax 5.6 µg/mL (range, 1.3 to 12.1), half-life 1.4 hours (range: 1 to 
2.2), and AUC0-24 36.1 µg*hour/mL (range: 11.9 to 95.9). The Ctrough MPA plasma 
concentrations of 0.6 (range: 0.15 to 3.8) were poorly correlated with the total AUC (r2= 0.021); 
the AUC0-8 correlated well with a 4-hour abbreviated AUC (r
2
 > 0.99) (Figure 13). 
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Figure 12. Concentration time profiles of MPA in 14 pediatric HSCT patients after 15mg/kg TID 
dose of MMF. 
 
 
Figure 13. Correlation of estimated AUC0-24 hours versus AUC0-4 hours of MPA in 14 pediatric 
HSCT patients on oral MMF dosing. 
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2.4.2.3 Pharmacokinetics of Mycophenolic acid glucuronide 
Plasma concentration versus time plot of MPAG after intravenous administration is shown in 
Figure 14. The MPAG concentrations were on an average more than 6 times higher than the 
corresponding MPA concentrations. The derived pharmacokinetic parameters are given in Table 
7.  The concentrations of MPAG after oral administration were about 12-fold higher as compared 
to the MPA concentrations after oral dosing (Figure 15). Table 8 shows the MPAG/MPA ratio of 
the current study in comparison with data from other adult and pediatric solid organ transplant 
studies.  Both adult and pediatric HSCT recipients showed a higher MPAG/MPA ratio for both 
IV and oral dosing.  
 
Table 7. Pharmacokinetic parameters of MPAG post IV short, IV continuous infusion and Oral 
dosing in pediatric HSCT patients in the study 
  Short Infusion (n = 19) Continuous Infusion (n = 19) Oral (n = 14) 
AUC0- 24(μg·hour/mL) 576.3(213-1896.23) 923.7(36-5376) 1179.2 (458.4-
2296.5) 
Css (μg/mL) - 38.49(1.5-224) - 
Mean Tmax (hours) 2.3 (2-3) - 2.3(1-8) 
Mean Cmax(μg/mL) 37.1 (14-94.3) - 67.9(21.3-104.3) 
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Figure 14. Concentration time profiles of MPAG of 19 pediatric HSCT patients on IV short infusion 
of MMF 
 
Figure 15. Concentration time profiles of MPAG for 14 pediatric HSCT patients on oral MMF 
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8
M
P
A
G
 c
p
n
ce
n
tr
at
io
n
 (
µ
g/
m
l)
 
Time(hours) 
0
20
40
60
80
100
120
0 1 2 3 4 5 6 7 8
M
P
A
G
 C
o
n
ce
n
tr
at
io
n
 (
µ
g/
m
l)
 
Time (hours) 
73 
 
 
Table 8. MPAG/MPA AUC ratio of adult and pediatric solid organ and hematopoietic stem cell 
transplant recipients 
Median MPAG/MPA ratio 
Transplant 
Population 
Adult Pediatrics 
PO IV PO IV 
Post Kidney Tx 
(>3weeks) 
11.7[40] - 8.9[40] - 
Post Liver Tx 
(>3weeks) mean 
8.0[18] - 11.6[162] - 
HSCT  29.7 [156] 26.8 [156] 29.4(Current study) 12.1(Current study) 
 
2.4.3 Clinical Outcomes 
2.4.3.1 Engraftment 
Eighteen of 19 patients (95%) engrafted at a median of 13 days (range: 8 to 41). One patient with 
severe congenital neutropenia did not achieve donor engraftment and had autologous count 
recovery by day +43. Patients receiving bone marrow transplants engrafted at 11 days post-
transplant (range: 8 to 43), whereas those receiving umbilical cord blood transplants engrafted at 
17 days (range: 15 to 41) (p = 0.01). All patients achieved platelet engraftment at a median of 39 
days post-transplant (range: 17 to 298). Patients receiving bone marrow transplants engrafted at a 
median of 31 days post-transplant (range: 17 to 298), whereas those receiving umbilical cord 
blood transplants engrafted at a median of 52 days (range: 28 to 123) (p = 0.23). Cord blood 
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transplant recipients received similar CI doses of MMF (57 ± 25 mg/kg/day) compared with 
bone marrow transplant patients (44 ± 6 mg/kg/day; p = 0.19). Steady-state MPA concentrations 
were not significantly different between the 2 groups. 
2.4.3.2 GVHD 
Six of 18 assessable patients (33%) developed grades II to IV aGVHD. Three patients with grade 
II aGVHD achieved remission with steroid therapy, whereas the other 3 patients with grades III 
to IV aGVHD required additional agents to go into remission. While on an intermittent IV. 
schedule, mean MPA levels were 0.5 μg/mL in those with aGVHD versus 0.6 μg/mL in those 
without aGVHD (p = 0.4). Two of 15 assessable patients with a minimum 1-year follow-up 
developed moderate to severe chronic GVHD. Both patients are in remission; 1 is off treatment 
and 1 is undergoing systemic immunosuppressive therapy. 
2.4.3.3 Overall and Relapse free survival 
There were no toxic deaths. The patient with severe congenital neutropenia experienced 
autologous recovery by 43 days post-transplant. Five patients with acute lymphoblastic leukemia 
relapsed, of whom 4 have died. Fifteen of 19 patients are alive with a median follow-up of 2.4 
years (range: 0.4 to 4.9) and 3-year event-free and overall survival rates of 68% and 79%, 
respectively (Figure 16). Table 9 shows the overall and event free survival at different stages 
follow up.  
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Figure 16. Overall and event-free survival over 5 years post HSCT in 19 pediatric patients 
 
 
Table 9. Overall and relapse free survival of 19 pediatric HSCT patients at different intervals of 
follow-up period 
Follow-up Period % Overall Survival %Event Free survival 
Till date 78.9 67.5 
2.4.3.4 Correlation of Novel Continuous infusion-based dosing to development of GVHD 
Non-parametric analysis was used for statistical analysis of the data owing to the small samples 
size.  A wilcoxon rank sum test was used to measure continuous variables. Patients who 
developed acute GVHD grade I-IV had steady state levels of less than 1.2 µg/ml whereas 
patients who had a Css level of more than 1.8 µg/ml did not develop GVHD (p=0.02).  
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2.5 DISCUSSION 
Pharmacokinetics of MPA and MPAG has been extensively studied in adult HSCT patients on 
reduced-intensity conditioning; however, the data in myeloablative transplants, especially in the 
pediatric patients is very limited [133, 163]. Despite the large inter and intra-patient 
pharmacokinetic variability, MMF continues to be used on a fixed-dose-flat dose schedule [164-
166]. A study conducted by Maris et al. [167] has reported that nonmyeloablative conditioning 
with post grafting cyclosporine and MMF given thrice daily was associated with improved 
engraftment rate (95%) compared with MMF given twice-daily (85%), as published by the group 
earlier[168]. 
The work in this chapter primarily focused on pharmacokinetic guided dosing of MMF to 
personalize MMF dosing for GVHD prophylaxis in pediatric HSCT patients. To our knowledge 
this is the first report of pharmacokinetic-guided dosing of MMF based on a target AUC 
exposure using a 24-hour continuous infusion dosing regimen of MMF in pediatric transplant 
patients. The main goal of this study was to determine the safety and feasibility of an AUC-based 
MMF dosing by giving it as a CI over 24 hours. This was feasible in all subjects but did require a 
dedicated line for IV dosing. All patients started with a 15 mg/kg/dose given thrice a day 
intravenously. The average daily dose required to maintain patients within the therapeutic range 
remained close to 45 mg/kg/day during CI and oral dosing. During CI, 17 of 19 patients (89%) 
achieved MPA Css within the target of 1.7 to 3.3 μg/mL. In a study conducted by Jacobson et al 
in 19 pediatric patients  receiving stem cell transplant [123], they  found a 10-fold variation in 
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total MPA AUC and a mean AUC0-24 of 37.5 μg·hour/mL was observed. Haentzschel et al. [159] 
have demonstrated feasibility of dosing MMF targeting an exposure as measured by AUC0-12 of 
35 to 60 μg·hour/mL in 29 adult HCT recipients. Bhatia et al.[150] reported pharmacokinetic 
data in 38 pediatric HSCT recipients receiving tacrolimus and an initial MMF dose of 900 mg/m
2
 
every 6 hours intravenously followed by dose adjustments to target total trough concentrations of 
1 to 3.5 μg/mL. The total MPA exposure was substantially higher, with an AUC0-24 of 157.6 
μg·hour/mL compared with 37.5 μg·hour/mL in Jacobson study and 46.5 μg·hour/mL in our 
study. However, these patients did receive a 2.7-fold higher MMF dose. Dose escalation should 
be carried out with caution because of concerns about MPA-related hematologic and 
gastrointestinal toxicities. A comparison of PK parameters in these studies and the current study 
are shown in Table 10. 
 In this study, we observed a much higher metabolite to parent exposure ratio 
(MPAG/MPA) in these subjects consistent with adult HSCT patients. This suggests a higher 
formation clearance of MPAG in HSCT patients as compared to adult and pediatric SOT 
patients. Also, the higher MPAG/MPA ratio after oral dosing (29.4) as compared to IV 
short(12.1) and IV CI (14.8) also suggests the involvement of the gut UGTs in the metabolism of 
MPA.  MPA is highly bound to plasma proteins [15].  This could possibly be explained by 
saturable protein binding of MPA that may result in greater MPA free fraction and a decrease in 
total concentration and allowing a greater percentage of the administered drug to be metabolized 
[169]. 
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Table 10. Comparison of pharmacokinetic parameters across all studies in pediatric HSCT patients 
on IV and PO dosing of MMF 
Study Dose Age(years) N AUC
0-8
 (µg*hr/ml) C
ss
 (µg/ml) C
max
 (µg/ml) 
Jacobson et al 15mg/kg q8 iv 0.25-11.7 16 12.6(4.9–49.2) 1.6(0.6–6.1) 5.0(1.8–18.0) 
Bhatia et al 
900mg/m
2
q6 iv 
0.33-16 31 26.82±12.35  4.73±7.22 12.31±7.99 
Bhatia et al 
900mg/m
2
q6 po 
0.33-16 15 26.50±19.03  5.38±3.55 13.15±12.04 
Current Study 15mg/kg q8 iv 0.9-21.5 19 14.8(5.6-22) 1.9(0.6-2.7) 5.9(1.5-9) 
Current Study 15mg/kg q8 po 0.9-21.5 14 14.0(4.0-32.0) 1.5(0.5-4.0) 5.6(1.3-12.1) 
Current Study 24-hour CI 0.9-21.5 19 - 1.7(0.9-2.7) 
  
- 
 
Similar to the results reported by Winter et al. we have also seen a higher MPA clearance 
in our patient population (10.9 ml/min/kg) as compared to that reported in kidney transplant 
recipients (7.1 ml/min/kg). A higher MPA clearance can be attributed to low albumin 
concentrations and concomitant use of cyclosporine. Low albumin concentration leads to lesser 
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binding of MPA to albumin and availability of more MPA to be eliminated leading to increased 
clearance and decreased exposure.  
Intense blood sampling for pharmacokinetic analysis especially in pediatric patients is 
inconvenient, and simple methods of quantifying exposure are necessary. Limited sampling 
strategies have been widely used in kidney transplantation with most of the strategies using a 3 
or 4 concentration-time point data over a 12-hour dosing interval after oral administration [93, 
98, 170, 171]. There are reports of couple of such studies in HSCT patients [99, 119] . Our 
results are consistent with previously reported studies showing that trough concentrations are not 
a good surrogate for MPA overall exposure (R
2
= 0.021). Abbreviated AUC as seen in our study, 
showed a significant correlation between the 4-hour AUC and the 24-hour exposure estimated 
based on the steady state 8-hour exposure. These results are promising to predict the overall 
exposure and would allow for a less intensive blood sampling.  
The MMF concentrations in our study were below the limit of quantitation for all patients 
after oral dosing. These observations are in concordance with the data in a study conducted in 
healthy subjects by Bullingham et al [11]. However, quantifiable MMF concentrations were 
observed in most patients after an IV short infusion and CI. The plasma concentrations were 
below quantitation limits in 17 of 19 patients within an hour after stopping the infusion. This 
suggests that the functional capacity of esterases that are responsible for its metabolism to the 
active form is intact in these patients. As seen in some other studies MPA exposure is associated 
with clinical outcomes, and hence optimum exposure in the immediate post-transplant period is 
very crucial [151, 164-166]. To ensure optimum exposure in the immediate phase post-transplant 
patients were switched to an individualized IV CI based on pharmacokinetic analysis of the short 
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infusion regimen. This helped patients not only to achieve but also maintain the desired steady-
state levels.  
In this study, we have observed low rates of aGVHD (grades II to IV, 33%; grades III to 
IV, 17%) and chronic GVHD (13%), and all patients with acute and chronic GVHD have 
responded to therapy. Also, MPA Css was significantly lower, (1.2 versus 1.8 μg/mL) in patients 
with aGVHD compared with those without aGVHD, respectively. This is consistent with what is 
known about MPA exposure and outcomes. Harnicar et al. [165]recently reported a higher rate of 
grades III to IV aGVHD in double cord blood transplant recipients who received doses ≤ 36 
mg/kg/day MMF and those with <0.5 μg/mL trough levels of MPA. Adult receiving reduced-
intensity double cord blood transplant recipients receiving 3 g/day showed a 49% relative risk 
reduction in grades II to IV aGVHD rate as compared to the 2g/day dosing [164]. 
ATG can also play a significant role in GVHD outcomes. Similar to our study, Van Hest 
et al.[157] used ATG in addition to MMF-cyclosporine A in unrelated donor transplants and 
observed a low incidence of grades III to IV aGVHD of 7%.  In a recent study by Al-Kadhimi et 
al. [147]conducted in a large cohort of 414 adult patients treated with a uniform MMF-
tacrolimus GVHD prevention regimen, found a high rate of grades III to IV aGVHD in sibling 
donor (22%) and unrelated donor (37%) recipients. Lower incidences of acute and chronic 
GVHD and non-relapse mortality were reported by studies (including ours) that have used a 
longer course of MMF with or without taper [172-174].  
In our study 95% (18 of 19 patients) achieved donor hematopoietic engraftment. Both 
neutrophil and platelet count recovery was faster in bone marrow compared with cord blood 
transplants. Our study is limited by small sample size and heterogeneity in stem cell sources. 
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Other factors including but not limited to duration of MMF and use of ATG might have affected 
clinical outcomes in unrelated donor transplants.  
Our approach of CI MMF administration may result in more constant IMPDH inhibition 
and avoid high peak level drug exposure. In renal transplant patients, lower IMPDH baseline 
activity is associated with lower dosing requirements and presumably lower MPA concentrations 
[114]. Optimization of MMF based prophylaxis can be further achieved by individualization of 
MMF dosing based on the IMPDH activity. We have established and validated an assay for ex-
vivo measurement of IMPDH activity from the conversion of inosine monophosphate to xanthine 
monophosphate in peripheral blood mononuclear cells. Application of this assay for a PK-PD 
study has been evaluated in further chapters. 
 
In conclusion, our study shows that individualized MMF dosing by targeting AUC of MPA is 
feasible, safe, and effective in the early phase after allogeneic HCT. There was a 10-fold 
variation in the clearance of MPA while patients are on CI. The pharmacokinetics studies 
showed significantly lower half-life and higher drug clearance in pediatric HCT recipients 
compared with stable pediatric renal transplant patients. The trough levels poorly correlated with 
AUC. However, AUC0-4 hour correlated well with AUC0-24. There was no evidence of 
enterohepatic recirculation of MPA in the study patient population. We observed no toxic deaths, 
excellent engraftment, and low rates of grades III to IV aGVHD and chronic GVHD. This 
regimen deserves further validation in a larger cohort of pediatric patients undergoing 
myeloablative transplantation. In future studies, monitoring IMPDH activity may also facilitate 
optimizing the dose of MMF. 
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3.0  DEVELOPMENT AND VALIDATION OF UPLC-MS METHOD FOR 
QUANTITATION OF MMF, MPA AND MPAG: APPLICATION TO A PROSPECTIVE 
PK-PD STUDY IN ADULT LUNG TRANSPLANT RECIPIENTS 
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3.1 ABSTRACT 
Mycophenolic acid (MPA) is the active moiety of MMF, a prodrug widely used as part of 
maintenance immunosuppressive therapy to prevent organ rejection in SOT patients and for 
GVHD prophylaxis in HSCT patients. Though not routinely monitored like other 
immunosuppressive drugs, there has been some justification to monitor MPA in transplant 
patients receiving MMF primarily owing to the large inter and intra-individual variability in PK, 
dose-related toxicity and the continued risk of acute rejection in organ transplant recipients. A 
key factor in TDM is the availability of a specific and sensitive assay for measuring all the 
relevant compounds in a small volume of sample with a shorter turnaround time. In this study, a 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for 
simultaneous quantification of MMF, MPA and MPAG in small volume of plasma.   Sample 
preparation comprised of protein precipitation with acetonitrile and subsequent centrifugation, 
drying and reconstitution of the residue with 50% methanol and 50% water. Deuterium labeled 
MPA was used as internal standard. The chromatographic separation was achieved on a UPLC 
HSS T3 column with a gradient flow. LC-MS/MS detection was performed using a triple-stage 
quadrupole mass spectrometer working in multiple reaction monitoring (MRM) mode with 
positive ESI. All three analytes were quantified in a single run within 5 min. The assay was 
linear over a concentration range of 0.01-10 µg/ml for MPA and MMF and from 0.1 -100 μg/ml 
for MPAG. The lower limits of quantification for MMF and MPA were 0.01 and for MPAG 0.1 
µg/ml. Inter and intra-day precisions and accuracies were less within 15%. Sample stability was 
measured at bench top temperature for up to 24 h, 5 freeze-thaw cycles and at 4 degrees Celsius 
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in the auto sampler. The described method can be used for quantitation of MMF, MPA and 
MPAG in plasma samples of small volumes for TDM and pharmacokinetic studies in transplant 
patients.   The applicability of the method was tested in a prospective study conducted in adult 
lung transplant recipients. The mean AUC of MPA and MPAG was 42.7and 814.1 µg*hr/mL 
respectively and MPA clearance was 27.1 L/h. The pharmacokinetic parameters observed in this 
study are comparable to that reported by other groups. Further studies should focus on tailoring 
MMF dosing strategies that optimize immunosuppressive regimen, improve rejection free 
survival and minimize toxicity in lung allograft recipients. 
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3.2 INTRODUCTION 
Lung transplant (LT) is the only therapeutic option for patients with end stage lung disease. 
Although acute clinical outcomes of lung transplant are favorable, long term survival outcomes 
are often limited by morbidities like Bronchiolitis obliterans syndrome (BOS), especially in the 
first-year post-transplant.[175] Risk factors for BOS include both acute cellular rejection; 
antibody mediated rejection and selected infections. [176-181] Immunosuppressive regimens 
consisting of tacrolimus, MMF, and corticosteroids, are commonly used to prevent rejection 
episodes after LT. Immune activity and responsiveness to immunosuppressive regimens in LT 
recipients (LTRs) are heterogeneous which necessitates personalized immunosuppressive 
treatment approaches. Immunosuppressive regimens consisting of TAC, MMF, and 
corticosteroids, are commonly used to prevent rejection post LT. In fact, both the 
immunosuppressive drugs- TAC and MPA, the active metabolite of MMF, demonstrate high 
inter-patient pharmacokinetic and pharmacodynamic variability. Tacrolimus dosing is 
individualized in LTRs based on a therapeutic drug monitoring strategy and the history of 
rejection and infections.[182] Tacrolimus is drug with a narrow therapeutic window and large 
inter and intra-patient pharmacokinetic variability. Trough blood concentration of tacrolimus is a 
good surrogate marker of drug exposure as measured by AUC. A therapeutic window has been 
established for tacrolimus based on the association between probability of acute rejection and 
adverse effects, with trough blood concentrations. As a result, dosing of tacrolimus is 
personalized by routine TDM. [183] MMF, the ester form of the active metabolite MPA exhibits 
high intra and inter-patient pharmacokinetic variability in solid organ transplant recipients.[184] 
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Studies in renal and heart transplant recipients have demonstrated decreased acute cellular 
rejection (ACR) episodes when the measured MPA area under the concentration time curve 
(AUC0-12) falls within the range of 30-60 mg*h/L, when used in combination with cyclosporine 
and steroids. [185] However, MPA AUC is difficult to measure in clinical practice due to the 
impracticality of the 12-hour time frame required and the cumbersome process of multiple blood 
draws. Unfortunately, trough MPA levels do not accurately reflect AUC and cannot be used as a 
surrogate marker of MPA exposure. For these reasons, MMF is currently dosed on a fixed flat 
dose strategy, which is suboptimal for LTRs. 
Owing to increased sensitivity and quick run time, ultra-performance liquid 
chromatography coupled with mass spectrometry (UPLC-MS/MS) based quantification of drug 
levels in plasma has gained popularity over other conventional methods of drug analysis. 
However, few methods have been developed to measure MPA and its metabolites 
simultaneously using UPLC-MS/MShttps://link.springer.com/article/10.1365/s10337-010-1715-
6 [186-189] and no studies have been reported to quantify MMF along with MPA and MPAG in 
the same run. Currently available assays are limited by the volume of sample required for 
quantitation of all the three analytes MMF, MPA and MPAG.  
In the current study, we established a fully validated, sensitive, and accurate UPLC-
MS/MS method for the simultaneous quantification of MMF, MPA and MPAG. This method is 
the first to report a simple two-step sample preparation method to quantify MMF and its 
metabolites in a plasma. We have used a volume of 50 μL which was diluted 20-fold to 
quantitate MMF, MPA and MPAG in one single run. This assay was used to quantify plasma 
samples from lung transplant recipient in this study and is also being used for in other ongoing 
studies in other solid organ transplant recipients. Furthermore, in this study was aimed to 
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optimize the sensitivity of the assays so that the required sample volume could be minimized. 
The added advantage of this assay is the ability to quantitate MMF levels in plasma. 
Measurement of MMF in plasma can help confirm conversion of MMF to MPA and thereby 
measure the functional capacity of the esterases involved in hydrolysis of MMF. Incomplete 
conversion of MMF to MPA can lead to reduced MPA exposure and this is crucial in lung 
transplant patients that are characterized by lower MPA exposure. The high dilution ratio of 20-
fold suggests that the assay can be potentially used to quantitate MMF, MPA and MPAG in 
much smaller plasma volume. The minimization of the sample volume is very crucial as the 
assay can be used for conducting pharmacokinetic studies of MPA in pediatric and in other 
transplant patients, where sample volumes are extremely limited. 
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3.3 MATERIALS AND METHODS 
3.3.1 Materials 
UPLC-MS grade methanol, acetonitrile and MS grade water was purchased from Fisher 
Scientific (Pittsburgh, PA). Formic acid and ammonium acetate was purchased from Sigma-
Aldrich (St. Louis, MO). The following chemicals were purchased from Toronto Research 
Chemicals (TRC): MMF Cat No: M831450, mycophenolic acid (MPA) Cat No: M831500, 
deuterated mycophenolic acid (MPA d-3) Cat No: M831502 and MPAG Cat No: M831520. 
Blank plasma was acquired from central reference testing laboratory.  
3.3.2 Clinical Samples for Analysis 
Plasma samples were collected from subjects enrolled in a prospective study conducted in adult 
lung transplant recipients. This study was approved by the local Institutional Review Board at 
the University of Pittsburgh. Patients on a fixed stable oral MMF dose were enrolled in the study. 
Patients were screened, and informed consent was obtained from eligible patients before 
enrolling them in the study.  Samples for pharmacokinetic evaluation were collected prior to the 
morning dose of a BID regimen. Serial blood samples were collected over the dosing interval at 
0.5, 1, 1.5, 2, 4, 6, 9 and 12 hours.  Blood samples (4 mL) were obtained from an indwelling 
arterial line and immediately transferred to sodium EDTA Vacutainer tubes (BD, 39 Franklin 
Lakes, NJ). Blood samples were centrifuged at 4°C for 10–15 min at 1500 x g.  The supernatant 
plasma was then transferred to cryovials and stored at −80°C until analysis. 
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3.3.3 Preparation of Calibration Standards and Quality Control Samples  
Three separate stock solutions were prepared for MMF, MPA and MPAG in acetonitrile at a 
concentration of 2 mg/mL. These solutions were spiked into blank plasma to produce standard 
working concentrations containing MMF and MPA concentrations ranging from 0.01-10µg/ml, 
while MPAG concentrations ranged from 1-100 µg/ml. Standard working solutions were stored 
in -80°C freezer until use.  
MPA d-3 was used as an internal standard (IS). A stock solution containing the internal 
standard with a final concentration of 1 mg/mL was prepared in acetonitrile and stored in -80°C 
until use. A working solution of IS with a concentration of 250ng/ml was prepared fresh in 
acetonitrile on day of assay.   For the internal quality control (QC) samples, a separate stock 
solution was prepared in methanol at a concentration of 2 mg/ml. QCs were prepared in blank 
plasma at 4 levels containing MMF and MPA at 0.04 µg/ml (A), 0.4 µg/ml (B), and 4 µg/ml (C) 
and 8 µg/ml (D) and MPAG at 0.4 µg/ml (A), 4 µg/ml (B), and 40 µg/ml (C) and 80 µg/ml (D) 
and stored at -80°C until analysis.  
Samples were processed by precipitating the protein with acetonitrile as follows- 
To 50 μL of plasma sample, 200 μL of acetonitrile containing 250 ng/ml of IS was added 
to an Eppendorf tube. The sample was vortexed rigorously for 30 seconds and then centrifuged at 
15000 rpm for 8 minutes at 4°C. Following centrifugation, 25 μL of supernatant was transferred 
to another Eppendorf tube and then diluted 20-fold with 475 μL of 50:50 acetonitrile: water. 
Sample was vortexed for 30 seconds and then 100 μL was transferred to a glass autosampler vial 
of which 1 μL was injected into the UPLCMS/MS.        
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3.3.4 UPLC and Mass Spectrometric Conditions  
Chromatographic separation and quantification was performed using a Waters Acquity Ultra 
Performance liquid chromatography (UPLC) H class coupled with a Xevo TQS triple quadrupole 
mass spectrometer. A Waters Acquity UPLC HSS T3 1.7 um, 2.1*100 mm column (Waters, 
Milford, MA) was used for the separation of the three analytes and the internal standard. The 
mobile phase consisted of a  gradient of solution A (95% water, 5% ACN with 2mM ammonium 
acetate and 0.1% formic acid ) and solution B (95% ACN, 5% Water with 2mM ammonium 
acetate and 0.1% formic acid) with an initial composition of 65% A held up until 1 min and 
changing to 50% at 1.5 min and then transitioning to 100% B held till 4 min and then switching 
back to 65% A at 4.1 min until the end of run. The flow rate was 0.3 mL/min and the column 
was maintained at 50°C and an injection volume of 1 μL was used.    Analytes were detected via 
MS/MS with an electrospray ionization source under positive mode. Ultra-high-purity nitrogen 
was used for source and collision cell gas.  The following settings were applied: Capillary 
voltage 2.5 kV, Cone voltage: 40 V, Desolvation temperature: 500 °C, Cone gas flow 150 l/hr 
and Desolvation gas flow 850 l/hr. The mass transitions for MMF, MPA, MPA d-3 and MPAG 
were as follows: 
MMF: 433.9>114, MPA: 320.96>206.97, MPA d-3: 323.9>209.9 and MPAG: 518.8> 343.1 
The auto sampler tray where the samples were stored during analysis was maintained at 
4°C. Sample injection volume was set to 1 µL for all compounds. Calibration standards were 
injected first in an increasing concentration followed by a set of QCs then the half of study 
samples, then second set of QCs rest half of the study samples, and lastly the third set of QCs. 
Between injections, the autosampler needle was washed with methanol/water (1/1, v/v). The 
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method validation and sample analysis were conducted by constructing calibration curves by 
plotting the analyte/IS chromatographic peak area ratio against the prepared analyte 
concentration in each calibration standard. Linear regression was used to fit the calibration curve 
with a weighting of 1/x
2
. Standards were then back calculated, and QC concentrations were 
determined by interpolation. QCs failed if they 3/4 were not within ±15% of nominal 
concentration. Calibration standards that failed to meet this criterion were excluded from 
regression, and as specified in the FDA bioanalytical guidelines at least ¾ of the calibrators were 
required to be included in regression. The lower limit of quantification (LLOQ) was defined as 
the lowest concentration of analyte with acceptable imprecision (≤15%) and mean accuracy 
(±15% of nominal concentration). At each QC concentration, at least 2 of the 3 replicates of 
prepared QC samples were required to be within 15%. 
3.3.5 Method Validation 
Validation was performed by assessment of LLOQ, intra and inter-day accuracy and imprecision, 
specificity, recovery and matrix effect, stock solution stability, and freeze-thaw stability. Ten 
plasma calibration standards ranging in concentration from 0.1 – 100 µg/mL for MPAG and 
0.01-10 µg/mL for MPA and MMF were prepared and analyzed in duplicate in 5 runs performed 
on 5 consecutive days. The LLOQ was determined as the minimum concentration that was 
quantifiable with an accuracy and precision within ±15% of the nominal value. The 
concentration which yielded a minimum value of a signal-to-noise ratio greater than 3:1 was set 
as the lower limit of detection (LLOD). Accuracy and precision were determined from replicate 
samples of spiked QC concentrations. Intra-day validation was performed from 5 replicates of 
each concentration assayed on the same day within the same analytical batch. Inter-assay 
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accuracy and precision at each concentration were calculated from a total of 18 replicates 
assayed over 5 days. Accuracy which is defined as the deviation of the calculated value (E) from 
that of its true value (T) and is expressed as a percent. It is calculated as relative standard error 
(RSE%), using the equation RE% = (E-T)/T*100.  Precision is calculated as the percent 
coefficient of variance (%CV) where %CV = standard deviation/mean x 100. An accuracy and 
precision within ±15% of the nominal value is considered acceptable.    
Freeze thaw stability of the analytes was tested with 5 freeze-thaw cycles and room 
temperature stability was determined over 6 hours. Recovery and matrix effect were determined 
at all the QC concentrations indicated in Table 12 . For each biological matrix, one QC set (set 
A, n = 3) was prepared according to normal sample processing method. Another set of QCs (set 
B, n = 3) was prepared as neat solution in 50% methanol. The third set of QCs (set C, n = 3) was 
prepared without analyte and spiking the sample into the matrix post-extraction. 
3.3.6 Comparison to published methods 
Several methods have been developed to quantify MPA and MPAG. This is the first method that 
has been used to quantitate MMF via UPLC-MS. Therefore, we aimed to expand on these 
current methods to develop an assay with greater sensitivity. We have used a small amount of 
sample and diluted it 100-fold. The sample volume was kept at 50 μL to avoid pipetting error. 
The use of UPLC-MS system facilitated for a shorter run time of 5 minutes. The novel approach 
of detecting MMF, MPA and MPAG in the same run using a UPLC-MS based separation has 
been developed for the first time.  This method has a potential for analysis of the three analytes, 
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namely MMF, MPA and MPAG in dried blot spots and for analysis in critically ill patients or 
pediatric patients where sample volume is a limiting factor. 
 
3.3.7 Pharmacokinetic Analysis 
Concentration-time data obtained from 4 lung transplant recipients were used to determine 
MMF, MPA and MPAG pharmacokinetics. Non-compartmental analysis using WinNonlin® 
pharmacokinetic software (Standard Edition, Version 6, Apex NC) was used for calculation of 
pharmacokinetic parameters. The pharmacokinetic parameters determined were: area under the 
curve for the dosing interval AUC0-τ, and dose normalized AUC0-τ, the maximum concentration 
obtained during the dosing interval (Cmax); dose-normalized Cmax, the time at which Cmax 
occurred (Tmax) and the clearance over the dosing interval. 
3.3.8 Statistical Analysis 
All statistical analysis for descriptive statistics was performed in Excel (version 14.0,  Microsoft 
Corp., Redmond, WA). 
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3.4 RESULTS 
3.4.1 Mass spectrometric conditions and Standard curve preparation 
Table 11 provides the mass spectrometric conditions for each of the compounds.  
Table 11. Mass spectrometric conditions for MMF, MPA and MPAG 
Analyte 
ESI 
mode Cone Voltage Desolvation temperature MRM transition 
MPAG Positive 40 V 500°C 518.8  343.1 
 
    MMF Positive 40V 500°C 433.9114 
 
    MPA Positive 40V 500°C 320.9 206.9 
 
Table 12 provides a summary of the standard and QC concentrations used for the plasma assay. 
Based on previous knowledge about clinical concentrations of MPA pharmacokinetics [28], 
calibration curve range was carefully selected to be most appropriate for the biological matrix 
and analyte to be used.  
Table 12. Standard curve and QC concentrations for MMF, MPA and MPAG 
Analyte Matrix Calibrator Concentration (µg/ml) 
QC concentrations (µg/ml) 
Level 1 Level 2 Level 3 Level 4 
       MPAG Plasma 0.1,0.25,0.5,1,2.5,5,10,25,50,100 0.4 4 40 80 
  
     
MMF Plasma 0.01,0.025,0.05,0.1,0.25,0.5,1,2.5,5,10 0.04 0.4 4 8 
  
     
MPA Plasma 0.01,0.025,0.05,0.1,0.25,0.5,1,2.5,5,10 0.04 0.4 4 8 
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Figure 17 shows the chromatographic separation of 4 compounds on UPLC -MS and the elution 
time for each of the compounds is as follows: MPAG (1.26 min), MMF (2.26 min), MPA (3.46 
min) and internal standard MPA d-3 (3.46 min). 
 
Figure 17. Chromatograms of drug MMF (2.3 min), MPA (3.5 min), MPAG (1.3 min) and deuterated 
MPA (3.5 min) in a standard solution. 
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3.4.2  Linearity, Accuracy and Precision 
All calibration curves were fitted well by linear regression with a weighting factor of 1/x
2
. In 
plasma, the standard curve of MMF was linear up to 5 µg/mL. Back-calculation of calibrator and 
QC concentrations were performed by interpolation and consistently yielded values within 20% 
of nominal concentration with an r
2
 for calibration curves typically being ≥0.99. Intra and inter-
day accuracy and precision data at each QC concentration level is summarized in Table 13 and 
Table 14 respectively. The method was highly accurate and precise. Mean values for intra- and 
inter-day accuracy (calculated as percent deviation) were within 15%, except for the lowest QC 
for MPAG which was within 20% while the imprecision in plasma for intra and inter-day assay 
did not exceed 15%. Figure 18 and Figure 19 shows the calibration curves for the three analytes. 
The lower limit of quantification in this assay was 0.01 μg/mL for MPA and MMF and 0.1 
μg/mL for MPAG. 
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Table 13. Intra-day accuracy and precision for MMF, MPA and MPAG for n=6 runs on the same day 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MMF 
Concentration 
(µg/mL) 
Mean calculated 
concentration 
(µg/mL) 
Accuracy 
(% 
deviation) 
Precision (% CV) 
0.04 0.0 -0.8 0 
0.4 0.4 -7.3 0 
4 4.0 -0.8 3.5 
8 7.4 -7.3 2.1 
MPA 
Concentration 
(µg/mL) 
Mean calculated 
concentration 
(µg/mL) 
Accuracy 
(% 
deviation) Precision (% CV) 
0.04 0.0 0 0 
0.4 0.4 -4.2 0 
4 4.3 6.7 5.4 
8 9.3 15.0 3.7 
MPAG 
Concentration 
(µg/mL) 
Mean calculated 
concentration 
(µg/mL) 
Accuracy 
(% 
deviation) Precision (% CV) 
0.4 0.3 -16.7 14.1 
4 3.9 -3.3 0.0 
40 37.6 -6.0 2.6 
80 79.0 -1.3 3.3 
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Table 14. Inter-day accuracy and precision for MMF, MPA and MPAG for n=20 runs on 4 different 
occasions 
MMF 
Concentration 
(µg/mL) 
Mean calculated 
concentration 
(µg/mL) 
Accuracy 
(% 
deviation) 
Precision (% CV) 
0.04 0.0 0.0 0.0 
0.4 0.4 3.8 8.6 
4 3.9 -2.9 4.9 
8 7.2 -9.8 4.0 
MPA 
Concentration 
(µg/mL) 
Mean calculated 
concentration 
(µg/mL) 
Accuracy 
(% 
deviation) Precision (% CV) 
0.04 0.0 0.0 0.0 
0.4 0.4 -1.2 5.5 
4 4.2 4.7 8.2 
8 8.9 10.6 15.0 
MPAG 
Concentration 
(µg/mL) 
Mean calculated 
concentration 
(µg/mL) 
Accuracy 
(% 
deviation) Precision (% CV) 
0.4 0.3 -16.3 19.5 
4 3.7 -7.6 5.5 
40 39.1 -2.3 4.2 
80 82.9 3.7 4.5 
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Figure 18. Calibration curve for MMF and MPA in plasma 
 
 
Figure 19. Calibration curve for MPAG in plasma 
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3.4.3 Recovery and Stability 
Analytes at all 4 QC levels pre-extraction were compared to the mean response post extraction.  
at low, medium and high levels, and IS at the level of use: pre-extraction spiked samples (n=3) 
are compared with mean response of post-extraction spiked matrix samples (n=3). For MPA, 
MPAG and MMF the extraction recovery was consistently between 75-100% for MPAG, 75-
106.4% for MMF and 75-94.3% for MPA.  The matrix effect ranged from 50-88% for MPAG, 
75-101.5% for MMF and 95.9-100% for MPA with the lower concentrations having no effect of 
matrix. The stability data for 5 freeze-thaw cycles, 24 bench-top and 4°C autosampler stability is 
shown in Table 15. 
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Table 15. Stability of MMF, MPA and MPAG in human plasma. Reported values are mean % of initial 
observed 
 
 
 
 
 
 
 
 
 
 
 
3.4.4  Assay Validation in Clinical Use 
The developed and validated assay was successfully applied to plasma samples from 4 adult lung 
transplant recipients receiving MMF as a part of their maintenance immunosuppression. These 
patients were receiving a fixed dose of 1g BID and at steady state. All patient samples were well 
above our LLOQ thus confirming the linearity range for this patient population.  Figure 20 and 
Figure 21 show the concentration time profiles for each individual patient. Figure 22 and Figure 
MMF (% stability) 
Concentration 
(µg/mL) 
24-hour at room 
temperature 
5 freeze-
thaw cycles 
Autosampler at 
4°C 
0.04 100.0 100.0 100.0 
0.4 100.0 118.0 100.0 
4 99.3 109.4 102.1 
8 100.7 105.7 99.8 
MPA (% stability) 
Concentration 
(µg/mL) 
24-hour at room 
temperature 
5 freeze-
thaw cycles 
Autosampler at 
4°C 
0.04 100.0 100.0 100.0 
0.4 100.0 118.0 104.3 
4 109.5 114.8 99.6 
8 105.7 126.0 94.5 
MPAG (% stability) 
Concentration 
(µg/mL) 
24-hour at room 
temperature 
5 freeze-
thaw cycles 
Autosampler at 
4°C 
0.4 100.0 92.9 97.5 
4 102.2 99.5 95.7 
40 100.9 106.6 106.1 
80 100.1 106.1 107.5 
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23 represent the mean concentration time profiles in these patients for MPA and MPAG 
respectively. 
 
Figure 20. Concentration time profiles of MPA in 4 adult lung transplant recipients. 
 
 
Figure 21. Concentration time profiles of MPAG in 4 adult lung transplant recipients 
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Figure 22. Mean MPA concentration time profile in adult lung transplant recipients 
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Figure 23. Mean MPAG concentration time profile in adult lung transplant recipients 
3.4.5 Pharmacokinetic Analysis of MMF, MPA and MPAG 
Table 16 summarizes the pharmacokinetic parameters of MPA and MPAG for the study patients. 
The lung transplant patients had significantly lower MPA AUC and higher clearance as 
compared to kidney and liver transplant recipients receiving the same dose.  The apparent steady 
state MPAG/MPA metabolic ratio (12.3) of these patients was comparable to other solid organ 
transplant patients.[18] suggesting no apparent changes in the formation clearance of MPAG. 
Overall the pharmacokinetic parameters are comparable to those seen in other lung transplant 
studies reported by Ensom et al and Ting et al. [190-192].  
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Table 16. Pharmacokinetic parameters of MPA and MPAG in adult lung transplant recipients 
 
The AUC0-24 correlated well with the abbreviated AUCs calculated over 2-hour (r
2
 > 0.93) and 4-
hour period (r
2
 > 0.98) as shown in Figure 24. 
 
Figure 24. Correlation of mini AUCs with total AUC in 4 adult lung transplant recipients on oral 1 
mg BID dose of MMF at steady state. 
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AUC0-24 (ug*hr/ml) 
Correlation of abbreviated AUC vs AUC0-24 
AUC0-24 vs AUC0-4
AUC0-24 vs AUC 0-2
Pharmacokinetic Parameters (Units) MPA MPAG 
AUC0-12 µg*hr/ml 21.3 ± 13.1 407.1 ± 250.2 
 Tmax( hours) 1.8 ±1.6 2.7 ± 1.3 
Half-life (hours) 4.0 ±1.8 - 
Clearance (CL/F) (L/hr) 27.9 ±17.2 
 
Cmax (µg/ml) 5.7 ± 3.5 46.8 ± 24.5 
MPAG/MPA ratio 12.3 
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3.5 DISCUSSION 
There are several studies characterizing the inter-patient and intra-patient variability in PK of 
MPA in other solid organ transplant recipients.[18, 185, 193]  To our knowledge, there are only a 
limited number of studies on the PK of MPA available in the lung transplant patient population.   
Unlike kidney and liver; lung is not directly involved in the elimination of MPA and hence 
extrapolations in lung transplant recipients cannot be made based on the pharmacokinetic data in 
other solid organ transplant recipients. Mycophenolate mofetil exhibits time-dependent changes 
in drug clearance in kidney and liver transplant recipients.[18, 193]  This is primarily due to the 
changes in protein binding in the immediate post-transplant phase. In kidney transplant patients, 
for the same MMF dose the total exposure was 30%–50% lower in the first few weeks post-
transplantation, as compared to the exposure in the maintenance phase (1-6 months post-
transplantation). Renal insufficiency is known to decrease the protein binding of MPA and 
increase the free fraction.  In a study conducted in 33 kidney transplant recipients[194] 13 had 
poor renal function and had 86% lower AUC and 2-fold higher free fraction and a corresponding 
higher oral clearance as compared to those having normal renal function on day 4 post-transplant 
but had comparable exposure on day 28.  
While all of the studies in SOT patients measure MPA, none have measured MMF, MPA and 
MPAG simultaneously. Measurement of MMF can facilitate understanding of functional 
capacity of estreases that are responsible for conversion of MMF to MPA and measurement of 
MPAG and the parent to metabolite ratio facilitates understanding of metabolism of MPA. All 
three compounds and the deuterated internal standard were simultaneously detected, identified, 
and quantified using a validated UPLC-MS/MS method.  All three compounds showed excellent 
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stability for 24 hours at room temperature. Additionally, we demonstrated that the matrix effect 
of plasma did not significantly affect the reliability and reproducibility of the assay, for all 
compounds measured. The high variability in the recovery did not affect quantitation of the 
clinical samples. 
A simple protein precipitation method coupled with a sensitive UPLC-MS/MS method was 
developed and validated. Advantages of this method include a wide yet clinically relevant 
concentration detection of MMF, MPA and MPAG, the small sample volume (50µl) and a 
shorter run time of 5 minutes. Although similar sample volume has been reported in other LC-
MS methods, we have diluted the sample 100 times. Validation of this method for a smaller 
starting sample volume of 10 µl is on-going.  Once the method is validated with smaller plasma 
volume; it can potentially be applied to pharmacokinetic studies of MMF in transplant patients 
and can thereby facilitate routine therapeutic drug monitoring of MPA and help in optimizing 
MMF dosing.   The utility, sensitivity and suitability of this assay were demonstrated by analysis 
of samples from a pharmacokinetic study of oral MMF in adult lung transplant recipients. The 
method was optimized to achieve high sensitivity for the detection of MMF and its metabolites 
(MPA and MPAG) by 100-fold dilution. The calibration was linear between 0.01-10 µg/ml for 
MMF and MPA and was linear over the range of 0.1-100 µg/ml for MPAG. To date this is the 
first report of a highly sensitive UPLC based quantitation method of MMF, MPA and MPAG in 
lung transplant recipients. 
As mentioned by other research groups [195, 196], the chromatographic separation of MPAG 
and MPA is very crucial as MPAG can undergo in-source fragmentation to MPA, which can 
potentially co-elute with MPA. A run time of 5 minutes provided adequate time for 
chromatographic separation of the 2 compounds.  
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Our study, being one of the only few conducted in lung transplant recipients can help 
characterize the pharmacokinetic profile and protein binding of MPA in stable lung transplant 
recipients in the immediate phase and during the maintenance phase post-transplantation. The 
pharmacokinetic parameters determined from this study are comparable to those reported in 
other studies[190, 191]. We observed a significant correlation between abbreviated AUC 
calculated over 2-hour and 4-hour periods with the total steady-state AUC. This study is however 
limited by the low sample size and therefore, results from our study cannot be generalized to all 
lung transplant recipients. 
The high intra and inter-patient variability warrants for future clinical studies to better 
understand the PK-PD relationship of MPA and help optimize dosing in this under-
studied transplant subpopulation. This variability further emphasized the need for monitoring 
IMPDH inhibition and using it as a potential marker for rejection and tailoring MMF dosing. 
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4.0  EX-VIVO QUANTITATION OF IMPDH ACTIVITY IN PERIPHERAL BLOOD 
MONONUCLEAR CELLS: HPLC-MS METHOD ESTABLISHMENT, VALIDATION 
AND APPLICATIONFOR PHARMACODYNAMIC MONITORING IN ADULT LUNG 
TRANSPLANT RECIPIENTS 
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4.1 ABSTRACT 
The immunosuppressive response to Mycophenolate Mofetil is based on the degree of inhibition 
of IMPDH activity. Once in systemic circulation, MMF gets hydrolyzed to the active form 
mycophenolic acid. Mycophenolic acid is a reversible non-competitive inhibitor of the enzyme 
IMPDH and is more selective towards T and B lymphocytes. Use of MMF is frequently 
associated with dose-dependent gastrointestinal or hematological side-effects like diarrhea, 
gastritis or leukopenia. Consequently, many patients require dose modification or have to 
discontinue MMF administration, the effect of which is suboptimal immunosuppression and 
increases the risk of acute rejection (AR). This underlines the importance of measuring the 
biological response to MMF, and thereby, helps personalize the MMF based 
immunosuppression. Therefore, measurement of pharmacodynamics effect by quantitating the 
IMPDH activity may provide direct information on the functional activity of MMF therapy in-
vivo. Several trials in solid organ transplant recipients have demonstrated large inter-patient 
variability in baseline IMPDH activity as also the time required for complete recovery of enzyme 
activity after MMF administration [114, 197, 198].  
Limited methods have been used to measure IMPDH activity. A critical requirement of a method 
is that it can detect IMPDH activity in a patient sample with a low PBMC count. Here we have 
established a robust LCMS-MS assay for ex-vivo quantification of IMPDH in isolated PBMC 
lysate preparation. The mean intra- and inter-assay accuracies ranged from 90-110%, and intra- 
and inter-assay imprecision did not exceed 15% for both XMP and adenosine monophosphate 
(AMP). We determined IMPDH activity in four lung transplant recipients on MMF and 
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retrospectively evaluated the IMPDH activity in 20 patients within 1-year post lung 
transplantation. The established assay was able to specifically and reliably measure IMPDH 
activity ex-vivo from patients with low PBMC count. The assay was successfully applied to 
quantitate and evaluate the pharmacodynamic activity in MMF-treated lung transplant patients. 
The IMPDH activity was very variable across both the prospective and retrospective studies. In 
the prospective study in lung transplant recipients, the IMPDH reached a nadir at the maximum 
concentration of MPA. The single time-point IMPDH activity in the retrospective study did not 
show any statistically significant association with rejection or infection. However, patients who 
rejected the graft did show a trend towards higher IMPDH activity. A close and continuous 
monitoring of the IMPDH could be effectively used as a prognostic marker of rejection. 
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4.2 INTRODUCTION 
Different strategies are used to optimize immunosuppressive drug dosing in transplant patients. 
Optimization of drug dosing based on exposure is the most common of all the approaches. 
However, this approach is severely limited by the feasibility of multiple sampling over a dosing 
interval.  Another approach is pharmacodynamic (PD) monitoring, which involves measurement 
of the biological response of the drug at its site of action. Measurement of PD alone or PK-PD 
analysis provides a novel method for optimization of drug dosing. This has been reported for 
CNIs like cyclosporine , tacrolimus [199-201], MMF [103, 202] and azathioprine [203].  
MMF, the prodrug of the active form MPA mediates its effect by inhibiting the enzyme 
IMPDH, which is involved in the de novo biosynthesis of purine nucleotides [204, 205] as 
represented in Figure 26. Suppression of IMPDH activity in the lymphocytes by MPA inhibits 
purine synthesis and arrests cell cycle progression in the G1→S phase.[183]   Data in renal 
transplant recipients illustrates that pre-transplant baseline IMPDH activity could predict 
episodes of ACR and infection post-transplantation.[110, 114, 115, 206] In a renal transplant 
recipients study conducted by Glander et al. i)IMPDH activity above a cut-off value, ii)MMF 
dose reduction and iii)age of recipient were shown to be the significant contributors for acute 
rejection. The study showed that patients with high baseline IMPDH activity and MMF dose 
reduction had the highest rejection rate (81.8% vs. 36.4%, p<0.01). In another study by Vethe et 
al. the IMPDH enzyme activity strongly correlated with the systemic MPA concentration 
throughout the dosing interval in all patients receiving MMF [206]. The minimum IMPDH 
activity with a median reduction of 92 % (range 74–98 %) compared to the baseline levels, 
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occurred shortly after MMF administration and coincided with the peak MPA which occurred at 
1 hour. Chiarelli et al. studied IMPDH activity in healthy subjects and renal transplant recipients 
on MMF treatment. Sommerer et al.[100]  evaluated the association between pharmacokinetic 
and pharmacodynamic parameters and the risk of adverse events in 66 adult renal transplant 
patients on EC-MPS. The median MPA concentrations over time were inversely corelated with 
IMPDH activity over time as seen in Figure 25. 
 
 
Figure 25. Median MPA concentrations and median IMPDH activities observed over the 12-h 
sampling period after 1 mg oral dose of EC-MPS in 66 adult renal transplant recipients. 
 
 
 
 Patients who rejected their graft were seen to have higher baseline IMPDH activity. In a 
pediatric renal transplant study by Fukuda et al. a simultaneous decrease in IMPDH enzyme 
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activity was seen with an increase in the MPA plasma concentration, with maximum inhibition 
coinciding with maximum MPA concentration indicating a direct concentration-response 
relationship. The EC50 value of 1.0 mg/L from the study was well aligned with the clinically 
established pre-dose (trough) concentration target range of 1.0 to 3.5 mg/L. However, baseline 
IMPDH activity and the effect of MPA on IMPDH post LT has never been characterized and 
associated with any clinical outcomes in LTRs. In this study, we have established a method for 
measuring the IMPDH activity in lung transplant recipients and propose to use this to personalize 
MMF dosing.  
Various assays for measuring the pharmacodynamic effect of MPA by measuring the ex-
vivo IMPDH activity in mononuclear cells during MPA therapy have been established [104, 106, 
207]. In adults on long term MMF administration, IMPDH activity displays wide inter-patient 
but relatively small intra-patient variability [208]. Recent chromatographic assays have used 
LCMS- MS for quantification of  XMP, the catalytic product of the enzyme, to indirectly 
measure the inhibition of IMPDH activity [209, 210] (Figure 26). However, these assays are 
limited by the large number PBMC count (5-10 million cells/ml of lysate) required for 
quantitation of IMPDH activity. Here we report a highly sensitive robust liquid chromatography-
mass spectrometry method based on Bemer et al. with slight modification to measure recipient 
pre-transplant IMPDH activity ex-vivo in isolated peripheral mononuclear cells (PBMCs) lysate 
based on the quantification of XMP formation normalized to intracellular AMP concentration. 
The established assay could quantitate IMPDH activity in lysate with PBMC concentration of 1-
5 million cells/ml. 
This study has retrospectively quantitated IMPDH activity in banked PBMCs from 20 
LTRs on MMF maintenance immunosuppression at University of Pittsburgh Medical Center 
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(UPMC). Thus, this study will address our central hypothesis that IMPDH activity highly 
influences the incidence of rejection and infections in LTRs. Through this study, we have also 
established the feasibility of PK-PD analysis by prospectively evaluating relationship between 
IMPDH activity and MPA exposure in 4 adult lung transplant recipients. IMPDH activity 
measurement can readily be translated into a routine clinical test in the future and can 
significantly improve MMF dosing and clinical outcomes in not only LTRs, but also in other 
solid organ transplant recipients.   
 
Figure 26. Indirect measurement of MPA based IMPDH activity inhibition by quantification of formed XMP 
normalized to the intracellular AMP levels.  
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4.3 METHODS 
4.3.1 Chemicals and reagents 
IMP, AMP, 8-bromoadenosine 5-monophosphate (Br-AMP), were ordered from Sigma Aldrich.  
XMP (Toronto Research Chemicals), sodium dihydrogen phosphate, potassium chloride, 
ammonium acetate, potassium hydroxide(Fisher), Dulbecco’s Phosphate Buffered Saline 
(Invitrogen), Ficoll-Paque solution (GE Healthcare,QC, Canada), SepMate 50 (Stem Cell 
technologies) 
4.3.2 Instruments and Column used  
We have used a Hypercarb, 100 mm x 2.1 mm, 5 microns, (Thermo #35005-102130) for the 
separation of analytes. Chromatographic separation was achieved on an Agilent HPLC/MS 
system series 1200 with a thermostatically controlled autosampler (Agilent Technologies, Palo 
Alto, CA) and SCIEX 4000 Q triple quadrupole ion trap mass spectrometer. Thermo Scientific; 
Sorvall Legend X1R (refrigerated) Centrifuge was used for isolation of PBMCs. 
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4.3.3 Sample Collection and Handling 
4.3.3.1 Prospective Study 
This was a prospective PK-PD study in adult lung transplant recipients (IRB Protocol number: 
PRO15080386) at the UPMC. The Institutional Review Board of the University of Pittsburgh 
approved the protocol. Patient samples were collected for a prospective PK-PD study over a 12-
hour dosing interval post morning oral dose of MMF. The study design is depicted in Figure 27. 
Upon obtaining informed consent from patient’s whole blood was collected in Lithium-
heparinized green top tubes. 
 
Figure 27. Study design for a prospective PK-PD study in adult lung transplant 
 
For the PD sampling, IMPDH activity measurements were obtained pre-dose and 1, 2, 4, 
and 6 hours post dose on sampling day by drawing 10 ml blood at each draw. PBMCs were 
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isolated from lithium heparin-anticoagulated whole blood using falcon tubes with Ficoll-Paque 
density gradient solution according to the manufacturer’s protocol within 6 hours of blood draw. 
Inclusion Criteria: 
 Patients must be over 18 years of age 
 Patients yet to receive a single or double lung transplant. 
 Patients must be maintained on a calcineurin inhibitor and mycophenolate mofetil or 
 mycophenolic acid 
 Patients must be provided with written informed consent 
 Patients must be able to swallow oral medications and must be on same dose of MPA for 
 at least 3 days.  
Exclusion Criteria: 
 Patients with a known hypersensitivity to MMF. 
 Prisoners 
 Pregnant women 
 Children 
 Patients with cystic fibrosis 
 Patients with systemic liver disease 
 Patients with nasogastric tubes inserted 
 Patients with MPA use prior to transplantation 
 Concomitantly on interacting medications (e.g. antacid, cholestyramine) 
 Hematocrit of less than 8 
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4.3.3.2 Retrospective Study 
This was a retrospective study in adult lung transplant recipients at the UPMC. The Institutional 
Review Board of the University of Pittsburgh approved the protocol. Patients enrolled in the 
Breathe-LTE biorepository study were eligible for this study. The study design is depicted in 
Figure 28. Breathe-LTE is a clinical biorepository at the UPMC with banked blood samples of 
over 296 lung transplant recipients. PBMC drawn on 20 lung transplant recipients within a year 
post-transplant were accessed.  The banked PBMCs were lysed in a sonicator and the lysate was 
stored at -80°C until analysis. 
 
Figure 28. Study design for a retrospective study for pharmacodynamic monitoring in adult lung transplant 
recipients. 
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4.3.3.3 PBMC isolation 
10 ml blood was diluted with 25 ml (1:2.5) of phosphate buffered saline (PBS). This was 
layered over 15 ml Ficol-Paque solution in Sep-mate tubes. Sep-mate tubes (50ml) were 
centrifuged at 1200 x g for 10 minutes at room temperature, with the brake on. Top layer, 
which contains the enriched MNCs, was poured off into a new Falcon tube not holding 
the SepMate™ tube in the inverted position for longer than 2 seconds. Cells were then 
washed with PBS and centrifuged at 300 g for 10 min to yield the pellet. The supernatant 
PBS was poured off leaving behind about 1.1 ml. The PMNC pellet was re-suspended in 
the remaining 1.1 mL of PBS, and 1.0 mL of the PBS-cell slurry was transferred to a 2 
mL tube. Cells were then manually counted using a hemocytometer and aliquoted and or 
diluted to yield 5 million cells/ml and were stored at -80°C until analysis. 
4.3.4 Assay Method 
4.3.4.1 Preparation of stock solution, working solution and incubation buffer, control 
incubation buffer 
Stock solutions were prepared by dissolving XMP (1mg/ml) and Br-AMP (1 mg/ml) in water 
and AMP (10 mg/ml) in 0.5% NH4OH. All solutions were stored at -80°C. Working solutions 
were prepared fresh to yield 0.1 mg/ml XMP and 1 mg/ml AMP. Calibration standards were 
prepared by diluting 50 μL of each working solution with 130 μL of solution consisting of 40 
mM sodium dihydrogen phosphate (pH7.4) and 100mM potassium chloride to yield target 
concentration of AMP ranging from 50-40,000 ng/ml and XMP concentration ranging from 5-
4000 ng/ml. The internal standard Br-AMP working solution (10µg/ml) was prepared from stock 
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solution at the time of assay.  4 quality control samples were prepared for XMP and AMP (XMP: 
8,80, 800 and 3500 ng/ml; AMP: 80, 800, 8000 and 35000 ng/ml). 
Incubation buffer was prepared to contain of 40 mM sodium dihydrogen phosphate (pH 
7.4) and 100 mM potassium chloride containing 1 mM of IMP and 0.25 mM of NAD+. 2 control 
buffers were prepared with IMP only and NAD+ only respectively. 
4.3.4.2 Assay Conditions 
IMPDH activity was evaluated in PBMC lysates as described by Bemer et al.[209] with slight 
modifications. IMPDH activity was calculated based on enzymatic production of XMP and was 
normalized to the intracellular AMP level. The incubation was initiated at 37°C for 180 min. The 
reaction was started by adding 50 μL of thawed lysate to 180 mL of incubation mixture 
consisting of 40 mM sodium dihydrogen phosphate (pH 7.4) and 100 mM potassium chloride 
containing 1 mM of IMP and 0.25 mM of NAD+. 
The incubation reaction was terminated at the end of 3 hours by addition of 1 ml 
methanol with a repeat pipette. Internal standard (20 µL of 10µg/ml of Br-AMP in deionized 
water) was then added to each incubation mixture, and then centrifuged at 15000 g for 10 min at 
37 °C. The supernatant was then transferred to 12 × 75 disposable culture tubes and evaporated 
to dryness under a stream of air at 30 °C. The residue was then dissolved in 100µL of deionized 
water and 5µL was injected on the LC-MS for XMP and 1 µL for AMP quantitation. Prepared 
samples were stored in the autosampler tray at 5°C. Injection volume was optimized as needed 
based on changes in instrument response for each compound (magnitude of chromatographic 
peak areas). Samples were injected in the following order: calibration standards (ascending order 
of concentrations), analyte-free samples with IS, QC set 1, half of the validation/study samples, 
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QC set 2, remaining validation/study samples followed by QC set 3. Between injections, the 
autosampler needle was washed with 60%acetonitrile, 40% water and 0.1% formic acid (v/v). 
Solvent delay was used to divert the sample to waste for the first 3 minutes and after 7 minutes 
till the end of the run. 
4.3.4.3 Chromatographic conditions 
The chromatographic separation was performed on an Agilent HPLC/MS system series 1200 
with a thermostatically controlled autosampler (Agilent Technologies, Palo Alto, CA). Thermo 
Scientific Hypercarb column (2.0mm × 100mm × 5µ, part no. 35005-102130; Thermo Scientific, 
Bellefonte, PA) was used for separation of the analytes. The mobile phase consisted of A: 
acetonitrile and B: 0.1 M ammonium acetate in LCMS water pH adjusted to 8.5 with ammonium 
hydroxide. Elution was achieved using a mobile phase gradient as follows: Starting at 5% 
acetonitrile for first 0.5 min then increased to 30% at 4 min and was held at 30% till 5 min and 
then switching back to 5% at 5.1 min. The sample run time was 10 min. The chromatographic 
gradient used to achieve separation is detailed in Table 17. The injector was maintained at 4 °C. 
The injection volume was 5 ul for XMP and AMP. The column temperature was set to 30.0 °C 
and the flow rate was maintained at 0.3 mL/min. The typical retention times were 4.25 min for 
XMP, 5 min for AMP and 7.0 min for Br-AMP. 
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Table 17. HPLC mobile phase gradient flow conditions 
Time 
(min) 
Solvent A 
(%) 
Solvent B 
(%) 
Flow 
(mL/min) 
0 5 95 0.3 
0.5 5 95 0.3 
4 30 70 0.3 
5 30 70 0.3 
5.1 5 95 0.3 
4.3.4.4 Mass spectrometric conditions 
A SCIEX 4000 Q triple quadrupole ion trap mass spectrometer electron spray (ES) in positive 
ion mode was used. The temperature of the drying gas (nitrogen) was maintained at 350 °C at a 
flow of 11 L/min. The MSD was run in the MRM mode. Monitored ions included m/z 365 for 
the positive ion of XMP, m/z 348 for the positive ion of AMP, and m/z 426 for the positive ion 
of the internal standard, Br-AMP. 
4.3.4.5 Partial Validation 
Since this assay was a modification of an existing fully validated bioanalytical assay we have 
performed a partial validation of the method. Validation of the assay in patient cell lysate 
preparations was performed. Ten calibration standards ranging in concentration from 5-3500 
ng/mL for XMP and 50-35000 ng/ml for AMP were prepared and analyzed in duplicate in 6 
analytical runs on 3 consecutive days. Throughout partial method validation and study sample 
analysis, calibration curves were determined by plotting the analyte to IS chromatographic peak 
area ratio against the prepared analyte concentration in each calibration standard. Calibration 
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curves were fit by linear regression for all analytes and a weighting of 1/y2 was applied to all 
calibration curves. The LLOQ was determined as the minimum value having an accuracy and 
precision within ±15% of the nominal value. The LLOD was determined by the minimum value 
with a signal-to-noise ratio of at least greater than 3:1.  
Accuracy and precision were determined by analyzing 4 levels of QC samples. AMP and 
XMP QC samples were prepared to yield A:8 ng/ml XMP and 80 ng/ml AMP, B: 80 ng/ml XMP 
and 800ng/ml AMP, C: 800ng/ml XMP and 8000 ng/ml AMP and D: 3500 ng/ml XMP and 
35000ng/ml AMP. Six samples of each QC were analyzed on 3 days. Accuracy was be expressed 
as relative standard error (RSE%), was calculated using the equation RSE% = (Calculated value-
True value)/True value*100. Precision was calculated as the percent coefficient of variance 
(%CV) where %CV = standard deviation/mean x 100. A ±15% deviation from the nominal value 
was considered acceptable. Stability of the analytes was tested for 24 hours at autosampler 
temperature and compared with freshly prepared calibration standards.  
For each cell lysate matrix, one QC set (set A, n = 3) was prepared according to normal 
sample processing method. Another set of QCs (set B, n = 3) was prepared as neat solution in 
water. The third set of QCs (set C, n = 3) was prepared without analytes XMP and AMP and 
spiking the sample into the matrix post-extraction. 
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4.3.5 Measurement of IMPDH activity 
Enzyme activity was expressed as produced XMP (µmol) per time unit (h) per µmol of AMP. As 
reported by others, here too we have used the concentration of intracellular AMP, rather than cell 
count or protein concentration was used to normalize results [207, 208]. The normalization of 
IMPDH activity using AMP better reflects the intracellular level of IMPDH released by 
disrupted cells and is relatively less affected by extracellular proteins or erythrocyte 
contamination. The following equation was used (XMP and AMP concentrations are expressed 
in micromoles per liter and incubation time in seconds):  
IMPDH activity (((μmol/second/mol of AMP)) = [produced XMP X10
6
/ (incubation time X 
measured AMP)]. 
Maximum inhibition of IMPDH activity (Imax) as described by Sommerer et al.[100] was 
calculated with the following formula: 
Imax= [1 –(Amin/Amax) × 100, 
Where Amin = minimum daytime enzyme activity 
 Amax = maximum daytime enzyme activity 
 
4.3.6 Statistical Analysis 
Statistical analysis was completed using SPSS software, version 23. In the matrix effects studies, 
IS-normalized MF values were compared using unpaired t-test (2 tailed). For all statistical tests, 
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a p<0.05 was considered significant. Normality for pharmacodynamic data from the 
retrospective study was determined using Shapiro Wilk test. T-Test was used for IMPDH activity 
by those who have rejection within ±3 months window prior to and after IMPDH activity. 
Univariable logistic regression model for ACR and infection within the ±3-month window with 
IMPDH as a predictor. Owing to the less enrollment of adult lung transplant patients in the 
prospective study no statistical analysis was performed.  
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4.4 RESULTS 
4.4.1 Assay Validation 
Table 18 shows the optimized mass spectrometric conditions for the assay. Figure 29, Figure 30 
and Figure 31 show chromatographic separation for XMP, AMP and the internal standard Br-
AMP at their lower limits of quantification.  
 
Figure 29. Chromatographic separation of XMP (5ng/ml) against background noise 
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Figure 30. Chromatographic separation of AMP (5 ng/ml) against background noise 
 
Figure 31. Chromatographic separation of Br-AMP (5ng/ml) against background noise 
A partial validation was performed for the IMPDH assay using HPLC-MS. The 
calibration curves were linear for in the range of 5-4000 ng/ml and 50-40,000 ng/ml for XMP 
and AMP respectively.  Figure 32 and Figure 33 shows the calibration curves for XMP and AMP 
respectively. The linearity as expressed by the correlation coefficients of the 1/y-weighted 
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calibration curves were in the range of 0.995 – 0.999 for both the compounds. The lower limit of 
quantification in this assay was 5 ng/ml and 50 ng/ml for XMP and AMP respectively.  The 
lower limit of detection for both XMP and AMP was 1ng/ml. 
Table 18. Mass spectrometric conditions for XMP, AMP and Br-AMP 
Analyte 
ESI 
mode Cone Voltage Desolvation temperature MRM transition 
XMP Positive 40 V 500°C 365.5  153.3 
 
    AMP Positive 40V 500°C 348.4136.3 
 
    Br-AMP Positive 40V 500°C 426.1 214.4 
 
The intra-day and inter-day precision and accuracy of the assay was less than 14.5% at 
each of the 4 QC levels. Results of the assay validation for intra and inter-day are presented in 
Table 19 and Table 20 respectively. The matrix effect at all QC levels in the cell lysate 
preparation was between 96.9-115% and 103.7-114.5% for XMP and AMP respectively. This 
demonstrates minimal matrix effects of cell lysate on the reproducibility and reliability of the 
assay. 
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Figure 32. Calibration curve for XMP in phosphate buffer 
 
Figure 33. Calibration curve for AMP in phosphate buffer 
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Table 19. Intra-day accuracy and precision of XMP and AMP 
XMP 
Concentration 
(ng/mL) 
Mean calculated 
concentration 
(µg/mL) 
Accuracy 
(% 
deviation) 
Precision (% CV) 
 8 7.7 -3.8 11.3 
80 82.5 3.1 12 
800 830.5 3.8 1.8 
3500 3390 -3.1 7.9 
AMP 
Concentration 
(ng/mL) 
Mean calculated 
concentration 
(µg/mL) 
Accuracy 
(% 
deviation) Precision (% CV) 
80 79.7 0 14 
800 853.2 -4.2 14.5 
8000 815.3 6.7 7.0 
35000 30566.7 12.6 14.5 
Table 20. Inter-day accuracy and precision of XMP and AMP 
XMP 
Concentration 
(ng/mL) 
Mean calculated 
concentration 
(µg/mL) 
Accuracy 
(% 
deviation) 
Precision (% CV) 
 8 7.9 -1.3 2.3 
80 86.8 7.9 7.4 
800 869.3 8.6 8.8 
3500 3710 6.0 13.8 
AMP 
Concentration 
(ng/mL) 
Mean calculated 
concentration 
(µg/mL) 
Accuracy 
(% 
deviation) Precision (% CV) 
80 80.3 0.4 14.4 
800 891.8 11.5 11.9 
8000 8062.8 0.8 6.5 
35000 29767(n=3) 14.8 9.5 
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4.4.2 Application of Assay to retrospective and prospective studies 
The assay was used for quantitation of MPA based IMPDH inhibition in 4 lung transplant 
recipients from a prospective PK-PD study over a dosing interval and from 20 lung transplant 
recipients in a retrospective study. All patients received a fixed MMF flat dose of 1 g BID., in 
combination with a calcineurin inhibitor. 
4.4.3 Single time point ex-vivo IMPDH activity post-transplant in lung transplant 
recipients 
IMPDH activity was monitored for patients on an existing retrospective biorepository study. 
PBMCs were isolated from patients at their routine bronchoscopy visits within the first-year 
post-transplant. Average single time point IMPDH activity monitored in adult lung transplant 
recipients was 17.8 μmol/second/mol of AMP.  IMPDH activity showed high inter-patient 
variability (~5-fold) from 7 to 33.5 μmol/second/mol of AMP as shown in Figure 34. 
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Figure 34. High variability of trough IMPDH activity in 20 adult lung transplant recipients. 
 
.  We have used a univariate logistic regression model for ACR and or infection within 
six months of IMPDH activity measurement with IMPDH as a predictor.  The model did not 
show any statistically significant association between ACR and IMPDH activity and infection 
and IMPDH activity. Although statistically not significant, patients rejecting the graft had a 
higher IMPDH activity as seen in Figure 35. 
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Figure 35. Mean trough IMPDH activity in rejecters and non-rejecters in adult lung transplant 
recipients. 
4.4.4 Pharmacodynamic activity of IMPDH of patients in a prospective study undergoing 
lung transplantation 
IMPDH activity was inversely related to MPA plasma concentration. Figure 36 shows the 
IMPDH activity of individual patient over a dosing interval. In some patients, the maximum 
inhibition occurred between 1-2 hours and coincides with the time to peak MPA concentrations 
as measured in the previous chapter, whereas others exhibited longer inhibition of the 
activity.Complete inhibition of IMPDH activity was observed only for a short time, followed by 
a rebound phenomenon after four hours. In the lung transplant patients, mean IMPDH activity 
was 12.3 μmol/second/mol and revealed large inter-patient variability (range: 1.0-40 
μmol/second/mol of AMP). The linear regression for MPA concentration and IMPDH activity is 
shown in Figure 37. Overall MPA concentrations are not correlated to the IMPDH activity. The 
mean Imax of MPA after oral dose of MMF within the dosing interval was 61.2 %( 31.2-93.2%). 
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 This study is the first to evaluate the pharmacokinetics of MPA in relation to inhibition of the 
pharmacological target enzyme IMPDH in adult lung transplant recipients. This ex-vivo 
measurement of IMPDH activity provided for a good pharmacodynamic marker of MPA-
induced immunosuppression at the lymphocyte level. Although preliminary data, this study still 
does provide the potential utility of combining PK and IMPDH biomarker data to optimize MMF 
therapy. It also suggests the importance of early monitoring of MPA PK and IMPDH inhibition 
to improve drug exposure and outcomes. 
 
Figure 36. Individual IMPDH activity over time for 4 patients undergoing lung transplantation 
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Figure 37. Relationship between post-transplant trough IMPDH activity and corresponding MPA plasma 
concentration (measured in chapter 3) from prospective study in lung transplant recipients 
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4.5 DISCUSSION 
Therapeutic drug monitoring has become very critical to optimize dosing of 
immunosuppressants. CNIs that form the backbone of immunosuppressive therapy in solid organ 
transplant recipients are routinely monitored and the doses are titrated to target trough level. 
MMF although used extensively in solid organ transplant recipients is however not routinely 
monitored. Measurement of 12-hour AUC is impractical in standard clinical practice settings. An 
alternate simpler approach to measure drug exposure is essential to optimize MMF therapy. 
Pharmacodynamic monitoring of IMPDH activity to determine the efficacy of MMF ex-vivo has 
been a useful approach for optimizing MMF therapy. The pharmacodynamic monitoring is not 
designed to replace the pharmacokinetic monitoring of MMF, instead to use it along with PK 
analysis to improve therapeutic monitoring and provide for a more effective way to individualize 
MMF dosing.  
Here we have established and validated a sensitive LCMS assay to explore the IMPDH 
activity in a retrospective and prospective study in adult lung transplant recipients. In this study, 
we demonstrated that this HPLC-MS method is useful for simultaneously measurement of XMP 
and AMP and thereby quantitate the pharmacodynamic activity. The measured IMPDH activity 
was normalized to the intracellular AMP concentration. This sensitive method required a small 
number of isolated PBMCs (~1-5 million/ml) for monitoring IMPDH activity in PBMCs. It is 
convenient for large prospective clinical studies aimed at determining IMPDH activity in any 
transplantation settings. This chapter provides preliminary data of exploring IMPDH activity 
quantitation as a promising biomarker for MMF based immunosuppression in solid organ 
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transplant recipients.  Although limited by sample size in both retrospective and prospective 
studies, these trials do demonstrate the feasibility of PD monitoring. 
A fixed dose MMF is used in lung transplant recipients and is similar to the dosing used 
in renal and heart transplant recipients. However, lung transplant patients have shown a different 
pharmacokinetic profile as compared to renal transplant recipients. Studies suggest a lower MPA 
exposure in lung transplant recipients. There is a scarcity of PK studies in lung transplant 
recipients let alone an individualized MMF dosing study based on PK-PD monitoring. The 
underlying hypothesis of this clinical trial was that sub-therapeutic levels on MMF in the absence 
of TDM and concurrent increase in the IMPDH activity could be the cause for high incidence of 
acute clinical rejection in adult lung transplant recipients. The objective of this study is to 
describe IMPDH activity in lung transplant recipients maintained on MPA for maintenance 
immunosuppression and to correlate this activity with clinical phenotypes seen in this 
population. 
This study is the first to document the pharmacodynamic activity of MPA as measured by 
the inhibition of the pharmacological target enzyme IMPDH in adult lung transplant recipients. 
Our study is limited, in that we started monitoring IMPDH concentrations at least 6 months post-
transplant and thus we have no information on pre-transplant IMPDH activity. Statistical 
analysis for a power of 80% with an odds ratio for rejection of 3, with an established 2-sided 
alpha level of 0.05, 70 single time point of IMPDH activity measurements will be required to 
find significance. Due to small sample size we were not able to establish a threshold for IMPDH 
activity to facilitate identification of rejecting and infecting phenotypes of IMPDH activity at this 
point.  
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Also, for the prospective PK-PD study, owing to the limited enrollment till the time of 
data analysis we were not able to establish a PK-PD relationship of MMF exposure to the 
IMPDH inhibition. However, for all patients the maximum concentration of MPA coincided with 
the maximum inhibition (lowest IMPDH activity). 
Single nucleotide polymorphisms (SNPs) in IMPDH-I and -II genes have been 
independently correlated with acute rejection. IMPDH is subject to genomic variability; and so, 
the activity is expected to be heterogeneous. Additionally, MPA exposure is influenced by 
genotype of the MRP2 as represented in Figure 38. The impact of MRP2 SNPs-rs717620, 
rs3740066 and rs2273697 upon plasma MPA exposure and IMPDH activity will also be 
evaluated. 
 
Figure 38.  IMPDH and MRP2 genotypes and effect on pharmacokinetics of MPA. 
 
DNA for the IMPDH II SNPs-rs4974081, rs11706052, 787C>T and the IMPDH I SNPs-
rs2278293 and rs2278294 will be collected and genotyped using a validated TaqMan® based 
allelic discrimination assay using the manufacturer protocol. Previous studies have implicated 
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SNPs associated with IMPDH I with MPA treatment related rejection and will be evaluated as a 
part of this ongoing trial.  Data from this study and future trials with larger number of patients 
should focus on further investigating whether differences in IMPDH activity can predict efficacy 
and dose requirements of MPA. Plasma samples from the current study can be used to evaluate 
the effect of unbound MPA concentration may affect IMPDH activity. 
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5.0  PREDICTING EXPOSURE OF MYCOPHENOLIC ACID AFTER IV AND ORAL 
ADMINISTRATION USING A COMBINED IN VITRO-IN-VIVO EXTRAPOLATION 
AND PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING APPROACH 
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5.1 ABSTRACT 
Mycophenolic acid is the active form of the prodrug MMF which was approved in 1995 for 
prevention of organ rejection in kidney transplant recipients. MPA shows high inter and intra- 
patient variability across transplant patient populations and yet is not routinely monitored and 
dosing not individualized. Therapeutic trough monitoring of this drug is not useful owing to the 
poor correlation between the trough concentration and overall AUC exposure[90, 170, 211] . 
Over the last decade several pharmacometric approaches have been applied to better capture the 
inter-subject variability and predict the exposure in solid organ and stem cell transplant 
populations[35, 212, 213]. 
We have built and validated a robust mechanistic physiologically based pharmacokinetic model 
of mycophenolic acid in healthy, Chinese healthy and renally impaired adult volunteers. We 
have built a full PBPK advanced dissolution absorption model (ADAM) in SimCYP Simulator 
V15. Physicochemical properties for mycophenolic acid were obtained from literature and a 
model was build and validated across IV and oral doses of MMF in population cohorts of healthy 
volunteers, Chinese healthy volunteers and patients with renal impairment. Pharmacokinetic 
parameters like Cmax, Tmax, AUC and Clearance were assessed and compared with the observed 
data. Parameter estimation using non-linear mixed effects was used to optimize tissue 
partitioning. Intrinsic clearance for each of the UGT enzymes was extrapolated from 
recombinant UGT data as reported by Picard et al using rUGT scalar. The simulated clinical 
trials were carried out in the 100 virtual subjects from population groups of SimCYP’s platform: 
i) healthy volunteers, ii) renal impairment with glomerular filtration rate (GFR) values between 
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30–60 iii) renal impairment with GFR below 30 and iv) a custom kidney transplant model and v) 
pediatric population. The model was robust in predicting MPA exposure in Caucasian and 
Chinese healthy subjects, renally impaired patients and renal transplant recipients. All predicted 
MPA PK parameters fell well within ±20% range of the corresponding PK parameters calculated 
from observed studies. Healthy pediatric data was not available to validate the model. The 
predicted MPS exposure in pediatric population was 5-fold higher than the in-house pediatric 
HSCT exposure.  This predicted difference could be due to physiological changes occurring in 
HSCT patients. The pediatric model could be used as a template to further build and validate a 
pediatric HSCT population. Sensitivity analysis revealed that unbound fraction and UGT 
abundance are the primary drivers of changes in MPA PK and could be responsible for the large 
inter and intra-patient variability in transplant population. This model predicted exposure can 
facilitate development of better dosing strategies in adult and pediatric HSCT patients.  
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5.2 INTRODUCTION 
Mycophenolic acid is the active form of the prodrug MMF which was approved in 1995 for 
prevention of organ rejection in kidney transplant recipients. It is concomitantly given with 
calcineurin inhibitors like cyclosporine or tacrolimus and corticosteroids. It is given PO as BID 
or is infused over ≥2 hours, when given intravenously. Two different oral formulations of MPA 
are available as capsules and tablets as MMF or as MPA in EC-MPS. MMF is an ester derivative 
of MMF and is readily hydrolyzed by the esterases in the body. Enteric-coated mycophenolate 
sodium (EC-MPS; myfortic®, Novartis Pharma AG, Basel, Switzerland) is an enteric-coated 
formulation which was developed to specifically to improve the upper GI tolerability of MPA. 
Enteric-coated-MPS 720mg is equivalent to MMF 1000 mg and provides similar drug exposure. 
Mycophenolate Mofetil, the prodrug gets metabolized to MPA by esterases located in the 
systemic circulation, gut wall, liver and tissues.[26]  MPA is undergoes phase II metabolism by 
UDP glucuronosyl transferases primarily in the liver and kidneys, forming an inactive 
metabolites MPAG and 7-O-glucoside while a small amount gets metabolized to an active 
compound acyl-MPA glucuronide. Metabolites are excreted in the urine and bile. MPA is 
excreted by MRP2 into the bile and MPAG and MPA present in the bile are subjected to MRP2 
mediated EHC. EHC shows a high inter-patient variability and is known to contribute 10 to 40% 
of the AUC of MPA in a dosing interval.[31, 36]  
MPA shows high inter and intra-patient variability across different transplant patient 
populations and yet is not routinely monitored. Trough therapeutic monitoring of this drug is not 
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recommended owing to the poor correlation between the trough concentration and overall 
exposure as measured by the AUC [24, 211, 214]. Over the last decade several pharmacometric 
approaches have been applied to better capture the inter-subject variability and predict the 
exposure in solid organ and stem cell transplant populations [35, 212, 213]. 
Several commercially available PBPK platforms like SimCYP (SimCYP Ltd., Sheffield, 
United Kingdom) and Gastroplus (Simulations Plus, Inc., Lancaster, CA), offer complex clinical 
trial design options and allow incorporation of multiple routes of drug administration. These 
software platforms also incorporate population variability, physiologic changes associated with 
various disease states, and can link exposure in different tissues to pharmacodynamic effects 
[215]. These softwares facilitate the industry to evaluate the potential clinical impact of 
physiological and disease specific changes and help design clinical trials. Physiologically based 
pharmacokinetic (PBPK) modeling is increasingly being used by the industry and the regulatory 
authorities for in vitro in-vivo extrapolations, assessment of risk to health and first in human 
dosing. [216-218]  Inclusion of modeling and simulation approaches in the recent drug 
interaction regulatory guidance updates from both the European Medicines Agency (EMA) 
(CHMP, 2012) and the U.S. FDA (CDER, 2012) have demonstrated the acceptance of the use of 
PBPK modeling to support drug registration by regulatory agencies.  
Especially for the purpose of integrating information of different PK properties, physiologically-
based pharmacokinetic (PBPK) modeling linked to in vitro in-vivo extrapolation (IVIVE) 
approaches (PBPK– IVIVE) has gained growing interest and application.  
In this study, we present a PBPK–IVIVE approach to predict human exposure of active 
drug after oral prodrug administration. PBPK modeling approach incorporates a drug’s 
physiochemical properties, human physiological variables and population variability estimates to 
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predict drug exposure. An initial PBPK model describes MPA PK after IV and oral (PO) 
administrations in healthy Caucasian and Chinese adults and patients with varying degree of 
renal impairment. The in-built pediatric population in the SimCYP simulator allowed us to 
predict the exposure of MPA in pediatric patients. However, due to lack of clinical data on 
healthy pediatric population the model could not be validated. This model can be further used to 
access the impact of various physiological factors in pediatric transplant patients to improve 
MPA therapy. 
To the best of our knowledge, the use of PBPK modeling in predicting MPA exposure in healthy 
adult and pediatric and transplantation population has not been explored. The objective of this 
work was to build and validate a PBPK model for IV and oral MPA in healthy adults and renally 
impaired and transplant recipients and to explore the factors that could be responsible for the 
high inter-patient variability associated with this drugs exposure and to determine the dosing 
required in pediatric HSCT patients based on the simulated data.  
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5.3 METHODS 
A systematic approach was used in developing the PBPK models, starting from screening of 
drug specific input parameters and clinical pharmacokinetic data from the published literature, to 
incorporating these data into the software and choosing the right physiological model to the final 
steps of visual as well as pharmacokinetic evaluation of the model. Physicochemical properties, 
protein binding, blood to plasma ratio  and permeability were obtained from an extensive 
literature search in Pubmed.[8] The dissolution kinetics data as reported by Lee et al. was 
digitized and built into the SimCYP simulator. [8] 
GetData Graph Digitizer V.2.26 was used to digitize published clinical pharmacokinetic 
data of mycophenolic acid. A full PBPK model was developed for IV and oral mycophenolic 
acid formulation using physiochemical properties[219], in-vitro metabolic profiles [23]and 
published IV mycophenolic acid pharmacokinetic data in healthy subjects. In this stepwise 
PBPK model, an IV dose was first simulated in healthy volunteers to avoid complexities 
associated with modeling oral absorption. This approach allowed for optimization of a wide 
range of drug-dependent parameters that govern the drug disposition, including clearance inputs 
and the percentage UGT enzyme contributions. When extending the model to oral dosing 
regimen, parameters from the previous steps were kept, and additional parameters that may 
potentially influence drug absorption, such as intestinal permeability, were included. Model 
naïve data for from different pharmacokinetic studies was used to perform inter-study 
validations. The simulated clinical trials were carried out in the following virtual population 
groups of SimCYP’s platform: i) healthy volunteers, ii) Chinese healthy volunteers iii) renal 
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impairment with GFR values between 30–60 iv) renal impairment with GFR below 30. All 
simulations run for 10 clinical trials of 10 subjects in each trial. The overall workflow for the 
development of model is shown in figure 1. A combined top-down approach using observed 
pharmacokinetic data and a bottom up using IVIVE approach was used for model building. This 
was accomplished by first developing and verifying a PBPK model using observed adult clinical 
data after IV and oral administration followed by simulating mycophenolic acid exposure in 
Chinese healthy, renally impaired and renal transplant recipients using the PBPK model and 
comparing the results with observed clinical data. The MMF dose was converted to MPA 
equivalents according to the equation MPA dose = FMW * MMF dose, where FMW is the 
fractional difference in molecular mass between MPA and MMF. For the oral and intravenous 
formulations of MMF, FMW is equal to 0.739.  
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Figure 39. PBPK model used for describing the kinetics of MPA. The absorption of MPA after oral administration was described by the 
ADAM model. [220]
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5.3.1 Absorption 
The advanced dissolution, absorption and metabolism (ADAM) model with the Simcyp default 
values of fasted gastric emptying time (mean 0.4 h with a coefficient of variation [CV] of 38 %) 
and small intestinal transit time (mean 3.33 h with Weibull distribution, α = 2.92 and β = 4.04) 
was used to predict drug absorption.[221] The model used is depicted in Figure 39. The 
predicted human jejunum permeability (Peff,man) of mycophenolic acid was 12.3063× 10−4 cm/s, 
which was obtained using in vitro Caco-2 permeability (Papp) data calibrated with reference 
values for propranolol.[222] In addition, the predicted absorbed fraction of mycophenolic acid 
was 1, which is consistent with mycophenolic acid being a highly permeable drug belonging to 
BCS class II. The pH-dependent dissolution data of the solid dosage form from Lee et al. was 
digitized and incorporated into the model. The pH-dependent solubility profile of MPA used in 
this model is provided in Figure 40. 
 
Figure 40. pH-dependent solubility of MPA used in the dissolution profile of the ADAM model. 
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5.3.2 Distribution 
The full PBPK model was used for predicting the volume of distribution. The volume of 
distribution at steady state (Vss) and the specific tissue-to-plasma partition coefficient (Kp) 
values were calculated by the Paulin and Theil method with the Berezhkovskiy correction.[223] 
The model predicted Vss value of 4.34 L/kg by this method was comparable to the reported 
value of 4 L/kg in the literature.[224] Tissue composition and blood flow rates as reported  by 
SimCYP® for the virtual healthy volunteer population were used for building MPA PBPK 
model (Figure 41 and Figure 42). 
A sequential sensitivity analysis was performed to identify the Kp values that had a significant 
impact on pharmacokinetic parameters like Cmax, Tmax and AUC. Tissue plasma partitioning of 
MPA in adipose tissue was optimized using non-linear mixed effects modeling using the 
parameter estimation module in SimCYP simulator.   
Figure 41. Tissue composition parameters used for building MPA PBPK model in healthy volunteer population. 
Screenshot from SimCyp® population-based simulator v15.1 (SimCYP limited, Sheffield, UK). EW: %Extracellular 
Water; IW : % Intracellular Water; NL : % Neutral Lipids; NP : % Neutral Phospholipids; AP : % Acidic 
Phospholipids; Kp,Alb : tissue-plasma partition coefficient for serum albumin; Kp,LPP : tissue-plasma partition 
coefficient for  lipoproteins 
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Figure 42. Blood flow rates associated with each of the physiological 
compartment that were used for building MPA PBPK model in healthy volunteer 
population. 
Screenshot from SimCYP® population-based simulator v15.1 (SimCYP limited, Sheffield, 
UK). 
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5.3.3 Elimination 
MMF is instantaneously metabolized to the active form MPA by esterases. MPA is extensively 
metabolized by phase II pathway to its glucuronide metabolites: MPAG and AcMPAG. Intrinsic 
clearance (CLint) values from in-vitro data in recombinant human UGT enzyme system were 
used for prediction of drug clearance.  The contributions of the individual UGT enzymes that 
are involved in the metabolism of mycophenolic acid was obtained from the literature. It has 
been reported that UGT1A9 is the major UGT enzyme, while UGT1A8, UGT1A10, UGT1A1 
and UGT2B7 are involved to a minor extent. Here we have used established IVIVE methods 
using enzyme specific microsomal metabolism data.  The inter-system extrapolation factors 
(ISEF) is used as a scalar to extrapolate recombinant in-vitro enzyme activities to in-vivo 
intrinsic clearance by using the following equation: 
 
Where ISEF is a scaling factor that corrects for the difference in the activity per unit of 
enzyme between recombinant systems and liver samples used in experiments whereas, CYPj 
(UGTs in this case) is the average amount of j
th
 enzyme per mg microsomal protein of human 
liver and MPPGL is the average amount of microsomal protein per gram of human liver. ISEF 
is a combination of relative activity factor (RAF) and the abundance of the enzyme and is 
related to RAF as follows, 
𝐼𝑆𝐸𝐹 =
𝑉𝑚𝑎𝑥 𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠 / 𝐶𝑌𝑃𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒
𝑉𝑚𝑎𝑥 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 𝑒𝑛𝑧𝑦𝑚𝑒𝑠
 
where RAF can be expressed as,  𝑅𝐴𝐹 =
Vmax endogenous microsomes
Vmax expressed enzymes 
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 Using the above equations, the RAF for each of the UGTs was calculated using the in vitro data 
from Picard et al and was incorporated into the model (Table 21and Table 22). 
Table 21. rUGT scalar calculation from endogenuous microsomal Vmax and enzyme specific Vmax 
Enzyme 
Abundance (pmol/mg of 
microsomal protein) 
Endogenous 
Microsomal V
max
 
Enzyme 
Specific V
max
 
rUGT Scalar 
MPAG   
  Liver Kidney GI Liver Kidney GI 
 
Liver  Kidney GI 
UGT1A1 48 6.1 8.5 5.16 12.94 0.71 0.11 46.91 117.64 6.45 
UGT1A7 0 13 7.1 5.16 12.94 0.71 7.14 0.72 1.81 0.10 
UGT1A8 0 4.9 5.6 5.16 12.94 0.71 7.27 0.71 1.78 0.10 
UGT1A9 31 79 5.9 5.16 12.94 0.71 11.82 0.44 1.09 0.06 
 
 
 
 
 
 
 
 
 
 155 
Table 22. Physicochemical Properties and In-vitro UGT enzyme kinetics data of Mycophenolic acid 
Parameter Reference Value Reference 
Molecular weight 320.33 Drugbank 
LogP 1.6 Lee et al 
Compound Type Monoprotic acid  
pKa 4.8 Lee et al 
Blood to plasma ratio 0.6-0.7 Lee et al( optimized) 
Fraction unbound in plasma 0.03  
Absorption Model ADAM - 
Caco 2 permeability  
(Apical pH 7.4 to Basolateral pH 7.4) 
26.33 X 10
-6
 cm/s   
Propranolol permeability 6.582 X 10
-6
 cm/s  
Predicted Peff 12.301 9 10
-4
 cm/s  
Distribution Model Full PBPK  
Prediction method Paulin and Theil method  
Elimination Enzyme Kinetics Picard et al 
UGT1A1 Clint (µL/min/mg protein) 0.26 (Pathway I) Picard et al 
UGT1A7 Clint (µL/min/mg protein) 14.88 (Pathway I) Picard et al 
UGT1A8 Clint (µL/min/mg protein) 5.22 (Pathway I) Picard et al 
UGT1A9 Clint (µL/min/mg protein) 73.86 (Pathway I) Picard et al 
UGT2B7 Clint (µL/min/mg protein) 1.08 (Pathway II) Picard et al 
UGT1A1 Clint (µL/min/mg protein) 0.08 (Pathway II) Picard et al 
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5.3.4 Sensitivity Analysis 
Sensitivity analysis allows to quantitatively analyze the uncertainty associated with a parameter 
and its impact on an outcome variable such as clearance or AUC. This uncertainty could be 
associated with a system parameter (e.g enzyme abundance or blood flow), or an in vitro 
parameter (e.g. intrinsic clearance) that has been determined experimentally. Such knowledge is 
important for assessing whether certain parameters need to be determined more accurately for 
the model under study and to get a more comprehensive understanding of the system being 
modelled.  
ASA (Automated Sensitivity analysis) is a user-friendly tool that allows the assessment 
of changes in an outcome variable (e.g. AUC or CL) as a function of the user-defined input 
variables (e.g. dose). Here we have performed sensitivity analysis on fraction unbound. MPA, 
being a highly protein bound drug, its pharmacological activity is largely dependent on the free 
fraction. It was optimized before incorporating in the model. MPA exposure in terms of AUC 
and Cmax was highly sensitive to the fraction unbound. Figure 43 shows the concentration time 
profiles of MPA for a range of 0.01-0.3 of unbound fraction. MPA is primarily metabolized by 
UGT1A9, 1A8, 1A2 and 2B7. We predict that changes in UGT abundance can potentially affect 
the MPA PK. A sesitivity analysis of the effect of abundance of UGTs on the MPA PK was 
carried out. Figure 44 shows the effect of changes in UGT ezymes’ abundance of the 
concentration time profile of MPA.  
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Figure 43. Sensitivity analysis of MPA exposure to unbound fraction of MPA over time 
 
 
Figure 44. Sensitivity analysis of varying percentages of UGT abundance to predict the MPA exposure 
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5.3.5 Clinical Pharmacokinetic Data 
The PubMed database was screened for single dose pharmacokinetic studies of mycophenolic 
acid in healthy adults, Chinese healthy volunteers and patients with varying degree of kidney 
impairment (GFR 30-60, GFR<30) with known age, sex, height and weight data and reported 
systemic drug concentration–time profiles. Data from a single IV and oral dose of 1500 mg of 
MMF from Bullingham et al was used to build the model in healthy volunteers.[11] Model 
naïve data from 4 other studies in adult healthy volunteers [41, 46, 54, 58, 225, 226], 3 Chinese 
healthy volunteers [32, 227, 228] and 3 in patients with impaired kidney function[46, 229] was 
used for validation. The pharmacokinetic data were either provided by the author as seen in 
Bullingham et al. [11] or scanned from the concentration time profiles [46, 54, 58, 226], using 
the graph digitizer GetData Graph Digitizer V.2.26. However, errors associated with data 
digitization did add variability to the model-based predictions of concentration time profiles. to 
the Additionally one publication that reported only the pharmacokinetic parameters, but not the 
concentration–time profiles [230], after administration of a single oral dose in healthy subjects 
was used in the comparison of the observed and predicted values of the chosen pharmacokinetic 
parameters. Table 22 shows the physico-chemical data used to build and validate the model. 
5.3.6 Model Evaluation 
The developed PBPK model was evaluated using visual predictive checks by overlaying the 
observed full concentration time profiles on the predicted profiles and a comparison of the 
observed and predicted values of various pharmacokinetic parameters. For publications where, 
pharmacokinetic parameters were not available they were calculated by a non-compartmental 
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analysis (NCA) from each observed profile and compared to its corresponding predicted value 
in each model (i.e. using the predicted values at the same time points), using Phoenix 
WinNonLin version 6 software. The area under the drug concentration– time curve from time 
zero to the time of the last measured concentration (AUClast), Cmax, Tmax were compared.   There 
are no established guidelines regarding an acceptable error range that should be used for the 
evaluation of predicted data by PBPK models. A 2-fold error is commonly used by researchers 
in this field. [231, 232]Some others have also used a wider (3-fold) range [233] or a stricter 
(1.5-fold) range. [234] In our study since we are validating a model across different populations 
we have used a stricter 1.5-fold error as the criterion. 
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5.4 RESULTS 
5.4.1 Healthy adult volunteers 
The simulations were performed following multiple single dose administrations of MMF as a 
1gm oral dose BID. The selection of the demographics of the virtual population and the dose for 
the simulation were based on the study details from the clinical study in adults. Ten trials of 10 
healthy subjects (i.e., 100 subjects) were run. The observed and predicted pharmacokinetic 
parameters are shown in Table 23. The predicted concentration time profiles for model building 
dataset after a 1500 mg single dose of oral MMF are represented in Figure 45. 
 
Figure 45. Mean observed (yellow circles) and predicted (green solid line) concentration time profile of MPA 
for a single 1500 mg dose in healthy volunteers. 
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Figure 46A, B and C show the predicted concentration time profiles after 1000 mg single oral 
dose of MMF. The observed concentrations over time are overlaid on the graph. The predicted 
concentration time profiles for all the model naïve datasets are within 1.5-fold of the observed 
values. In healthy adults, with the exception of a few concentration observations, the simulated 
mean profiles with the 5th and 95th percentile curves can capture the observed PK data for all 
individuals obtained after administration of 1000 mg doses of oral MPA. The calculated PK 
parameters for virtual population of healthy volunteers, Cmax, AUC and Clearance, are in good 
correlation with values from the literature and are presented in Table 23. 
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Figure 46. A, B and C: Mean observed (yellow circles) and predicted (green solid line) concentration time 
profile of MPA for a single 1000 mg dose in healthy Caucasian volunteers. 
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5.4.2 Healthy Chinese Volunteers 
The SimCYP Chinese healthy volunteer population was used to validate the robustness of the 
model while transitioning between different populations in SimCYP. The predicted 
concentration time profiles after 1000 mg single oral dose are represented in Figure 47 A, B and 
C. The calculated PK parameters for virtual population of Chinese healthy volunteers, mainly 
Cmax, AUC and Clearance, are within 1.5-fold of the observed values and are presented in Table 
23. 
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Figure 47. A, B and C: Mean observed (yellow circles) and predicted (green solid line) concentration time 
profiles of MPA for a single 1000 mg dose in healthy Chinese volunteers from three independent model naïve 
datasets. 
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5.4.3 Renally impaired patients 
The predicted concentration time profiles for patients with End stage renal disease with varying 
degrees of GFR are presented in Figure 48A, B and C. Similar to the adult healthy Caucasian and 
Chinese volunteer predictions, the predicted profiles as also the pharmacokinetic parameters 
(Table 23) for patients with varying degree of renal impairment were within 1.5-fold of the 
observed data. 
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Figure 48. A, B and C: Mean observed (yellow circles) and predicted (green solid line) concentration time 
profile of MPA for a single 1000 mg dose in patients with varying degree of renal impairment; GRF<30 (A B), 
GRF:30-60(C)
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Table 23. Observed and predicted Pharmacokinetic parameters with fold change for healthy adults, Chinese healthy volunteers and patients with 
varying degree of renal impairment 
 
 
 
 
 
 
 
 
 
Observed Predicted Fold change Observed Predicted Fold change Observed Predicted Fold change Observed Predicted Fold change
Bullingham et al Healthy 1.5 gm IV Building
Bullingham et al Healthy 1.5 gm Oral Building 34 37.2 1.09 0.99 0.72 0.73 101 100 0.99 11.58 12.37 1.07
Johnson et al Healthy 1 gm Oral Validation 25.3 25.2 1.00 0.75 0.67 0.89 45 - N/A N/A 12.37 N/A
Kees et al Healthy 1 gm Oral Validation 21.7 22.5 1.04 0.53 0.72 1.36 33.3 39.4 1.18 16.4 13.6 0.83
Rupprecht et al Healthy 1 gm Oral Validation 27.9 23.7 0.85 0.53 0.62 1.17 40 39.4 0.99 19.2 16.5 0.86
Parker et al Healthy 1 gm Oral Validation 24.3 23.2 0.95 0.5 0.7 1.40 - - - - - -
Naderer et al Healthy 1 gm Oral Validation 20.4 23.1 1.13 0.5 0.7 1.40 56.2 63.3 1.13 15.52 13.02 0.84
Jiao et al Chinese healthy 1 gm Oral Validation 16.4 14.4 0.88 0.6 0.72 1.20 30.9 36.4 1.18 10.2 11.3 1.11
Zhang et al Chinese healthy 1 gm Oral Validation 26.4 25.2 0.95 0.8 0.72 0.90 58.3 66.8 1.15 15.8 12.5 0.79
Shen et al Chinese healthy 1 gm Oral Validation 35 28.2 0.81 0.81 0.68 0.84 58.34 52.3 0.90 17.1 15.1 0.88
Johnson etal GFR<30 1 gm Oral Validation 16.3 17.5 1.07 1 0.96 0.96 78.6 81.2 1.03 - - -
Machphee et al GFR<30 1 gm Oral Validation 16.01 18.7 1.17 0.66 0.72 1.09 55.7 57.3 1.03 - - -
Johnson et al GFR 30-60 1 gm Oral Validation 19 20.2 1.06 1 0.96 0.96 75.8 90 1.19 - - -
PK parameters 
Cmax Tmax AUC ClearancePublication Dose Route ModelPopulation
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5.4.4  Renal Transplant Population 
 Virtual renal transplant population was built by modifying existing SimCYP® healthy volunteer 
population [235].  Since renal transplant recipients have only one functioning kidney, the number 
of functioning nephrons was halved in the virtual renal transplant population to 0.807 million 
nephrons per subject from 1.615 million nephrons in healthy adults. However, MPA being 
primarily a drug metabolized by the liver the changes in stable renal transplant are not expected 
to cause changes in the MPA PK. In the immediate phase post- transplant, the MPA total 
concentrations are reduced due to hypoalbuminemia but return to normal after 3 weeks post-
transplantation. Figure 49 represents the observed  PK profile of MPA 3 weeks post-kidney 
transplantation[62] overlaid with the model predicted profile. The predicted exposure as 
measured by AUC0-12 and Cmax (76.7 µg*hr/ml and 21.4 µg/ml) were within 20% of the observed 
Figure 49. Predicted concentration time profile of MPA (CSys) in stable adult renal transplant recipients at steady state 
after multiple oral dosing of 1 gm BID. 
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values (AUC0-12= 61.4 µg*hr/ml and Cmax= 25.5 µg/ml).  
However, the kidney transplant model needs to be refined to incorporate the changes associated 
with hypoalbuminemia to better predict the MPA PK in the immediate phase post-transplant.  
5.4.5 Healthy pediatric population 
SimCYP Pediatric version 16 (Release 1) was used as the pediatric PBPK modeling platform 
with input of drug specific data as used in the MPA PBPK model previously developed for 
adults. Due to lack of clinical PK data in healthy pediatric and lack of availability of UGT 
abundance data in pediatric the model could not be validated in this population. The predicted 
concentration time profiles of MPA for a comparable weight based (15mg/kg) and body surface 
area-based dosing (600/m
2
) are represented in Figure 50A and B respectively.  
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Figure 50 A Predicted plasma concentration time profile of MPA in pediatric population after a single oral 
dose of 15mg/kg. B Predicted concentration time profile of MPA in pediatric population after a single oral 
dose of 600 mg/m
2
. 
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We compared the model simulated concentration time profiles and PK parameters from 
in-house data in pediatric HSCT patients. The model predicted concentration were five times 
higher than the observed data after a 15mg/kg TID dose of MMF. This suggests a much higher 
MMF dose requirement. As suggested by the sensitivity analysis, changes in fraction unbound 
and in the abundancies of UGTs can affect the MPA total concentrations. This hypothesis can be 
further evaluated on availability of in-vitro data and quantitating unbound concentrations of 
MPA in future studies.  This suggests that protein binding and/or UGT expression could be 
different in pediatric HSCT patients and hence the healthy pediatric model is not able to capture 
the PK profiles optimally.  This discrepancy in observed and predicted data can also be explained 
by the wide variability of age in our pediatric HSCT study. The pediatric study was also limited 
by the wide age range of patients. MPA PK can vary largely based on age of the subjects. PBPK 
modeling also did predict age related changes in MPA clearance as shown in Figure 51. 
 
 
Figure 51. MPA Clearance at different age groups
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5.5 DISCUSSION 
In this study, we have built and validated full-PBPK models of IV and oral MPA dosing in 
healthy Caucasian and Chinese and renally impaired patients across clinically relevant doses of 
MMF.  The full-PBPK, ADAM model that we have built incorporates the tissue disposition of 
MPA and enzymatic metabolism by UGTs.  The model is robust across all built-in healthy 
volunteer populations in SimCYP. Incorporation of the Caco-2 permeability data made the 
model more mechanistic. Use or permeability-based ADAM model and incorporation of enzyme 
kinetics data to calculate the RAF values made the model reproducible across populations. This 
is primarily because rate of absorption (Ka) was predicted based on permeability and dissolution 
data of MPA unlike the first order model where in the Ka is based on clinical data used to build 
the model making the model more mechanistic in nature. The model predicted concentration-
time profiles are consistent with observed data across 6 independent, model naïve studies. The 
predicted IV and PO MPA PK parameters are within 1.5-fold range of the corresponding PK 
parameters calculated from the observed studies.  We have also validated the model in a custom 
built renal transplant population. Plasma concentrations of MPA in patients in special 
populations like pediatric patients were also predicted for weight based and body surface area-
based dosing.  
The model was first developed and validated in adult healthy Caucasian patients and was 
then used to build and validate a model in Chinese healthy volunteer population. The predicted 
MPA PK did not reveal any differences between the 2 population. Our observations are in line 
with a population analysis done by Ling et al.[236] to evaluate the ethnic differences in MPA 
 173 
disposition. The group’s population PK model indicated that ethnicity is unlikely to affect MPA 
PK in healthy subjects and was consistent with NCA results.   
Based on predicted concentration time profiles from sensitivity analysis, changes in 
fraction unbound and UGT abundance can cause significant changes in MPA PK. A better 
understanding of the protein binding, UGT ontogeny, activity and abundance data in HSCT 
patients is required to further validate the model in this population. Based on SimCYP 
simulations, we predict upto a 2-fold increase in AUC for a 25% reduction in abundance of 
UGTs. Confounding factors in transplantation like organ dysfunction, concomitant medications 
could be affecting the fraction unbound and could directly influence MPA PK. 
Generally, SimCYP® platform represents a “bottom-up” PBPK approach where in vitro data are 
extrapolated to possible in-vivo results, in this study, the simulated clinical trials were based on 
known in-vivo parameters. This was to combine clinical data (top-down) to “bottom-up” PBPK 
models. This study represents a novel approach for the estimation of PK parameters and 
population variability in MPA across different populations.  
PBPK approaches have been previously used to predict exposure of active drug after 
prodrug administration [237] and to predict exposure in neonates and infants after intravenous 
administration of oseltamivir [238]. However, predictions in these studies were largely based on 
extrapolating in-vivo animal data and clinical data to predict human exposure and involved 
extensive model development and refinement. The enterohepatic recycling of MPA is reported to 
contribute up to 40% to the overall MPA exposure. In our model, ignoring MRP2 based EHC of 
MPA did not result in a complete misprediction of the PK profile for MPA for all validation 
datasets. However, on close inspection of the logarithmic concentration time profiles do show 
that additional in-vivo data on the enterohepatic recycling may be required to better understand 
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the PK profile and tease out the variability associated with clearance in MPA and consequently 
improve the PBPK model predictions. 
We are currently working on building a stem cell transplant population to predict the 
pharmacokinetics of MPA in these patients and to further facilitate optimization of MMF dosing 
in HSCT patients. The current model failed to fit the in-house data from the pediatric HSCT 
patients study. We have used the built-in pediatric population in SimCYP to predict the 
concentration time profiles in pediatric population. However, due to lack of availability of MPA 
PK data in healthy pediatric population we were not able to validate the model. The model 
predicted MPA exposure was five-fold higher as compared to what we observed in our in-house 
MPA PK data in pediatric HSCT patients. This difference can be attributed to physiological 
changes, changes in UGT expression and abundancies and/or interaction with other drugs that 
these patients are being administered concomitantly.   
This study will help generate MPA dosing guidance in young patients of varying age and 
weight. Use of a PBPK approach especially in special populations leverages the limited clinical 
PK data and can serve as a practical application for the establishment of individual dosing of 
MMF in transplant patients. This robust ADAM PBPK model of MPA along with future 
availability of physiological data in transplant patients can be used to build and validated other 
transplant populations and design dosing guidelines to optimize MMF dosing in transplantation. 
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6.0  SUMMARY AND FUTURE DIRECTIONS 
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6.1 SUMMARY 
Through this work we have extensively reviewed the literature to present an overview of MPA 
and its different formulations, the pharmacokinetics, pharmacodynamics and pharmacogenomics. 
We have also described the effect of physiological factors post-transplant such as albumin levels, 
renal function and co-medication and other factors that are known to affect the pharmacokinetics 
in transplant patients. Several pharmacokinetic studies across solid organ and stem cell transplant 
patients have established MPA AUC from 30-60 mg*h/L as an efficacious therapeutic window. 
The main objective of this work was to optimize MMF dosing in transplantation using the 
following approaches: 
6.1.1. Pharmacokinetics guided dosing 
6.1.2. Pharmacodynamics guided dosing 
6.1.3 Model based personalized drug dosing 
  
6.1.1 Pharmacokinetics guided dosing 
Pharmacokinetics guided dosing can be attained by a complete PK profiling of the drug and itsd 
metabolites. This approach although very useful is very tedious and involves the patient having 
to spend long hours in the hospital. Such studies are often met with poor recruitment and higher 
number of patients tend to drop out from the study. Limited sampling strategies are a clinically 
feasible option of PK guided dosing. Better validation of these strategies can lead to 
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incorporation of PK evaluation as a part of routine TDM. Through the understudied pediatric 
HSCT and LT patients we have studied this approach of personalized dosing. 
6.1.1.1 Optimizing MMF administration in pediatric HSCT patients 
MMF dosing in HSCT patients has been primarily extrapolated from data in renal transplant 
recipients. However, pharmacokinetic studies suggest a lower MPA exposure in HSCT 
recipients, some as low as 30-50%, with standard starting MMF doses compared to kidney 
transplant recipients. HSCT patients have a much lower half-life (2-4 hours) as compared to 
solid organ transplant recipients, which necessitates a dosing regimen of at least three to four 
times a day which is clinically not practical to achieve in these patients. Low MPA exposure has 
been associated with higher rates of acute GVHD and graft rejection, and lower response rates in 
the treatment of acute GVHD. Several strategies like higher MMF dose, increased dosing 
frequency have been attempted in the HSCT setting to achieve AUC and trough concentration 
targets similar to those targeted in renal transplants, but the results are not consistent in 
improving MPA exposure. It is very crucial to maintain optimum MPA exposure in the 
immediate phase post- HSCT to avoid GVHD. A novel approach to this problem is continuous 
infusion administration of MMF; a dosing method that has not been previously reported in the 
literature for this drug. This strategy has been successfully used for CNI immunosuppressive 
drugs in this population. Continuous infusion allowed for continuous steady state exposure of 
MPA with minimal fluctuation in MPA levels.  
W designed a personalized dosing strategy for pediatric HSCT patients. This involved 
performing pharmacokinetic analyses of MMF, MPA and MPAG following intermittent IV 
dosing schedule and then designing a personalized CI, and oral administration schedule for 
patients. This allowed us to better control factors that contribute to variable exposure of MPA 
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and helped us to optimize MMF therapy for GVHD prophylaxis. We evaluated the 
pharmacokinetics of MPA after IV short infusion dose. The personalized CI dosing of MMF was 
able to achieve a target exposure of AUC0-12 of 30-60 µg*hr/mL and MMF oral dose was also 
individualized before discharge. We have also studied the safety outcomes of this MMF dosing 
approach in pediatric HSCT recipients undergoing myeloablative transplantation. This is the first 
report of using a 24-hour MMF IV continuous infusion regimen in transplant patients. The 
information obtained from this study will be utilized to define future studies to individualize 
prophylactic and/or therapeutic MMF regimen that can be used to achieve specific target 
concentrations in the plasma and to optimize efficacy and minimize toxicity.  
All patients started with a 15-mg/kg/dose every 8 hour intravenously. The average daily 
dose required to maintain patients within the desired therapeutic range remained close to 45 
mg/kg/day during CI and oral dosing periods. During CI period, 17 of 19 patients (89%) 
achieved target MPA Css of 1.7 to 3.3 μg/mL. We observed no delays with neutrophil and 
platelet engraftment. This regimen had excellent survival outcomes with 3-year event-free and 
overall survival rates of 68% and 79%, respectively. Although this was feasible in all subjects, 
they did require a dedicated IV line, and this may put patients at increased risk of central line–
associated bloodstream infections. Promising results from the pilot study deserve further 
validation in a larger cohort of pediatric patients undergoing myeloablative transplantation.  
 
6.1.1.2 MMF PK in adult lung transplant recipients 
MMF is increasingly being used in lung transplant recipients, with more than 80% transplant 
centers across US using MMF as a part of maintenance immunosuppressive regimen.  To date, 
only few studies evaluating MPA PK-IMPDH relationship are available in MPA-treated adult 
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kidney transplant patients and no data have been reported in lung transplant recipients. The 
objective of this investigation was to systematically study the PK-PD of MPA in adult lung 
transplant recipients in early post-transplant period for the first time. 
We first established and validated a highly sensitive UPLC-MS assay for quantitation of 
MMF, MPA and MPAG in plasma. The assay was used to monitor MMF, MPA and MPAG 
levels in adult lung transplant recipients. This was designed as a pilot study evaluating the PK 
and PD of MMF, MPA and MPAG in adult LT recipients. MMF PK parameters were determined 
in 4 adult lung transplant recipients with intense sampling for up to 12 hours within a dosing 
interval. Pharmacokinetic parameters were comparable to that seen in other published LT 
studies. AUC0-24 did show a good correlation with abbreviated AUCs calculated over 2 and 4-
hour time periods. Clearance was comparable to other SOT recipients.  
6.1.2 Pharmacodynamic guided dosing  
Pharmacodynamic activity can be measured by quantitating the IMPDH activity in 
PBMC lysate. Currently, PK monitoring is preferred over PD measurement because PD assays 
are often tedious and time consuming. We have established and validated a rapid, sensitive 
HPLC-MS/MS assay for XMP and AMP in order to quantify IMPDH activity ex-vivo to 
understand the pharmacodynamic activity of MPA. The utility of IMPDH activity monitoring 
has been tested in a retrospective and a prospective study in LT recipients. The assay can 
quantitate IMPDH activity in PBMC lysate with cell concentration as low as 1million/ml making 
it highly useful in transplant patients with a low PBMC count. The IMPDH activity was highest 
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pre-dose and dropped with administration of MMF with nadir reaching at the Tmax of MPA in the 
prospective LT study.  
The retrospective study was designed to investigate the association between incidence of 
infection and rejection during the first post-transplant year with trough IMPDH activity and 
genotype in banked PBMC samples in LT recipients surviving at least 1-year post LT. We 
predicted that LT recipients with low baseline IMPDH activity will have more infections and LT 
recipients with high baseline IMPDH activity will have more rejection episodes during the first-
year post transplantation.  The results from the retrospective study wherein IMPDH activity was 
monitored at a single time point were clinically and statistically inconclusive owing to the low 
sample size. However, the IMPDH activity tended to be higher in rejecting phenotypes.  
6.1.3 Model-based Personalized Drug Dosing 
Modeling based approaches entail defining appropriate models that mathematically define the 
drug exposure, response and effect of physiological and pathological factors that can affect the 
exposure and in turn clinical outcomes.  
We have developed and validated a physiologically based pharmacokinetic model to 
describe the MPA concentration-time profiles obtained using data from 7 studies in Caucasian 
healthy volunteers, 3 studies in Chinese healthy volunteers and 3 studies in patients showing 
varying degree of renal impairment. In this work we have explored the variables that could be 
responsible for difference in exposure in transplant patients.  The data were best described using 
the ADAM absorption model. The ADAM model[239] enables simulation of the absorption of 
drugs from solution as well as from solid dosage forms, including modified and controlled 
release formulations. It also facilitates simulation of metabolic and transporter mediated drug-
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drug interactions as well as metabolite formation and relevant interactions in the small intestine. 
The ADAM model facilitates more mechanistic explanation of gut absorption, transport, 
metabolism and interactions. We have built a virtual renal transplant population by modifying 
existing SimCYP® healthy volunteer population[235].  Since renal transplant recipients have 
only one functioning kidney, the number of functioning nephrons was halved in the virtual renal 
transplant population to 0.807 million nephrons per subject from 1.615 million nephrons in 
healthy adults. This custom renal transplant population was used to validate the MPA PBPK 
model.  
We have also simulated concentration time profiles of MPA in pediatric population. The 
robustness of this model in predicting pediatric MPA PK could not be determined owing to lack 
of data in healthy pediatric subjects. 
Although, SimCYP® platform provides a “bottom-up” PBPK approach where in vitro data are 
extrapolated to possible in vivo results, in this study, we have used a middle out approach using 
in-vivo PK data (top-down) as also drug dissolution and permeability data (bottom-up) to 
simulate concentration time profiles from several clinical trials. This is the only report of a PBPK 
model for describing PK profile of MPA in healthy volunteers.  Our model did not account for 
the EHC. Although, it did not result in any misprediction of the PK profile for MPA when not 
incorporating the EHC it does highlight the importance of EHC for improving model 
performance. The current model shows good predictive performance but does require further 
validation and refinement using in-vitro data about UGT expression and patient data. 
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6.2 CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS 
The discovery and implementation of strategies for monitoring MPA exposure and outcomes has 
evolved over the past decade and we continue to learn more about safe and effective 
interventions to optimize MMF-based immunosuppression. This has triggered a shift in dosing 
strategies as we are seeing a shift from traditional fixed-flat dose regimen to a more 
individualized approach for dosing MMF.  
The success of the novel CI dosing of MMF based on an individualized dosing approach 
has paved way for future studies in HSCT recipients on MMF dosing. The safety and feasibility 
of CI dosing that was established through this work can be extended to adult HSCT patients.  
The design of CI dosing was based on a target AUC0-12 of 30-60 µg*hr/mL. This corresponds to 
a steady-state concentration of 1-7-3.3µg/mL. This target Css was used to determine the infusion 
rate for CI based on individual patient’s clearance that was determined from the initial short 
infusion. This target concentrations and CI strategy of attaining them can be further applied to 
other SOT and adult HSCT patients. Efforts should be made to further evaluate the clinical 
feasibility and efficacy of this personalized dosing approach in a larger PK study in both adult 
and pediatric subjects.  IMPDH activity is known to be inhibited during MMF therapy. It will be 
worthwhile to study the IMPDH activity in patients receiving continuous MMF infusion and 
determine if improved outcomes are a result of continuous suppression of IMPDH activity.   
 
The most concerning issue in the field of lung transplantation is the lack of improvement 
in morbidity and mortality. TDM is a valuable clinical tool for guiding dosing of 
immunosuppressive agents that exhibit a wide pharmacokinetic and pharmacodynamic 
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variability. However, routine TDM is not practical with MPA therapy. To address this clinical 
need this is the first attempt of a MPA PK-PD study in LT recipients. Unlike, kidney transplant 
recipients, LT recipients tend to stay longer in the hospital post-transplantation. This provided us 
a unique opportunity to conduct a time intensive study when the patients were stable and were at 
steady-state. We have collected blood samples after the morning MMF dose at 9 time- points 
over a dosing interval of 12 hours. This facilitated us to study complete PK profile of MPA and 
MPAG in LT recipients. Abbreviated AUC over 2 and 4-hour periods were able to capture the 
overall exposure of MPA. This abbreviated AUC can be used as a TDM tool in the maintenance 
phase post-transplantation. The shorter time (up to 4 hours) required to collect PK samples can 
thus make TDM a routine procedure when patients come for their bronchoscopy or biopsy visit 
post-transplantation. 
Although the prospective LT study was limited by small number of subjects owing to 
enrollment issues, the promising results from this prospective study does call for a larger PK-PD 
study in LT recipients and will facilitate optimization of MMF dosing.  
We have also successfully established the feasibility of monitoring IMPDH activity in 
lung transplant recipients. An HPLC-MS assay for quantitation of IMPDH activity e-vivo in 
lysate with a PBMC concentration as low as 1-5 million/ml was developed and validated. The 
sensitivity of the assay shall allow for quantitation of IMPDH activity in LT samples with a low 
PBMC count. This could be further extended to other solid organ transplant recipients. Along 
with the PK monitoring in the prospective study, we have also determined PD profile up to 6 
hours post-dose in LT recipients.  We have also retrospectively evaluated single time point 
IMPDH activity in 20 LT patients within first year post-transplantation. The trial is currently 
recruiting and will further investigate the association between incidence of infection and 
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rejection during the first-year post-transplantation with IMPDH activity and genotype in banked 
PBMC in 70 lung transplant recipients surviving at least 1-year post LT. Proposed sample size 
for this study was based on association of IMPDH activity with the clinical outcome of rejection 
or infection tested by logistic regression analysis. Based on a similar study conducted in kidney 
transplant recipients by Chiarelli et al[115], we assumed an odds ratio for rejection of 3, 80% 
power and an established 2-sided alpha level of 0.05, seventy single time-point of IMPDH 
activity measurements will be required to find significance.  The study is still ongoing and 
recruiting additional patients. We predict that LTRs with low IMPDH activity will have more 
infections and LTRs with high IMPDH activity will have more rejection episodes during the 
first-year post transplantation. 
We do acknowledge that there currently is no established therapeutic range for IMPDH 
activity supported in the literature. However, we hope that evaluating single time-point activity 
in 70 patients will help us phenotypically establish IMPDH activity as rejecting or infecting. 
Based on the results on this study we can further propose a dosing regimen based on the IMPDH 
activity. We expect that LTRs with lower IMPDH activity will have increased infection episodes 
and that LTRs with higher IMPDH activity will have increased rejection episodes as seen in 
other solid organ transplant studies. We also anticipate that IMPDH genotype will predict the 
respective baseline activity. In the presence of MMF, we further anticipate that MRP2 genotype 
will influence MPA exposure and thus will influence IMPDH activity in response to MMF. We 
also anticipate that LTRs receiving IMPDH-adjusted MMF therapy will have improved clinical 
outcomes. Overall this study on meeting the proposed sample size will address the  clinical need 
of PD monitoring within the field by evaluating  the relationship between baseline IMPDH 
activity and genotype and incidence of rejection and infection events, evaluating the relationship 
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between MPA exposure and IMPDH activity, and determining  the impact of a precision-
medicine guided approach to MMF dosing using IMPDH activity after LT. IMPDH activity 
measurement can readily be translated in to a routine clinical test in the future and can 
significantly improve MMF dosing and clinical outcomes in not only LTRs, but may also in 
other SOT patients. 
 Future studies should be designed to adjust the dose of MMF in LT recipients during the 
first two weeks to four months after LT to achieve a defined therapeutic range for IMPDH 
activity and comparing the clinical outcomes of this personalized IMPDH activity based MMF 
dose-adjusted cohort to a historical standard-of-care group maintained on fixed-dose MMF.  
Over the last decade, the need for more robust pharmacometric PK analysis has been 
recognized and applied.  Many pop-PK analyses have been conducted across majority types of 
transplants and have identified several covariates like age, weight, cyclosporine co-
administration as important determinants of variability associated with MPA exposure. Another 
pharmacometric method is PBPK modeling. 
 Here, we have attempted to build and validate a PBPK model for MPA to predict the 
exposure in healthy and renally impaired patients. Based on in-house data, a renal transplant 
population was built into SimCYP® to predict the exposure of MPA in renal transplant patients. 
The model was robust and was able to capture MPA PK across healthy Caucasian, healthy 
Chinese, renally impaired and the custom renal transplant population. Currently there is scarcity 
of data on UGT abundancies and transporter expression. As MPA is primarily metabolized by 
UGTs, changes in MPA PK occurring in patients due to changes in UGT expression cannot be 
captured.  Current efforts are focused on fine-tuning this transplant population. We have also 
simulated the concentration time profiles and predicted the PK parameters in pediatric patients 
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for a weight based and BSA based dose.  Due to absence of healthy pediatric data we were not 
able to validate the model.  
This approach of first developing an adult model by using existing drug and patient data, 
and scaling down this model to children, helped leverage prior information to mechanistically 
characterize changes in drug disposition with age. The model can also be used to study the DDI 
effect of MPA as a victim or perpetrator on other drugs that are metabolized by UGT enzymes. 
In future, PK data collected from an opportunistic study can be used to evaluate the pediatric 
population PBPK model. A robust pediatric PBPK model can then be used to perform 
simulations to identify optimal pediatric dosing and thereby diminish the need for more complex 
PK trials involving richer sampling. 
To conclude, MPA PK and PD demonstrate a high inter and intra-patient variability. TDM 
approaches based on LSS can be used to tailor MPA exposure. Target IMPDH activity can be 
used to distinguish phenotypes for rejection and infection in transplant patients and when used 
along with PK LSS can be used to improve outcomes.  PBPK model can be extended to optimize 
MMF dosing in lung and pediatric HSCT patients. Finally, an integration of all the PK, PD and 
model-based strategies can be intuitive and can facilitate clinical decision making of MMF 
dosing in transplantation. 
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APPENDIX A [PRO09120501]   
A1. ABSTRACT 
Graft-versus-host disease (GVHD) remains a major barrier to the success of allogeneic blood and 
marrow transplant (BMT) therapy. Acute GVHD is seen in 30-80% of patients and, once 
established, often responds poorly to therapy and is associated with chronic disease and 
increased risk of death. Although the combination of methotrexate (MTX) and a calcineurin 
inhibitor has been the "standard of care" for more than a quarter century, there is little consensus 
on the most effective and least toxic approach to GVHD prevention. MTX use is associated with 
painful mucositis, delay in engraftment, and potential pulmonary toxicity. For cord blood 
transplants, commonly, a calcineurin inhibitor is used with corticosteroids and antithymocyte 
globulin. These transplants are frequently complicated by high rates of infection, hyperglycemia, 
and hypertension. There is emerging data to support the use of alternative GVHD prophylaxis 
regimens containing sirolimus, mycophenolate mofetil (MMF), or monoclonal antibodies such as 
etanercept. In small randomized trials, many of these approaches have been shown to be 
equivalent or superior, when compared with the standard of cyclosporine A (CsA) and MTX. 
 
Mycophenolate mofetil (MMF), whose metabolite mycophenolic acid (MPA) inhibits 
proliferation of lymphocytes, is approved for prevention of organ transplant rejection. MMF in 
combination with CsA is widely used for GVHD prevention in patients receiving reduced-
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intensity conditioning BMT. It has also been successfully used in primary and salvage therapy of 
acute GVHD. In myeloablative transplants, while the GVHD outcomes appear comparable, this 
regimen appears to have superior toxicity profile in comparison to CsA and MTX, faster 
hematopoietic engraftment, and reduced severity and duration of mucositis. A number of 
pharmacokinetics studies including our preliminary data suggest significantly lower MPA 
exposure in BMT patients with standard starting MMF doses used in kidney transplant 
recipients. Low total and unbound MPA trough concentrations are associated with higher rates of 
acute GVHD and graft rejection, and lower response rate in treatment of acute GVHD. MMF 
dose-escalation has been safely achieved by increasing the dose, shortening dose intervals, or 
both. However, these attempts to not consistently result in higher MPA trough concentration, 
especially in the immediate post-conditioning phase. There is also poor correlation between 
MPA trough concentration and area under the curve concentration (AUC). While most previous 
studies have used fixed MMF dosing, recently one study in adults has shown feasibility of AUC-
based individualized MMF dosing. 
 
This pilot study will use an AUC-based targeting of MMF for GVHD prophylaxis in pediatric 
patients undergoing allogeneic BMT. We propose a novel continuous infusion (CI) method for 
MMF administration to achieve total MPA steady state concentration of 1.7-3.3 mcg/mL. 
Pharmacokinetics studies will be performed on initial intermittent IV dosing, during CI, and 
following conversion to oral administration of this drug. Total MPA and unbound MPA levels 
will be measured. This work should lead to a larger-scale multi-center clinical trial to test salient 
findings emerging from this study in replicate studies of pediatric and adult patients undergoing 
allo-BMT. 
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A2. STUDY OBJECTIVE AND SPECIFIC AIMS 
Objective: What is the overall purpose of this research study?  (Limit response to 1-2 sentences.) 
The purpose of this research study is to evaluate safety and feasibility of AUC-based 
mycophenolate mofetil targeting for GVHD prophylaxis in pediatric patients undergoing 
myeloablative conditioning.    
  
Specific Aims: List the goals of the proposed study (e.g., describe the relevant hypotheses or the 
specific problems or issues that will be addressed by the study). 
Specific aim 1 is to evaluate safety and feasibility of AUC-based mycophenolate mofetil 
(MMF) targeting for GVHD prophylaxis in pediatric patients undergoing myeloablative 
conditioning. 
Specific aim 2 is to study MMF pharmacokinetics with continuous infusion and intermittent IV 
MMF dosing, between IV and oral MMF, and between early and late post-transplant phases. 
Specific aim 3 is to describe the relationship between total and unbound MPA levels. 
Specific aim 4 is to study the safety and feasibility of continuous-infusion MMF dosing. 
Specific aim 5 is to measure salivary MPA and urine MPA and MPAG concentrations, and to 
correlate these levels with those in the plasma. 
Specific aim 6 is to correlate acute and chronic GVHD, engraftment, transplant-related 
complications, relapse, and survival outcomes with historical controls.  
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A3. BACKGROUND 
MMF for Treatment of Acute and Chronic GVHD 
In the BMT setting, MMF has been used for primary and salvage therapy of acute and chronic 
GVHD. Several published studies have reported treatment responses in the range of 26-81% in 
acute GVHD and 26-100% in chronic GVHD (see attached file Table 1). MMF has been well-
tolerated, and GI complaints, most notably diarrhea, and hematologic toxicities are common 
adverse effects. Several studies have reported a high incidence of infectious complications, 
especially in those with refractory acute or chronic GVHD [27-30]. A lower response rate for gut 
involvement with acute GVHD was noted by Kiehl et al, possibly related to poor absorption 
following oral administration of MMF and low MPA levels [31]. 
MMF Pharmacokinetics in HSCT 
MMF use in HSCT patients has been primarily extrapolated from data in solid organ transplant 
recipients [24,35,36]. Standard MMF pediatric dosing for prophylaxis of renal transplant 
rejection is 600 mg/m2/dose twice daily; maximum dose: 1 g twice daily. MMF dose has been 
targeted to a total MPA AUC(0-12) of 30-60 mcg*hr/mL or total MPA Ctrough of 1-3.5 mcg/mL 
[37,38]. Individualization of MMF therapy has been recommended in liver transplant patients 
[39], and MPA target concentrations (total Ctrough >1 mcg/mL, total Css >3 mcg/ml, and 
cumulative 24-h unbound AUC >0.600 mcg*h/mL) have recently been proposed in the BMT 
population [40]. 
Pharmacokinetics studies suggest lower MPA exposure in BMT recipients, some as low as 30-
50%, with standard starting MMF doses used in kidney transplant [24,36,41]. Jacobson and 
colleagues performed a prospective study in 30 adult patients undergoing nonmyeloablative bone 
marrow transplant who received MMF 3 g/day, half of whom were dosed at 1.5 g BID and half 
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of whom were dosed at 1 g TID [41]. A total MPA trough concentration ≥1 mcg/mL was 
achieved in 20-53% of subjects, while the Css target ≥3 mcg/mL was reached in only 13-27% of 
subjects. Lower MMF exposure seems to be particularly true during the early post-transplant 
phase, and these patients have achieved significantly higher steady state levels later in the post-
transplant course. Bhatia and colleagues recently reported PK data on a MMF+TAC GVHD 
prophylaxis regimen in 38 pediatric patients undergoing myeloablative or reduced-intensity 
transplants [42]. With 900 mg/m2/dose q6h MMF dosing, mean total MPA Ctrough levels were 
0.33 mcg/mL on day +1, 0.68 mcg/mL on day +7, and 0.72 mcg/mL on day +14. Furlong and 
colleagues found the total MPA median AUC and Cmax to be lower in the acute GVHD patients 
(15.8 mcg*hr/mL and 4.8 mcg/mL, respectively) when compared to those treated for chronic 
GVHD (49.9 mcg*hr/mL and 12.0 mcg/mL, respectively) (P<0.0001) [43]. Jacobson and 
colleagues studied pharmacokinetics in 19 children undergoing myeloablative BMT with MMF 
and CsA GVHD prophylaxis and found that even with 15 mg/kg IV q8 hourly dosing, the 
median total MPA area AUC(0-8) was 12.6 mcg*h/mL and Ctrough 0.27 mcg/mL [44]. 
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 A4. SIGNIFICANCE 
MMF use in BMT patients has been primarily extrapolated from data in renal transplant 
recipients. However, pharmacokinetics studies suggest lower MPA exposure in BMT recipients, 
some as low as 30-50%, with standard starting MMF doses used in kidney transplant. Low MPA 
exposure has been associated with higher rates of acute GVHD and graft rejection, and lower 
response rates in the treatment of acute GVHD. Several strategies have been attempted in the 
BMT setting to achieve AUC and trough concentration targets similar to those targeted in renal 
transplants, but none have been successful in consistently resulting in higher MPA exposure. A 
novel approach to this problem is a continuous infusion for MMF administration, a method that 
has not been previously reported in the literature. 
Performing pharmacokinetics analyses on intermittent IV dosing, during continuous infusion, 
and after conversion to oral administration will allow us to better understand factors correlated 
with low/high exposure, and its potential causes will help us optimize MMF therapy in our BMT 
population for GVHD prophylaxis. The information obtained from this study will also be utilized 
to define future studies to individualize prophylactic and/or therapeutic MMF regimens that can 
be used to achieve specific target concentrations in the plasma and to optimize efficacy and 
minimize toxicity. 
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A5. CONSENT FORM 
TITLE:  A Pilot Study of Pharmacokinetics-based Mycophenolate Mofetil Dosing for Graft-
Versus-Host-Disease Prophylaxis in Pediatric Blood and Marrow Transplantation 
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CONSENT FOR A CHILD TO BE A SUBJECT IN A MEDICAL EXPERIMENT AND 
AUTHORIZATION TO PERMIT THE USE AND DISCLOSURE OF IDENTIFIABLE 
MEDICAL INFORMATION (PROTECTED HEALTH INFORMATION) FOR 
RESEARCH PURPOSES 
 
 
Why Is This Study Being Done? 
 Your child’s doctor has recommended that your child have a blood and marrow transplant 
(BMT). This treatment is a way of replacing blood forming cells that were destroyed by 
treatment of underlying disease. These donor blood forming cells, also called stem cells, are 
given after chemotherapy with or without radiotherapy to help the bone marrow recover and 
continue to produce healthy cells. After receiving the donor stem cells, patients undergoing 
transplant receive medications to suppress their immune system in order to help reduce or 
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prevent a complication of transplant called graft-versus-host-disease (GVHD). GVHD is a 
disease that may occur following transplant when the donated cells attack a patient’s body’s cells 
because the donated cells see your child’s body as “foreign.” When GVHD occurs, donor cells 
can target the skin, liver, and intestines which may cause your child to develop a rash, stomach 
pains, vomiting, or diarrhea.  
  
This is a study of giving a medicine called mycophenolate mofetil (MMF) for GVHD 
prevention. MMF has been approved by the Food and Drug Administration (FDA) for the 
prevention of organ rejection and has been used in children for over 15 years. Although not 
FDA-approved for such purposes, it has also been successfully used for treatment and prevention 
of acute GVHD in adults and children undergoing BMT. MMF belongs to a group of medicines 
called immunosuppressive agents (drugs used to prevent the rejection of transplanted organs and 
tissues). It is used to lower the body’s immunity in patients who receive transplants.  
  
In previous clinical trials, MMF has been successfully used for prevention and treatment of 
GVHD in children. Different patients have been found to have different blood levels of 
mycophenolic acid (MPA, the active form of MMF) when they are given the same dose of MMF 
appropriate for their body size. It is NOT the dose of MMF but the amount of MPA in the body 
that determines the effects and side effects of the drug. Previous clinical trials have shown that 
low amounts lead to more risk of GVHD.  Likewise, high amounts can cause greater side effects 
of the drug. Other studies have shown that keeping blood MPA levels in a target range leads to 
better GVHD control. Most studies have given a standard dose of MMF into the vein (IV) based 
on a patient’s size. Recently, it has been shown that MMF dosing can be adjusted to achieve a 
desired blood level of MPA safely, in individual patients. We would like to test a method of 
giving MMF by continuous IV infusion over 24 hours to achieve a target-specific amount of 
MPA in the blood. We will also try to apply the findings from this research to develop a better 
dosing guideline for MMF, improve the treatment effects of MMF, and minimize side effects.  
 
The use of MMF as described in this study for control of GVHD is experimental.  
 
The goals of this study are: 
 
 To study the handling of MMF by an individual subject’s body and use that information 
to give a MMF dose in a way that is most optimal for its intended use 
 
 To study the factors (such as age, body weight, blood chemistry, liver function, blood 
levels of other drugs) that might affect blood MPA levels in different subjects 
 
We would also like to learn more about differences in drug blood levels between IV versus oral 
(by mouth) way of giving MMF, and between early and later time periods after BMT. 
Furthermore, we would like to try measuring MPA levels in the urine and saliva and see how 
they compare to MPA levels in the blood. Another goal of the study is to learn about the chance 
of GVHD and other transplant complications with this trial when compared with what is known 
from previous experience.  
  
What Is The Current Standard Of Treatment For This Disease? 
 213 
Participants on this study will receive an allogeneic BMT (bone marrow or cord blood stem cells 
from another person). BMT will be performed for a medical condition for which it is considered 
to be an accepted, standard treatment. This will be discussed with you, in detail, by your child’s 
doctor. Please read the information about the BMT plan which can be found in Attachment #1, 
along with the side effects and risks of chemotherapy, GVHD drugs, radiation therapy and BMT 
which can be found in Attachment #2.  As part of BMT preparation, subjects are given medicines 
to decrease the risk of getting GVHD. The standard treatment for GVHD prevention is to give 
cyclosporine and methotrexate with or without antithymocyte globulin (ATG) for bone marrow 
transplants and cyclosporine, prednisone and ATG for cord blood transplants. Subjects receiving 
umbilical cord blood transplants, mismatched transplants and unrelated marrow receive ATG as 
part of their GVHD prophylaxis regimen. If you have any specific concerns about any 
information in the attachments, please discuss with your child’s physicians. 
 
What are my child and I being asked to do? 
 Your child is being asked to take part in this study which will use a medicine called 
mycophenolate mofetil (MMF) for GVHD prevention. The effectiveness of MMF depends on 
blood levels of mycophenolic acid (MPA, the active form of MMF). The purpose of this study is 
to give MMF to the subject based on the child’s blood levels of MPA to make sure that there is 
the desired (target) amount of the drug in your child’s body.  
  
Your child will receive a standard BMT with one difference. He or she will receive MMF instead 
of methotrexate if donor bone marrow will be used for transplant, or MMF will be used instead 
of prednisone if cord blood cells will be used for transplant. This study is testing if methotrexate 
and prednisone can be safely replaced by MMF, thereby potentially reducing side effects. 
 
 It is common to enroll children and adolescents who need BMT in a clinical trial that seeks to 
improve transplant procedure. Clinical trials include only people who choose to take part. Many 
different treatment programs are used for BMT in children. You will have a choice between 
other BMT treatments and this clinical trial. 
  
 Please take your time to make your decision. Discuss it with your friends and family.  We 
encourage you to include your child in the discussion and decision to the extent that he or she is 
able to understand and take part. 
 
How Many People Will Take Part In This Study? 
This study will enroll male and female subjects between the ages of 6 months and 21 years at the 
Children’s Hospital of Pittsburgh.  The total number of subjects to be enrolled on this study is 
expected to be 20. 
 
What Will Happen On This Study That Is Research? 
MMF is given every 8 hours to subjects by IV over 2 hours or by mouth. Children who receive 
MMF as part of standard BMT treatment get periodic blood samples taken for measurement of 
MPA levels as part of his/her standard medical care. These blood samples are typically taken just 
before the subject is due to get the next dose and is called a trough level. All study samples will 
be collected in the Children’s Hospital of Pittsburgh, in both the inpatient BMT unit and 
outpatient BMT clinic. 
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Your child will receive MMF for GVHD prevention on this study. The part that is research is 
made up of: 
 
1. Giving MMF in a dose that is individualized to your child based not only on trough levels but 
by conducting a detailed analysis of how your child’s body handles the study drug (called 
pharmacokinetics). This is done by taking a series of blood samples after a dose and, based on 
how MMF is cleared from your child’s body, calculating the appropriate dose to get the desired 
target blood level. 
 
Three to seven days after transplant, around a dose of IV MMF, seven blood samples (a half-
teaspoon each, or 3 teaspoons total) will be collected at hours 0 (prior to infusion), 2 (at 
completion of infusion), 3, 4, 5, 6, and 8 from your child’s central line. Each blood draw will 
take up to 5 minutes. Results from these studies will be used to get correct daily dose for your 
child to be given by continuous IV, as described in the next section. 
 
2. Giving MMF as continuous infusion by IV over 24 hours in order to achieve constant target 
drug levels during the early part of transplant. During this phase, your child’s blood samples will 
be checked two to three times a week to make adjustments to the MMF dose if necessary. 
Sometimes, blood samples may be taken twice in a day to check for fluctuations in the MPA 
drug levels. Each blood draw will take up to 5 minutes. 
 
3. Your child will start taking MMF by mouth instead of IV when he/she is able to tolerate oral 
medications and is near the time of discharge. Once your child is switched to taking MMF by 
mouth, a second series of blood samples will be taken. Seven blood samples (a half-teaspoon 
each, or 3 teaspoons total) will be collected just prior to (0 hr) and at 0.5, 1, 2, 3, 6, and 8 hours 
after MMF is given by mouth. Results from these studies will be used to find out the correct dose 
by mouth for your child. Each blood draw will take up to 5 minutes. 
 
4. In older children and adolescents who are able to spit into a sterile container, saliva samples 
will be collected each time blood is drawn for the pharmacokinetics studies described above in 
parts (1) and (3). Saliva samples will not be collected from infants, toddlers, and other subjects 
who are unable to provide samples on their own. MPA levels in saliva will be used to compare to 
MPA levels in blood. Each collection of saliva will take up to 5 minutes. 
 
5. Also during the two pharmacokinetics studies, urine will be collected from older children and 
adolescents who are able to provide a voided specimen so that we may measure levels of MPA 
and one of its metabolites (a chemical that your body converts MPA into). The urine collection 
will start immediately before the first blood draw and continue for 8 hours, or until after the last 
blood sample is drawn. Each time your child voids, the urine will be collected in a container and 
stored in a refrigerator until completion of the collection period.  Urine samples will not be 
collected from infants, toddlers, and other subjects who are unable to provide specimens on their 
own. Each urine collection will take up to 5 minutes. 
 
6. Whenever possible, the blood samples drawn above will also be used to understand the 
metabolic effects of MMF in your child’s body. This includes measuring levels of inosine 
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monophosphate dehydrogenase (IMPDH), a chemical in the body that is suppressed, or turned 
off, by MMF and can potentially serve as an alternative measure of MMF’s effectiveness. 
Results from these tests will not be available to you or your child’s doctor and will not be used to 
make changes to your child’s management. These tests may allow us to understand the factors 
that affect why different subjects handle MMF differently and to explore ways that subjects can 
get the most benefit from the use of this drug for BMT and minimize its side effects. 
 
In summary, subjects will start MMF therapy with intermittent IV dosing.  Based on 
pharmacokinetics information, it will then be converted to a continuous infusion over 24 hours. 
Once subjects are able to tolerate oral medications, MMF will be converted to an oral 
formulation. 
 
 
How Long Is The Study? 
Subjects in this clinical trial are expected to receive the study drug for approximately 3 months. 
We will continue to review medical information from your child’s ongoing care with regards to 
transplantation, status of the underlying pre-transplant disease, presence of GVHD, other post-
transplant outcomes, and results of laboratory tests and other procedures for up to 5 years after 
the last subject starts the study. 
 
Can my child stop being in the study? 
Your child’s doctor or the research doctors running the study may decide to take your child off 
this study under the following circumstances: 
 if he/she believes that it is in your child’s best interest 
 if your child experiences side effects from the study procedure that are considered too 
severe 
 if new information becomes available that shows that another treatment would be better 
for your child 
 
You can stop your child from participating at any time.  However, if you decide to have your 
child stop participating in the study, we encourage you to talk to the research doctors running the 
study and your child’s regular doctor first. 
 
What are the possible risks, side effects, and discomforts of this research study? 
As with any experimental procedure, there may be adverse events or side effects that are 
currently unknown and not anticipated, and certain of these unknown risks could be permanent, 
severe or life threatening. 
 
The use of MMF instead of methotrexate or prednisone may cause more complications. The use 
of MMF as described in this research may cause more side effects than how it is used as standard 
of care.  
 
It is possible that MMF may be less effective than the current standard treatment. 
 
 
 
 216 
 
 
 
 
 
 
 
 
Risks and side effects related to Mycophenolate Mofetil (MMF) include those which are: 
Likely 
(“Likely” refers to a side effect 
that is expected to occur in more 
than 20% of patients.)  
Less Likely 
(“Less likely” refers to a side 
effect that is expected to occur in 
20% or fewer patients.) 
Rare, but Serious 
(These possible risks have been 
reported in rare occurrences, 
typically less than 2% of patients.  
They may be serious if they occur.) 
 Diarrhea  
 Stomach pain  
 Upset stomach  
 Nausea and vomiting  
 Difficulty falling asleep 
or staying asleep  
 
 Pain, especially in the 
back, muscles, or joints  
 Constipation  
 
 Swelling of the hands, feet, 
ankles, or lower legs  
 Difficulty breathing  
 Shaking hands that you 
cannot control  
 Unusual bruising or 
bleeding  
 Headache  
 Fast heartbeat  
 Excessive tiredness  
 Dizziness  
 Pale skin  
 Weakness  
 Blood in stools  
 Bloody vomit  
 Loose, floppy muscles  
 White patches in mouth or 
throat  
 Swelling of gums  
 Vision changes  
 Rash  
 Low blood counts 
 Damage to unborn baby 
 Limited effectiveness of 
birth control 
 Progressive Multifocal 
Leukoencephalopathy, a 
rare, life-threatening 
disease that affects the 
central nervous system 
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There is also a risk of breach of confidentiality associated with collection of pharmacokinetic and 
medical data. However, the investigators will do their best in order to safeguard the 
confidentiality. Samples will be coded and no subject identifier will be recorded on the sample. 
Samples will be kept as long as is necessary to complete the study. 
 
 
For Females: 
The study drug can affect an unborn child. Your child should not become pregnant or breast feed 
a baby while being treated on this study. If your child is sexually active and is at risk of getting 
pregnant, your child and your child’s male partner(s) must use an effective method to avoid 
pregnancy or your child must not have sex. The study doctor will talk to your child about 
acceptable methods to avoid pregnancy while he/she is being treated on this study. Your child 
will have to use the chosen method to avoid pregnancy or abstain (not have sexual intercourse) 
the whole time he/she is being treated on this study. Your child may need to continue this for a 
while, even after they finish the cancer treatment, so talk to your child’s doctors about the length 
of time they need to avoid pregnancy or abstain. Natural family planning and the rhythm method 
will not be permissible means of avoiding pregnancy during study participation. If you/your 
child have questions about this or want to change your child’s method to avoid pregnancy during 
therapy, please ask your child’s doctor. If your child becomes pregnant during the research 
study, please tell the study doctor and your child’s regular doctor immediately. 
 
If your child is nursing a baby, the study drug used in this research could pass into the breast 
milk. Your child should not nurse a baby for the whole time she is getting the study medicines. 
Your child may need to continue this for a while, even after she finishes the cancer treatment, so 
talk to your child’s doctors about the length of time she needs to avoid nursing. 
 
For Males: 
The study drug can damage sperm. Your child should not father a child while on this study drug 
as it may indirectly affect an unborn child. If your child is sexually active and is at risk of 
causing a pregnancy, your child and your child’s female partner(s) must use a method to avoid 
pregnancy that works well or your child must not have sex. The study doctor will talk to your 
child about the acceptable methods to avoid pregnancy while he is being treated on this study. 
Your child will have to use the chosen method to avoid pregnancy or abstain (not have sexual 
intercourse) the whole time he is being treated on this study. Your child may need to continue 
this for a while, even after he finishes the cancer treatment, so talk to your child’s doctors about 
the length of time your child needs to avoid pregnancy or abstain. Natural family planning and 
the rhythm method will not be permissible means of avoiding pregnancy during study 
participation. If you/your child have questions about this or want to change your child’s method 
to avoid pregnancy during therapy, please ask your child’s doctor. If your child’s partner 
becomes pregnant during the research study, please tell the study doctor and your child’s regular 
doctor immediately. 
 
Please refer to Attachment #2 for risks and side effects associated with standard transplant 
procedures. 
 
What are possible benefits from taking part in this study? 
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We hope that your child will get personal medical benefit from participation in this clinical trial, 
but we cannot be certain. These potential benefits could include having fewer side effects from 
GVHD prevention medications and possibly better control of GVHD.  
 
What alternatives are available to my child if I don’t give my OK for my child’s participation 
in this study? 
Instead of being in this study, your child has these options: 
 Current standard therapies, with methotrexate for bone marrow transplants or 
prednisone for umbilical cord blood transplant, for GVHD prevention 
 You may consider some other approach for GVHD prevention than the 
standard treatment 
 You may choose a chemotherapy approach (if BMT is for a type of cancer)  
instead of transplantation for your child 
 You may decide for your child not to receive treatment at this time 
 
Please talk to your child’s doctor about these and other options.  Participation in this study is 
entirely up to you.  Choosing not to participate in this study will not affect you or your child’s 
present or future relationship with the Children’s Hospital of Pittsburgh of UPMC or any hospital 
or affiliated health care providers or the University of Pittsburgh. 
 
What if there is new information while my child is in this study? 
If any information is learned that might affect your willingness to have your child continue 
participation in this research, you will be informed. 
 
Will an autopsy be requested if my child dies?  
Yes.  The outcome of this experimental study cannot be predicted, nor can all the side effects be 
anticipated.  If your child dies, information about the cause(s) of death and side effects is very 
important for future care of patients.  Therefore, if your child dies, your permission for an 
autopsy (post-mortem examination) will be requested.  Autopsies for research subjects are 
offered free of charge to patients who die at Children’s Hospital of Pittsburgh (CHP). 
May I refuse to give my OK for the use of my child’s medical information for the purpose of 
this research study? 
Your OK to use and disclose your child’s medical information for the purpose of this research 
study is completely up to you.  However, if you do not provide your OK, your child will not be 
allowed to participate in this study. 
Will my insurance provider or I be charged for the costs of any procedures performed as part 
of this research study? 
Neither you, nor your child’s insurance provider, will be charged for the costs of  the research 
procedures performed (MMF pharmacokinetics testing, urine and saliva collection, and other 
research tests on blood samples) for the purpose of this research study.  You or your insurance 
company will be charged, in the standard manner, for the transplant, hospitalization and regular 
medical care, including the cost of MMF and the routine clinical monitoring of MMF blood 
levels.  
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Will my child be paid for participation in this research study? 
You will receive no payment or money for taking part in this study. 
 
Who will pay if my child is injured as a result of taking part in this study? 
CHP researchers and their associates who provide services at CHP or UPMC recognize the 
importance of your child’s voluntary participation in their research studies. These individuals 
and their staffs will make reasonable efforts to minimize, control, and treat any injuries that may 
arise as a result of this research. If you believe that your child is injured as a result of the 
research procedures being performed, please contact immediately the Principal Investigator or 
one of the co-investigators listed on the first page of this form.   
 
There is the possibility with any medical treatment or research that a child may suffer some 
physical illness or injury. In the unlikely event of an injury or illness resulting from this research, 
any immediate emergency treatment that may be necessary will be provided without charge at 
Children’s Hospital of Pittsburgh. There is no plan for monetary compensation. You do not, 
however, waive any legal rights by signing this form. 
 
Who will know about my child’s participation in this research study? 
Any information about your child obtained from this research will be kept as confidential 
(private) as possible.  All records related to your involvement in this research study will be 
stored in a locked file cabinet or in password-protected computerized records. Your child’s 
identity on these records will be indicated by a case number rather than by his/her name and the 
information linking these case numbers with your child’s identity will be kept separate from the 
research records.  
 
Will this research study involve the use or disclosure of my child’s identifiable medical 
information? 
This research study will result in identifiable information that will be placed into your child’s 
medical records held at CHP. The nature of the identifiable information resulting from your 
child’s participation in this research study that will be recorded in your child’s medical record 
includes results of the testing indicated in this consent form. 
 
Names of participants or material identifying participants (except as described above) will not be 
released without written permission, unless required by law. 
 
If results of this study are published, your child’s identity will remain confidential. 
 
Efforts will be made to keep your child’s personal information confidential.  We cannot 
guarantee absolute confidentiality.  Your child’s personal information may be disclosed if 
required by law. 
 
It is very unlikely that the research testing might uncover important information about your 
child’s current or future health.  If this unlikely event occurs, the researchers may contact your 
child’s doctor about what the research tests might mean.  Only the doctor will be notified and the 
information will not become part of your child’s medical record.  It will remain confidential.  
Your child’s doctor may discuss this unexpected finding with you.  Your child’s doctor may 
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recommend consultation with a genetic counselor or repeat testing in a clinical (not research) 
laboratory if needed.  It is possible that your child’s doctor may recommend that no additional 
action is necessary. 
 
Who will have access to identifiable information related to my child’s participation in this 
research study? 
In general, research records are kept confidential.  Paper records are stored in locked cabinets, 
and computerized records are password-protected.  There are, however, some disclosures of your 
child’s research-related medical information that may occur. 
 
In addition to the investigators listed on the first page of this authorization (consent) form and 
their research staff, the following individuals will or may have access to identifiable information 
(which may include your child’s identifiable medical information) related to your child’s 
participation in this research study: 
 
 Authorized representatives of the University of Pittsburgh Research Conduct and 
Compliance Office may review your child’s identifiable research information (which may 
include your child’s identifiable medical information) for the purposes of monitoring the 
appropriate conduct of this research study. 
 Authorized representatives of the UPMC hospitals or other affiliated health care providers 
may have access to identifiable information (which may include your child’s identifiable 
medical information) related to your child’s participation in this research study for the 
purpose of (1) fulfilling orders, made by the investigators, for hospital and health care 
services (e.g., laboratory tests, diagnostic procedures) associated with research study 
participation; (2) addressing correct payment for tests and procedures ordered by the 
investigators; and/or (3) for internal hospital operations (i.e. quality assurance). 
 Authorized representatives of the US Food and Drug Administration (FDA) and the Office 
for Human Research Protections (OHRP) may review and/or obtain your identifiable health 
information for the purpose of monitoring the accuracy of research data and to ensure that the 
research is being conducted according to the FDA regulations.  While the FDA has provided 
its assurance that it will not release your child’s identifiable medical information to anyone 
else, Children’s Hospital of Pittsburgh cannot guarantee this. 
 
Research investigators may be required under Pennsylvania law to report any suspicion of child 
abuse to child protection services.  If the investigators learn that your child or someone with 
whom your child is involved is in serious danger of potential severe harm, they may need to 
warn those who are in danger and contact other agencies to ensure safety. 
 
For how long will the investigators be permitted to use and disclose identifiable information 
related to my child’s participation in this research study? 
The investigators will be permitted to use your child’s health information until the study is 
completed. 
 
The investigators may continue to use and disclose, for the purposes described above, 
identifiable information (which may include your child’s identifiable medical information) 
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related to his/her participation in this research study for a minimum of seven years after final 
reporting or publication of a project. 
 
May I have access to my medical information that results from my child’s participation in this 
research study? 
In accordance with the CHP Notices of Privacy Practices document that you have been provided, 
you are permitted access to information (including information resulting from your child’s 
participation in this research study) contained within your child’s medical records filed with 
his/her health care provider. 
 
Is my child’s participation in this research study voluntary? 
Your child’s participation in this research study, to include the use and disclosure of your child’s 
identifiable information for the purposes described above, is completely voluntary. (Note, 
however, that if you do not provide your consent for the use and disclosure of your child’s 
identifiable information for the purposes described above, you will not be allowed, in general, to 
have your child participate in the research study.) Whether or not you provide your consent for 
your child’s participation in this research study will have no effect on your current or future 
relationship with the Children’s Hospital of Pittsburgh. Whether or not you provide your consent 
for your child’s participation in this research study will have no effect on your current or future 
medical care at a UPMC hospital or affiliated health care provider or your current or future 
relationship with a health care insurance provider. 
 
Your child’s physician is involved as an investigator in this research study.  As both your child’s 
physician and a research investigator, he/she is interested both in your medical care and the 
conduct of this research study.  Before agreeing to participate in this research study, or at any 
time during your study participation, you may discuss your child’s care with another doctor who 
is not associated with this research study.  Your child is not under any obligation to participate in 
any research study offered by his/her doctor. 
 
May I withdraw, at a future date, my consent for my child’s participation in this research 
study? 
You may withdraw your consent, at any time, for your child’s participation in this research 
study, to include the use and disclosure of your child’s identifiable information for the purposes 
described above. (Note, however, that if you withdraw your consent for the use and disclosure of 
your child’s identifiable medical record information for the purposes described above, your child 
will also be withdrawn, in general, from further participation in this research study.) Any 
identifiable research or medical information recorded for, or resulting from, your child’s 
participation in this research study prior to the date that you formally withdrew your consent may 
continue to be used and disclosed by the investigators for the purposes described above. 
 
To formally withdraw your consent for your child’s participation in this research study, you 
should provide a written and dated notice of this decision to the principal investigator of this 
research study at the address listed on the first page of this form. 
 
Your decision to withdraw your consent for your child’s participation in this research study will 
have no effect on your or your child’s current or future relationship with the Children’s Hospital 
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of Pittsburgh. Your decision to withdraw your consent for your child’s participation in this 
research study will have no effect on your child’s current or future medical care at a UPMC 
hospital or affiliated health care provider or your child’s current or future relationship with a 
health care insurance provider. 
 
************************************************************************ 
 
 
 
VOLUNTARY CONSENT 
All of the above has been explained to me and all of my current questions have been answered. I 
understand that I am encouraged to ask questions about any aspect of this research study during 
the course of this study, and that such future questions will be answered by the researchers listed 
on the first page of this form. 
 
Any questions which I have about my child’s rights as a research participant will be answered by 
the Human Subject Protection Advocate of the IRB Office, University of Pittsburgh (1-866-212-
2668). 
 
_______________________________ 
Participant’s (Child’s) Printed Name 
 
I understand that, as a minor (age less than 18 years), the above-named child is not permitted to 
participate in this research study without my consent. Therefore, by signing this form, I give my 
consent for his/her participation in this research study. 
 
_______________________________     ___________________________ 
Parent’s Name (Print)                     Relationship to Participant (Child) 
 
______________________________       _____________ 
Parent’s Signature          Date 
 
 
CERTIFICATION of INFORMED CONSENT 
I certify that I have explained the nature and purpose of this research study to the above-named 
individual(s), and I have discussed the potential benefits and possible risks of study participation. 
Any questions the individual(s) have about this study have been answered, and we will always be 
available to address future questions as they arise. I further certify that no research component of 
this protocol was begun until after this consent form was signed. 
___________________________________   ________________________ 
Printed Name of Person Obtaining Consent   Role in Research Study 
 
_________________________________   ____________ 
Signature of Person Obtaining Consent   Date  
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ASSENT (For children who are not capable of understanding the study procedures and 
their potential discomforts and benefits). 
 
I do not believe the child/my child is capable of giving assent for participation. 
      
 ______________________________________________________ 
Signature of Parents(s) 
 
 
ASSENT (For children who are capable of understanding the study procedures and their 
potential discomforts and benefits).  
 
 
I have explained this research to the child-subject in words and pictures that he/she understands, and 
I believe he/she understands what this research involves. 
 
     ______________________________________ 
     Signature of Person Explaining the Research 
 
I believe my child understands what this research involves and that he/she has given his/her assent 
for participation. 
 
_________________________________________________________________ 
Signature(s) of Parent(s)  
 
 
VERIFICATION OF EXPLANATION 
I certify that I have carefully explained the purpose and nature of this research to (name of child) 
in age appropriate language. He/she has had an opportunity to discuss it with me in detail. I have 
answered all his/her questions and he/she provided affirmative agreement (i.e., assent) to 
participate in this research.  
 
________________________________  ______________  
Principal/Co-Investigator Signature   Date  
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CONSENT FOR CONTINUED RESEARCH PARTICIPATION  
I understand that I am currently participating in a research study. I further understand that 
consent for my participation in this research study was initially obtained from one of my parents.  
I have now reached the age of 18 and I am able to provide direct consent for continued 
participation in this research study.  
 
The above information has been explained to me and all of my current questions have been 
answered. I understand that I am encouraged to ask questions, voice concerns or complaints 
about any aspect of this research registry during the course of this study, and that such future 
questions, concerns or complaints will be answered by a qualified individual or by the 
investigator(s) listed on the first page of this consent document at the telephone number(s) given. 
I understand that I may always request that my questions, concerns or complaints be addressed 
by a listed investigator. I understand that I may contact the Human Subjects Protection Advocate 
of the IRB Office, University of Pittsburgh (1-866-212-2668) to discuss problems, concerns, and 
questions; obtain information; offer input; or discuss situations in the event that the research 
team is unavailable. By signing this form I agree to continued participation in this research study. 
  
By signing below, I agree to continue my participation in this research study. A copy of this 
consent form will be given to me.  
 
 
______________________________   ____________  
Participant’s Signature    Date  
 
 
 
 
INVESTIGATOR’S CERTIFICATION 
I certify that the nature and purpose, the potential benefits, and possible risks associated with 
participation in this study have been explained to the above individual and that any questions 
about this procedure have been answered. 
 
 
________________________________  ___________________ 
Investigator’s Signature    Date 
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A6. SAMPLE COLLECTION FORM 
Sample Bu-Cy-ATG-CSA-MMF form 
 
ABLATIVE PREP ORDERS 
 
Allogeneic BMT using a preparative therapy of busulfan + cyclophosphamide and antithymocyte 
globulin.   
 
Ht.  _______ cm  Wt.  ____ kg  BSA  ____ m2 
 
1) Begin hydration on admission ( __/__/__ ) with  D5 Sodium Chloride 0.45% + Potassium 
Chloride 20 mEq/L at ______ ml/hour.Total IV fluids/day = 3000 ml/m2/ day. BMT Team to 
enter 
 
2) Fosphenytoin _____ mg phenytoin equivalent (PE) (15 mg PE/kg) IV on day –10 
(__/__/__) at 4 PM x1, then begin Fosphenytoin _____ mg PE (2.5 mg/kg/dose) every 8 hrs at 
4AM on Day -9 (__/__/__) and d/c after  last dose 8AM Day -4 __/__/__. Pharmacy staff to 
enter.  
 
 Check Phenytoin level (troughs) on days -8 (__/__/__) and  Day -6 (__/__/__) 
  
3) Ondansetron  ____ mg IV (0.15mg/kg/dose) 30 min prior to Busulfan on day –9 
(__/__/__), then begin  ___ mg/day (0.3 mg/kg/day) by continuous infusion at 2 ml/hr and 
continue daily for EHS - Pharmacy staff to enter.  
4) Busulfex (busulfan) ____ mg (1.1 mg/kg/dose < 12kg, 0.8mg/kg dose > 12 kg) IV over 2 
hrs every 6 hours x 4 days.  Administer on 8-2-8-2 schedule beginning Day –9 __/__/__ at 0800 
AM and last dose will be on __/__/__ at 0200 AM (16 doses total) Pharmacy staff to enter. – 
Doses diluted to final concentration 0.5 mg/ml 
  
 
5) After the first dose of Busulfan is given at 0800 AM on Day –9 (__/__/__), draw 1-3 ml 
of blood in a green top tube (Heparin Sodium) at the times given below: 
 Draw sample #1 at 1000 AM on Day –9 
 Draw sample #2 at 1015 AM on Day –9 
 Draw sample #3 at 1030 AM on Day –9 
 Draw sample #4 at 1100 PM on Day –9 
 Draw sample #5 at 1200 PM on Day –9 
 Draw sample #6 at 1300 PM on Day –9 
 Draw sample #7 at 1400 PM on Day –9 
 
**Must draw sample from a different catheter 
Using a permanent marker, mark each tube with the corresponding sample number and write the 
exact time on the form provided. 
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Example: Sample #3 drawn at 1030 would be marked as #3 on the tube and the time “1030” 
would be written on the label. If the blood is not drawn exactly on the hour or half-hour please 
write exactly when it is drawn. 
 
After the tube is drawn place it immediately in the ice being stored in the utility room 
refrigerator 
 
When all the samples are drawn, after 1400 PM, please page Jason at 8288. 
 
6) Cyclophosphamide _____ mg (50 mg/kg/dose) + Mesna  ____  mg (15 mg/kg) in D5%W 
Sodium Chloride 0.45% to final volume ____ ml (200 ml/m2) IV over 1 hour beginning at 10 
AM daily on days -5, -4, -3, and -2 (__/__/__, __/__/__, __/__/__). Pharmacy staff to enter. 
 
  
Cyclophosphamide Monitoring 
• I/O’s every 4 hours.   
• Dip all urine for specific gravity and blood.  
• Maintain urine output at least ___ml/hour (2 ml/kg/hour) post-cytoxan with patient 
urinating every 2-3 hours.   
• If urine output < ___ml/hour (2 ml/kg/hour) and any of the following (O>I by 30%; 
weight decreased; SG ≥ 1.015), then increase IV fluids to ___ ml/hr (by 25%) and reassess.   
• If evidence of fluid overload (periorbital or peripheral edema, rales, etc) or I>O by 30% 
over 8 hours, obtain serum sodium and contact BMT attending to consider Lasix ___ mg (0.5 
mg/kg/dose, 40 mg single max dose). BMT team to enter 
 
 Do not decrease intravenous hydration without prior approval from BMT Attending. 
 
7) Furosemide ___ mg (0.5 mg/kg/dose, 40 mg single max dose) IV daily at Hours 2 and 6 
hrs after each Cytoxan dose daily on days -5, -4, -3, and -2 (__/__/__, __/__/__, __/__/__, and 
__/__/__). Pharmacy staff to enter. 
 
8) Mesna ____ mg (15 mg/kg) IV over 15 minutes diluted in hydration fluids at Hours 3, 6, 
9, and 12 hours after each Cyclophosphamide dose daily on days -5, -4, -3, and -2 (__/__/__, 
__/__/__, __/__/__, and __/__/__). Pharmacy staff to enter. 
9) Methylprednisolone ____mg (0.5mg/kg/dose) IV every 6 hours  (2mg/kg/day) with 1st 
dose 12 hours before Atgam, on day –5 (__/__/__) at 10 PM.  Continue every six hours until 
__/__/__ at 4 am, Day -1.  Pharmacy Staff to enter 
 
  
10)  Patient will receive Anti-thymocyte Globulin – Equine (ATGAM®) 
 Anti-thymocyte Globulin (Equine) (ATGAM®) ____ mg (15 mg/kg/dose; 30 mg/kg/day) 
IV in Sodium Chloride 0.9% to final concentration 4mg/ml (minimum 120ml) IV over 4 hours 
every 12 hrs x 6 total doses over 4 hours. Pharmacy staff to enter 
 Begin at 11 AM on Day –4 (__/__/__) and continue through Day -2 (__/__/__)with last 
dose __/__/__ 11 PM.    
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 Administer Anti-thymocyte Globulin (ATGAM®) intradermal skin test at 9 AM on Day 
– 4 (__/__/__) prior to first dose): 
0.1 ml. intradermal injection of 1:1000 ATGAM® 0.1 ml Sodium Chloride 0.9% intradermal 
injection. Pharmacy staff to enter and prepare 
 
DO NOT give diphenhydramine within 72 hours of skin test. 
Vital signs every 15 minutes for the first hour and then every 
hour during infusion. 
 
11) Premedication prior to each Anti-thymocyte Globulin ATGAM®  dose every 12 hrs x 6 
total doses on Days -4 through Day -2: 
a.) Acetaminophen ____ mg (15 mg/kg/dose, max single dose 650mg) PO one hour prior, 
then every 4 hours as needed for fever >38.5 C. Pharmacy Staff to enter 
 
b.) Diphenhydramine ____ mg (0.5 mg/kg/dose, max single dose 50mg) IV 30 minutes pre-
Anti-thymocyte Globulin, then every 6 hours as needed for rash. Pharmacy Staff to enter  
 
12) On day -1 (__/__/__) at 10 AM, decrease hydration fluid rate to ___ ml/hr (85 ml/m2/hr).  
Total IV fluids should equal 2000 ml/m2/day. BMT team to enter 
 
13) Cyclosporine A   ____ mg/day( 5 mg/kg/day – dose reduced to 1.65 mg/kg/day due to 
concurrent voriconazole) IV in D5%W to final volume 48 ml IV at 2 ml/hour beginning on day -
2 (__/__/__) at 6 AM, for EHS.  Infuse via the same lumen each day. Cyclosporine should 
always be infused through one dedicated line (Central of Peripheral).  Do not switch to another 
central venous catheter lumen (Broviac, Mediport, PICC or other types of catheter) without prior 
approval from the medical team.  Pharmacy staff to enter. 
 
14) Cyclosporine level at 6 AM Day 0 (__/__/__) and every Monday and Thursday.  Draw 
level via opposite broviac from dose infusion. BMT team to enter. 
 
15) Filgrastim ____ mcg (5 mcg/kg/day; dose rounded to nearest 15 mcg) IV over 1 hour 
daily.  Give the first dose 24 hours after the infusion of the stem cells. Pharmacy staff to enter. 
 
16) MYCOPHENOLATE MOFETIL (15mg/kg/dose) ____ mg IV given as a 2 hour infusion 
three times a day started Day 0 (__/__/__) at 8 AM 
 
MPA Pharmacokinetic Studies will be performed around the 1600 (4PM) IV dose of 
Mycophenolate Mofetil on Day +3 (__/__/__). 
For Intravenous dose: Blood work will be drawn before the dose and then at 120, 180, 240, 300, 
360 and 480 minutes after the start of the infusion.  2 ml of blood will be drawn into green top 
Vacutainers. 
 Draw sample #1 at 1545 AM on Day +3 
 Draw sample #2 at 1800 AM on Day +3 
 Draw sample #3 at 1900 PM on Day +3 
 Draw sample #4 at 2000 PM on Day +3 
 Draw sample #5 at 2100 PM on Day +3 
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 Draw sample #6 at 2200 PM on Day +3 
 Draw sample #7 at 2400 PM on Day +3 
- All MPA levels will be sent to the lab at the time of blood draw.  Do not hold the samples 
on the unit. 
- Cellcept (MMF) should always be infused through one dedicated line (Central of 
Peripheral).  Do not switch to another central venous catheter lumen (Broviac, Mediport, PICC 
or other types of catheter) without prior approval from the medical team.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 [PRO15080386] 
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APPENDIX B 
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B1. ABSTRACT 
Lung transplantation is a viable treatment option for multiple end-stage pulmonary disorders 
including cystic fibrosis, COPD, and idiopathic pulmonary fibrosis. Although lung 
transplantation improves the quality of life and short-term survival of the patient, long-term 
survival remains poor, with only 55% of patients surviving 5 years post-transplantation. Acute 
cellular rejection (ACR) is a common complication post-lung transplantation, with more than 
one-third of patients being treated for acute rejection within one year of transplantation. 
Furthermore, ACR appears to be a risk factor for the development of bronchiolitis obliterans 
syndrome (BOS), which is the primary cause of mortality in lung transplant recipients at 5 years. 
Longer and recurrent episodes of ACR also appear to have a stronger correlation with BOS. 
ACR is a direct result of inadequate immunosuppression. There are also complications in lung 
transplant patients that are a result of over-immunosuppression including increased rate of 
infections and hypogammaglobulinemia. Both of these complications put lung transplant patients 
at an increased risk of mortality.  
 
Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is commonly used in 
combination with the calcineurin inhibitors, cyclosporine and tacrolimus, to prevent ACR and to 
prevent BOS progression. Due to the large variability in the pharmacokinetics of these 
immunosuppressive drugs, dosing of calcineurin inhibitors (CNIs) are individualized to attain a 
certain range of trough concentrations, that is known to correlate with drug exposure as 
measured by the area under the plasma concentration vs time curve (AUC). However, MMF is 
given at a fixed dose and rotuine monitoring of trough level is not performed as it does not 
correlate with AUC. Studies in kidney and heart transplant recipients have clearly demonstrated 
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improved clinical outcomes when the drug exposure as measured AUC (0-12) of MPA falls 
within the range of 30–60 mg*h/L. We predict that lower MPA exposure (AUC), in the absence 
of TDM and concurrent increase in the IMPDH activity could be the cause for the high incidence 
of acute clinical rejection in adult lung transplant recipients. Our long term goal is to optimize 
MMF dosing based on drug exposure, in order to decrease incidence of ACR in lung transplant 
patients. Measuring the AUC of MPA is often cumbersome and expensive to perform clinically. 
Recent studies in kidney transplant and bone marrow patients have focused on the use of limited 
sampling strategies (LSSs) as an indirect measure of MPA exposure that have the potential to 
improve and individualize MPA dosing. We hypothesize that LSS can be used as a surrogate 
marker for drug exposure (AUC) and used for optimizing the dose of MMF.The limited 
sampling strategy (LSS) and IMPDH measurement could provide a more feasible way to 
measure mycophenolate activity within lung transplant recipients in order to optimize therapy. 
The LSS is considered "limited sampling" because it uses less blood draws than the full 
pharmacokinetic profile. The LSS will use utilize up to 5 blood draws over 4-6 hours whereas 
the full pharmacokinetic profile utilizes 9 samples over 12 hours. The LSS will be correlated to 
the full PK profile to provide a more feasible way of measuring mycophenolate within the body.  
 
Mycophenolic acid acts by inhibiting ionosine monophosphate dehydrogenase (IMPDH) in 
PBMC. The biological response to MPA can therefore be measured by the inhibition of IMPDH 
activity. We hypothesize that monitoring IMPDH activity can also help in optimizing MMF 
dosing and minimize ACR burden, BOS progression, hypogammaglobulinemia, and infection 
episodes in lung transplant patients.  
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In this pilot study we will identify the optimal sampling time for LSS and evaluate the 
relationship between MPA exposure and IMPDH activity in lung transplant patients. Subjects 
will participate in three studies. Study 1 will be performed between days 7-21 post 
transplantation. Study 2 will be performed around 3 months post transplantation. Study 3 will be 
performed between months 6-12. Multiple blood samples will be collected from study subjects 
over a dosing interval and MPA levels will be measured in plasma and IMPDH activity will be 
measured in PBMC. Results of this pilot study will provide data for a future study of a 
prospective individualized MMF dosing based on LSS and IMPDH activity in order to minimize 
ACR. 
 
B2. OBJECTIVE AND SPECIFIC AIMS 
Objective: What is the overall purpose of this research study?  (Limit response to 1-2 sentences.) 
The objective of this study is to establish an optimal limited sampling strategy (LSS) for 
mycophenolic acid (MPA) in lung transplant patients by characterizing the pharmacokinetics 
(PK) over a dosing interval and to identify the relationship between MPA exposure and its 
pharmacological activity (inosine monophosphate dehydrogenase-IMPDH activity) in order to 
optimize MMF dosing regimen in adult lung transplant recipients. The LSS and IMPDH 
measurement could provide a more feasible way to measure mycophenolate activity within lung 
transplant recipients in order to optimize therapy.  
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Specific Aims: List the goals of the proposed study (e.g., describe the relevant hypotheses or the 
specific problems or issues that will be addressed by the study). 
Aim 1:  
To establish a limited sampling strategy to estimate MPA exposure using a minimal number of 
blood samples collected during a dosing interval in adult lung transplant patients. This will be 
accomplished by evaluating the pharmacokinetics of MPA over a dosing interval in an adult 
cohort of lung transplant recipients.  
 
Aim 2:  
To determine the activity of MPA by measuring the ex-vivo IMPDH activity in peripheral blood 
mononuclear cells. IMPDH activity measurements will be obtained pre-transplant (baseline), pre 
dose, and at 5 additional time points during the full PK profile.  
 
Aim 3: 
To characterize the relationship between MPA exposure and IMPDH activity over time in lung 
transplant patients. 
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B3. BACKGROUND 
Lung Transplantation and Immunosuppression: 
Lung transplantation is the treatment of choice for patients with end stage lung diseases 
including cystic fibrosis. Since the early 1990s, more than 25,000 lung transplants have been 
performed at centers around the world (1). Maintenance immunosuppressive therapy is 
administered to all lung transplant recipients to help prevent acute and chronic rejection and the 
loss of the lung allograft. Calcineurin inhibitors (cyclosporine and tacrolimus) form the backbone 
of the immunosuppressive regimen. The dose of cyclosporine is targeted to maintain a trough 
levels of 250 to 300 ng/mL during the initial post-transplant year and at 200 to 300 ng/mL in the 
later phase. Ninety % of the the lung transplant recipients in the United States are on tacrolimus 
and are dosed to target a trough level of 5-15ng/ml (2). MPA a selective, reversible, and 
noncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH) that acts by 
blocking the de novo synthesis of lymphocytes and inhibiting proliferation of activated T and B 
lymphocytes is also used in most transplant patients. MPA is administered as its prodrug MMF. 
Approximately 80 percent of lung transplant recipients in the United States receive MMF as a 
core constituent of their maintenance immunosuppression (2). MMF has replaced azathioprine in 
cyclosporine or tacrolimus-based anti-rejection regimens in renal and heart transplant recipients. 
At UPMC Presbyterian Hospital, lung transplant recipients undergo induction 
immunosuppression with alemtuzumab or basiliximab and are maintained on maintenance 
immunosuppression thereafter. The preferred maintenance immunosuppression regimen at 
UPMC consists of tacrolimus, steroids, and mycophenolate mofetil. 
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MPA pharmacokinetics and Pharmacodynamics in Lung Transplant Patients: 
To date only a few studies have characterized the pharmacokinetics of MPA in lung transplant 
population. Studies conducted in lung and heart transplant recipients have shown significantly 
lower levels of MPA in lung transplants. However, no prospective study has been conducted to 
evaluate the impact of baseline IMPDH activity and IMPDH activity during a dosing interval in 
lung transplant recipients to guide MMF therapy. We predict that baseline IMPDH can serve as a 
good initial marker to guide the AUC based MMF therapy in adult lung transplant recipients and 
may serve as an initial marker to guide the exposure and target MPA exposure. (13-14) 
 
Effect of Pharmacogenetics on Mycophenolate Mofetil therapy: 
Genes encoding for uridine diphosphate glucuronosyltransferase, organic anion transporting 
polypeptides, MRP-2 and inosine-5-monophosphate dehydrogenase have shown single 
nucleotide polymorphisms (SNPs). Several studies conducted in solid organ transplant recipients 
have demonstrated large inter-individual variability. Such studies have prompted interest in 
studying the pharmacegentic influence on MMF-based immunosuppression. Prospective studies 
conducted in solid organ transplant recipients have shown a potential contribution of genetic 
variants in the UGT1A9, UGT2B7, IMPDH II and MRP2 on pharmacokinetics of MPA (15-19). 
 
PK/PD-Based MMF Targeting in lung transplant patients:  
Based on the limited published pharmacokinetic data and paucity of any PD data, this study 
would examine the feasibility of a limited sampling based PK-PD based MMF targeting in adult 
lung transplant recipients. 
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B4. SIGNIFICANCE 
Therapeutic drug monitoring has become very crucial to optimal dosing of immunosuppressants. 
CNIs that form the backbone of immunosuppressive therapy in solid organ transplant recipients 
are routinely monitored and the doses are titrated to target a trough level. MMF although used 
extensively in solid organ transplant recipients is however not routinely monitored. This is 
primarily because MPA trough levels are poorly correlated with the total exposure (AUC). 
Studies in kidney and heart transplant recipients have demonstrated improved clinical outcomes 
when the measured AUC (0-12) of MPA falls within the range of 30 – 60 mg*h/L and is given 
with cyclosporine and steroids. Measurement of 12 hour AUC is impractical in standard clinical 
practice settings. An alternate simpler approach to measure drug exposure is very essential to 
optimize MMF therapy.  
A fixed dose MMF is used in lung transplant recipients and it is similar to the dosing used in 
renal and heart transplant recipients. However, lung transplant patients have shown a different 
pharmacokinetic profile as compared to renal transplant recipients. Studies suggest a lower MPA 
exposure in lung transplant recipients. A better understanding of the pharmacokinetics of MPA is 
necessary to optimize MMF therapy. 
More recent studies have focused on limited sampling strategies (LSSs) that have the potential to 
improve MMF monitoring. LSS represents total exposure to MPA by measuring concentrations 
at fewer time points. There is a scarcity of PK studies in lung transplant recipients let alone an 
individualized MMF dosing study based on limited sampling strategy. Also there have been no 
reports of IMPDH monitoring in lung transplant recipients. We predict that sub-therapeutic 
levels on MMF in the absence of TDM and concurrent increase in the IMPDH activity could be 
the cause for high incidence of acute clinical rejection in adult lung transplant recipients.  
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We hypothesize that individualized dosing of MMF based on MPA exposure by LSS and 
monitoring IMPDH activity will reduce ACR burden, BOS progression, 
hypogammaglobulinemia, and infection episodes in lung transplant patients. This pilot study will 
establish the basis for future studied to be performed in lung transplant recipients with PK-PD 
guided MMF dosing. 
 
B5. CONSENT FORM 
  
TITLE: Limited sampling strategy for predicting exposure and efficacy of mycophenolic 
acid in adult lung transplant recipients 
 
PRINCIPAL INVESTIGATOR: 
Raman Venkataramanan, Ph.D. Professor of Pharmaceutical Sciences and Pathology  
718 Salk Hall, University of Pittsburgh School of Pharmacy, 3501 Terrace Street, Pittsburgh, PA 
15261, Phone: 412-400-7027 
  
Co-investigators:  
Department of Pharmaceutical Sciences: 
Christopher Ensor, PharmD, Assistant Professor, Pharmacy and Therapeutics, 708 Salk Hall, 
School of Pharmacy, 3501 Terrace Street, Pittsburgh, PA 
Phone: 412-864-1962 
Cody Moore, PharmD. Transplant Pharmacy Fellow, 534 Salk Hall, 3501 Terrace Street, 
Pittsburgh, PA 15261 
Phone: 814-771-2901 
Rujuta Joshi, Graduate student, 731 Salk Hall, 3501 Terrace Street, Pittsburgh, PA, 15261 
Phone: 816-804-1161 
  
Thomas Starzl Transplantation Institute: 
John McDyer, MD ; Matthew Morrell, MD; Jonathan D’Cunha, MD, PhD 
Montefiore Hospital, 3459 Fifth Avenue, Pittsburgh, PA 15213 
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SOURCE OF SUPPORT: Clinical Pharmacokinetics Laboratory Funds, University of 
Pittsburgh School of Pharmacy 
Why is this research being done? 
After lung transplant you will receive a drug called mycophenolate mofetil to prevent rejection 
of the lungs. The primary objective of this study is to understand how mycophenolate mofetil is 
handled by the body after lung transplantation, and to develop a simple strategy to measure the 
blood level of mycophenolate mofetil in lung transplant patients that may be more useful in 
preventing rejection. The secondary objective of this study is to determine the effect of 
monitoring blood levels of this drug in lung transplant patients. The results of this study may 
provide valuable information to clinicians on how to more effectively use this drug and minimize 
rejection of the transplanted lungs. 
 
 
 
Who is being asked to take part in this research study? 
You are being invited to take part in this research study because you are between the ages of 18 
and 65 and will be receiving a lung transplant. You will participate in this study only if you 
receive mycophenolate mofetil as part of your clinical treatment as a medication to prevent 
rejection of your transplanted lungs. This study will take place at the University of Pittsburgh 
Medical Center, Pittsburgh, PA, and will include approximately 20 participants.  
 
 
How will the study be done? 
No medications will be administered for the purposes of this study. You will participate in this 
study only if you are given mycophenolate mofetil as part of your standard of care, post-
transplant course. If you decide to participate in this study, you will undergo a screening 
procedure and participate in the study at four time points (before your transplant, 7-upto 2 month 
following transplantation, around 3 months, and around 6 to 12 months following 
transplantation). The duration of the study will be five minutes before transplant, 12-13 hours at 
the 7- upto 2 month study period, and not more than 6 hours at the 3 and 6-12 months study 
period. The entire duration of your participation would be about a year following your 
transplantation. We will collect information on your medical and surgical history from your 
hospital, as well as surgical and clinic records during your study participation, and for up to 5 
years after transplantation. We will also be testing left over blood samples for certain 
biochemicals from routine clinical testing samples that were taken from the time of your 
transplant. Information collected will be confidentially held and used only for the purposes of the 
research study.   
 
Screening 
Screening is required to determine if you are qualified to take part in this clinical study. This will 
be done following your selection as a recipient for lung transplantation. To determine if you meet 
the criteria for participation in this study, your doctor will review and collect information about 
your medical history including but not limited to your age, gender, weight, height, medical 
history, as well as clinical laboratory test results indicative of your liver and kidney function. If 
you are a woman of child-bearing age, pregnancy testing is normally performed as part of the 
standard of care. Once you meet all the study participation criteria, you will be approached by 
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the investigators to determine your interest in participating in this research study. If you express 
interest, the study will be explained to you by one of the coordinators and you will be allowed 
sufficient time to read and understand the consent form and sign the consent. No study 
procedures will be performed until after you sign the consent.  
 
Pre-transplant 
Prior to your transplant, 15 mL (one tablespoon) of blood will be drawn for genetic testing 
related to the proteins in your body that handle mycophenolate mofetil and mediate its effect.  
Genetic testing is inherited information (a blueprint) about the structure and functions of cells in 
the human body that make up the color of our hair and eyes and may influence the way our 
bodies respond to certain stimuli such as an illness or infections. This activity will take about 5 
minutes.   
 
Early Post-transplant study: 7-upto 2 month following transplantation 
● Blood samples (4 ml or approximately 1 teaspoon) will be collected before your dose of 
regularly scheduled mycophenolate mofetil and around 30 minutes, 1 hour, 1.5 hours, 2 
hours, 4 hours, 6 hours, 9 hours, and 12 hours after taking the medicine. In addition, there 
will also be 10 ml (2 teaspoons) of blood drawn at no more than 5 time points during the 
same time period. A total of 86 ml (6 tablespoons) of blood will be collected over a 12 
hour time period. 
● This activity will take about 12–13 hours.  
● Blood samples taken during this part of the study will be drawn from an existing 
intravenous line 
 
Post-transplant: 3 months and 6-12 months Post-transplantation 
This study will take place around your 3-month and 6-12 months follow-up visits.  These visits 
will occur at the time of the routine bronchoscopy, lavage, and biopsy and will last 
approximately 4-6 hours. On this day the transplant clinical team will perform routine work-up. 
You will be asked to hold your morning dose of mycophenolate prior to coming to clinic.  Please 
bring your dose of mycophenolate to clinic with you. 
● You will be asked to take your morning dose of mycophenolate in the clinic.  Please 
bring this dose with you to clinic.   
● Blood samples (14 ml or 1 tablespoon) will be collected before you take the dose of 
mycophenolate mofetil and 4 more times after your mycophenolate dose. A total of 70 
mL (approximately 5 tablespoons) of blood will be taken  
● Blood samples taken during this part of the study will also be drawn from an existing 
intravenous line 
 
The total volume of blood that will be drawn for the entire study will be 241 mL (approximately 
16 tablespoons).  
 
Biological Samples for Future Research 
All biological samples already collected during your clinical visits may also be used for future 
testing related to this study or use of medications in lung transplant patients.   The samples that 
will be collected in this study include blood, plasma, and a type of cell within the blood known 
as peripheral blood mononuclear cells (PBMCs).  The samples will be stored indefinitely in the 
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Clinical Pharmacokinetics Laboratory at the University of Pittsburgh under the direct supervision 
of the primary investigator Dr. Raman Venkataramanan. Only members of the research team or 
laboratory personnel conducting the laboratory tests will have access to the samples. Samples 
will be labeled with the numerical code assigned to the subject in order to correlate with clinical 
data obtained during the study and only the study team members will know to whom the sample 
belongs. You will not be notified about pending results on these tests, as they have no bearing on 
your medical management.  These samples may be shared with other investigators who are 
interested in transplant, but none of the samples shared will contain your identifiers.   
 
What are the possible risks, side effects, and discomforts of this research study? 
There may be certain risks associated with participation in this study.  These may include the 
following:  
 
Blood Draws or Intravenous Line Insertion: 
Bruising, bleeding, fainting, swelling, pain and, rarely, infection 
 
Breach of Confidentiality 
There is also a remote risk associated with breach of confidentiality related to genetic testing. 
There is a possibility that, if the results of the research studies involving your biologic materials 
were to become generally known, this information could impact future insurability, 
employability, or reproduction plans, or have a negative impact on family relationships, and/or 
result in stigmatization. To minimize this risk, any information about you obtained from this 
research will be kept as confidential (private) as possible. All records or samples related to your 
involvement in this research study will be stored in a secure, double-locked area or password-
protected computer database that is accessible only by members of the research team. Your 
identity on these records and samples will be indicated by your subject identification number 
rather than by your name, and the information linking your subject identification number with 
your identity will be kept separate from the research records 
 
What are possible benefits from taking part in this study? 
There is no direct benefit from participating in this study. However, the information learned from 
this study may help others who undergo transplantation in the future. 
  
If I agree to take part in this research study, will I be told of any new risks that may be found 
during the course of the study? 
You will be promptly notified if, during the conduct of this research study, any new information 
develops which may cause you to change your mind about continuing to participate in this study. 
  
Will my insurance provider or I be charged for the costs of any procedures performed as part 
of this research study? 
Some of the services you will receive during this time are “research only services” that are being 
done only because you are in the study. These services will be paid for by the study and will not 
be billed to your health insurance company or you. Examples are certain blood draws, 
biochemical measurements, and genetic testing. 
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Some of the procedures that you will undergo during this study are considered to be “routine 
clinical services” that you would have even if you were not in the study. Examples are the actual 
lung transplant surgery, other transplant-related tests, use of immunosuppressive medications and 
routine care medications, hospitalization and all associated costs. These services will be billed to 
your health insurance company or you, if you do not have health insurance. 
 
Will I be paid if I take part in this research study? 
You will not receive any payment for taking part in this clinical research study.  Your biological 
sample or genetic material may lead, in the future, to new inventions or products. If the research 
investigators are able to develop new products from the use of your biological sample or genetic 
material, there are currently no plans to share with you any money or other rewards that may 
result from the development of the new product. 
  
Who will pay if I am injured as a result of taking part in this study? 
University of Pittsburgh investigators and their associates who provide services at UPMC 
recognize the importance of your voluntary participation in their research studies. These 
individuals and their staff will make every reasonable effort to minimize, control and treat any 
injuries that may arise as a result of this research. If you believe that you are injured as the result 
of the research procedures being performed, please contact the principal investigator or one of 
the investigators listed on the first page of this form. 
  
Emergency medical treatment for injuries solely and directly related to your participation in this 
research study will be provided to you by the hospitals of UPMC. Your insurance provider may 
be billed for the costs of this emergency treatment, but none of those costs will be charged 
directly to you. If your research-related injury requires medical care beyond this emergency 
treatment, you will be responsible for the costs of this follow-up care. At this time, there is no 
plan for any additional financial compensation. 
  
Who will know about my participation in this research study? 
Any information about you obtained from this research will be kept as confidential (private) as 
possible. All records related to your involvement in this research study will be stored in a locked 
file cabinet. Your identity on these records will be indicated by a case number rather than by 
your name, and the information linking these case numbers with your identity will be kept 
separate from the research records. You will not be identified by name in any publication of the 
research results. 
  
Will this research study involve the use or disclosure of my identifiable medical information? 
This research study will involve the recording of past, current and/or future identifiable 
(pertaining to only you) medical information from your hospital and/or other (e.g., physician 
office) records. The information that will be recorded will be limited to information concerning 
your transplant (e.g., diagnostic information, lab results, medications, medical history).  This 
information will be used to determine your eligibility for this study and to follow your response 
once you are enrolled in the study.  
 
This research study will not result in identifiable information that will be placed into your 
medical records held at UPMC  
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Who will have access to identifiable information related to my participation in this research 
study? 
  
In addition to the investigators listed on the first page of this authorization (consent) form and 
their research staff, the following individuals will or may have access to identifiable information 
(which may include your identifiable medical information) related to your participation in this 
research study: 
  
Authorized representatives of the University of Pittsburgh Research Conduct and Compliance 
Office may review your identifiable research information (which may include your identifiable 
medical information) for the purpose of monitoring the appropriate conduct of this research 
study. 
  
Authorized representatives from the Food and Drug Administration may review and or obtain 
your identifiable (which may include your identifiable medical information) related to your 
participation in this research study for the purposes of monitoring the accuracy and completeness 
of the research data.  While the U.S. Food and Drug Administration understands the importance 
of maintaining the confidentiality of your identifiable research and medical information, the 
UPMC and University of Pittsburgh cannot guarantee the confidentiality of this information after 
it has been obtained by the U.S. Food and Drug Administration. 
  
Authorized representatives of UPMC hospitals or other affiliated health care providers may have 
access to identifiable information (which may include your identifiable medical information) 
related to your participation in this research study for the purpose of (1) fulfilling orders, made 
by the investigators, for hospital and health care services (e.g., laboratory tests, diagnostic 
procedures) associated with research study participation; (2) addressing correct payment for tests 
and procedures ordered by the investigators; and/or (3) for internal hospital operations (i.e. 
quality assurance). 
 
In unusual cases, the investigators may be required to release identifiable information (which 
may include your identifiable medical information) related to your participation in this research 
study in response to an order from a court of law.  If the investigators learn that you or someone 
with whom you are involved is in serious danger or potential harm, they will need to inform, as 
required by Pennsylvania law, the appropriate agencies. 
 
Records of your participation in this study will be held confidential except as disclosure is 
required by law or as described in this informed consent document (under "Confidentiality" or 
"Authorization to Use and Disclose Protected Health Information").  The study doctor, the 
sponsor or persons working on behalf of the sponsor, and under certain circumstances, the 
United States Food and Drug Administration (FDA) will be able to inspect and copy confidential 
study-related records, which identify you by name.  Therefore, absolute confidentiality cannot be 
guaranteed.  If the results of this study are published or presented at meetings, you will not be 
identified. 
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For how long will the investigators be permitted to use and disclose identifiable information 
related to my participation in this research study? 
The investigators may continue to use and disclose, for the purposes described above, 
identifiable information (which may include your identifiable medical information) related to 
your participation in this research study for a minimum of seven years after final completion or 
publication of the project and for as long (indefinite) as it may take to complete this research 
study. 
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov as required 
by US Law.  This website will not identify you.  At most the website will include a summary of 
the results.  You can search this site at any time. 
  
Is my participation in this research study voluntary? 
Your participation in this research study, to include the use and disclosure of your identifiable 
information for the purposes described above, is completely voluntary. (Note, however, that if 
you do not provide your consent for the use and disclosure of your identifiable information for 
the purposes described above, you will not be allowed to participate in the research study). 
Whether or not you provide your consent for participation in this research study will have no 
effect on your current and future care at a University or Pittsburgh or UPMC hospital or 
affiliated health care provider or your current or future relationship with a health care insurance 
provider. If you choose not to participate in this study, it will not impact your care or your 
chances of receiving a lung transplant.   
 
Your doctor may be an investigator in this research study, and as an investigator, is interested 
both in your medical care and in the conduct of this research. Before entering this study or at any 
time during the research, you may discuss your care with another doctor who is in no way 
associated with this research project. You are not under any obligation to participate in any 
research study offered by your doctor. 
 
May I withdraw, at a future date, my consent for participation in this research study? 
You may withdraw, at any time, your consent for participation in this research study, to include 
the use and disclosure of your identifiable information for the purposes described above.  (Note, 
however, that if you withdraw your consent for the use and disclosure of your identifiable 
medical record information for the purposes described above, you will also be withdrawn, in 
general, from further participation in this research study).  Any identifiable research or medical 
information recorded for, or resulting from, your participation in this research study or blood 
samples collected prior to the date that you formally withdrew your consent may continue to be 
used and disclosed by the investigators for the purposes described above.  
  
To formally withdraw your consent for participation in this research study you should provide a 
written and dated notice of this decision to the principal investigator of this research study at the 
address listed on the first page of this form. 
  
If I agree to take part in this research study, can I be removed from the study without my 
consent? 
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It is possible that you may be removed from the research study by the researchers if you 
experience unexpected conditions and in the opinion of the investigators that it is in your best 
interest. If your mycophenolate mofetil is stopped at the recommendation of your physician, you 
will also be removed from the study.  If this happens, your data may still be kept and used 
depending when your mycophenolate mofetil is discontinued.   
 
 
VOLUNTARY CONSENT 
 
 All of the above has been explained to me and all of my current questions have been answered.  
I understand that I am encouraged to ask questions about any aspect of this research study during 
the course of this study, and that such future questions will be answered by the researchers listed 
on the first page of this form. 
  
Any questions which I have about my rights as a research participant will be answered by the 
Human Subject Protection Advocate of the IRB Office, University of Pittsburgh (1-866-212-
2668).   By signing this form I consent to participate in this research study and provide my 
authorization to share my medical records with the research team.  A copy of this consent form 
will be given to me. 
  
________________________________                       __________________ 
Participant’s Signature                                                Date/Time 
 
 
  
CERTIFICATION of INFORMED CONSENT 
 
I certify that I have explained the nature and purpose of this research study to the above-named 
individual(s), and I have discussed the potential benefits and possible risks of study participation.  
Any questions the individual(s) have about this study have been answered, and we will always be 
available to address future questions as they arise. I further certify that no research component of 
this protocol was begun until after this consent form was signed. 
  
___________________________________                  ________________________ 
Printed Name of Person Obtaining Consent                Role in Research Study 
  
  
_________________________________          ________________________ 
Signature of Person Obtaining Consent                   Date/Time 
 
 
 
